{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "9e6ed5f8",
   "metadata": {},
   "source": [
    "# Clinical Trials CLassification"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "673a03cf",
   "metadata": {},
   "source": [
    "### Data Reading Phase"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "f487ae39",
   "metadata": {},
   "outputs": [],
   "source": [
    "import numpy as np\n",
    "import matplotlib.pyplot as plt\n",
    "import pandas as pd\n",
    "import seaborn as sns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "b5b8a839",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/tmp/ipykernel_7816/28611935.py:1: DtypeWarning: Columns (35,36,37,38,39) have mixed types. Specify dtype option on import or set low_memory=False.\n",
      "  df = pd.read_csv('/home/haider/Desktop/Office/Python/Projects/clinical-trials-analysis/data/updated_cancer_trials.csv')\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nctid</th>\n",
       "      <th>orgstudyid</th>\n",
       "      <th>title</th>\n",
       "      <th>organization_fullname</th>\n",
       "      <th>leadsponsor</th>\n",
       "      <th>collaborators</th>\n",
       "      <th>studytype</th>\n",
       "      <th>phase</th>\n",
       "      <th>overallstatus</th>\n",
       "      <th>startdate</th>\n",
       "      <th>...</th>\n",
       "      <th>centralcontact_name</th>\n",
       "      <th>centralcontact_role</th>\n",
       "      <th>centralcontact_phone</th>\n",
       "      <th>centralcontact_phoneext</th>\n",
       "      <th>centralcontact_email</th>\n",
       "      <th>numcentralcontacts</th>\n",
       "      <th>location_facility</th>\n",
       "      <th>location_city</th>\n",
       "      <th>location_state</th>\n",
       "      <th>location_country</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT03878979</td>\n",
       "      <td>J1923</td>\n",
       "      <td>Preoperative Immune Checkpoint Inhibitor Thera...</td>\n",
       "      <td>Sidney Kimmel Comprehensive Cancer Center at J...</td>\n",
       "      <td>Sidney Kimmel Comprehensive Cancer Center at J...</td>\n",
       "      <td>Bristol-Myers Squibb</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>2019-07-08</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>?</td>\n",
       "      <td>Johns Hopkins Sidney Kimmel Comprehensive Canc...</td>\n",
       "      <td>Baltimore</td>\n",
       "      <td>Maryland</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT04591379</td>\n",
       "      <td>REG-083-2020</td>\n",
       "      <td>Intratumoral Influenza Vaccine for Early Color...</td>\n",
       "      <td>Zealand University Hospital</td>\n",
       "      <td>Zealand University Hospital</td>\n",
       "      <td>University of Copenhagen</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>2021-02-26</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>?</td>\n",
       "      <td>Zealand University Hospital</td>\n",
       "      <td>Køge</td>\n",
       "      <td>Zealand</td>\n",
       "      <td>Denmark</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT06671379</td>\n",
       "      <td>SHR-A2009-301</td>\n",
       "      <td>A Randomized, Open-label, Multicenter, Phase I...</td>\n",
       "      <td>Suzhou Suncadia Biopharmaceuticals Co., Ltd.</td>\n",
       "      <td>Suzhou Suncadia Biopharmaceuticals Co., Ltd.</td>\n",
       "      <td>NaN</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>2024-11-29</td>\n",
       "      <td>...</td>\n",
       "      <td>Fei Qiu</td>\n",
       "      <td>CONTACT</td>\n",
       "      <td>0518-82342973</td>\n",
       "      <td>?</td>\n",
       "      <td>fei.qiu@hengrui.com</td>\n",
       "      <td>?</td>\n",
       "      <td>Guangdong Provincial People's Hospital</td>\n",
       "      <td>Guangzhou</td>\n",
       "      <td>Guangdong</td>\n",
       "      <td>China</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT04361279</td>\n",
       "      <td>SIBP-02-03</td>\n",
       "      <td>A Phase III, Multicenter, Randomized, Double-b...</td>\n",
       "      <td>Shanghai Institute Of Biological Products</td>\n",
       "      <td>Shanghai Institute Of Biological Products</td>\n",
       "      <td>NaN</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>2019-07-25</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>?</td>\n",
       "      <td>The First Affiliated Hospital of College of Me...</td>\n",
       "      <td>Hangzhou</td>\n",
       "      <td>?</td>\n",
       "      <td>China</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT05799079</td>\n",
       "      <td>VICCHEM2163</td>\n",
       "      <td>Phase 2 Study of Decitabine and Cedazuridine i...</td>\n",
       "      <td>Vanderbilt-Ingram Cancer Center</td>\n",
       "      <td>Sanjay Mohan</td>\n",
       "      <td>National Comprehensive Cancer Network, Taiho O...</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>2024-01-29</td>\n",
       "      <td>...</td>\n",
       "      <td>Vanderbilt-Ingram Services for Timely Access</td>\n",
       "      <td>CONTACT</td>\n",
       "      <td>800-811-8480</td>\n",
       "      <td>?</td>\n",
       "      <td>cip@vumc.org</td>\n",
       "      <td>?</td>\n",
       "      <td>Vanderbilt University/Ingram Cancer Center</td>\n",
       "      <td>Nashville</td>\n",
       "      <td>Tennessee</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>NCT04164979</td>\n",
       "      <td>20195426</td>\n",
       "      <td>Phase 2 Study of Cabozantinib Combined With Pe...</td>\n",
       "      <td>University of California, Irvine</td>\n",
       "      <td>University of California, Irvine</td>\n",
       "      <td>Exelixis</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>2020-02-04</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>?</td>\n",
       "      <td>Chao Family Comprehensive Cancer Center, Unive...</td>\n",
       "      <td>Orange</td>\n",
       "      <td>California</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>NCT00313079</td>\n",
       "      <td>HEMALL0003</td>\n",
       "      <td>A Phase I Study of mAb 216 With Chemotherapy f...</td>\n",
       "      <td>Stanford University</td>\n",
       "      <td>Steven E. Coutre</td>\n",
       "      <td>NaN</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>2006-05</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>?</td>\n",
       "      <td>Stanford University School of Medicine</td>\n",
       "      <td>Stanford</td>\n",
       "      <td>California</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>NCT00005079</td>\n",
       "      <td>UCLA-9810046</td>\n",
       "      <td>Timing of Breast Cancer Surgery, Menstrual Cyc...</td>\n",
       "      <td>National Cancer Institute (NCI)</td>\n",
       "      <td>Jonsson Comprehensive Cancer Center</td>\n",
       "      <td>National Cancer Institute (NCI)</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>1999-01</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>?</td>\n",
       "      <td>Rebecca and John Moores UCSD Cancer Center, Jo...</td>\n",
       "      <td>La Jolla, Los Angeles</td>\n",
       "      <td>California, California</td>\n",
       "      <td>United States, United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>NCT05108779</td>\n",
       "      <td>QLF32004-101</td>\n",
       "      <td>Phase Ia Clinical Study of Safety, Tolerabilit...</td>\n",
       "      <td>Qilu Pharmaceutical Co., Ltd.</td>\n",
       "      <td>Qilu Pharmaceutical Co., Ltd.</td>\n",
       "      <td>NaN</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>UNKNOWN</td>\n",
       "      <td>2021-11-09</td>\n",
       "      <td>...</td>\n",
       "      <td>Jin Li</td>\n",
       "      <td>CONTACT</td>\n",
       "      <td>021-38804518</td>\n",
       "      <td>?</td>\n",
       "      <td>sunypclinicaltrial@163.com</td>\n",
       "      <td>?</td>\n",
       "      <td>Shanghai East Hospital</td>\n",
       "      <td>Shanghai</td>\n",
       "      <td>Shanghai</td>\n",
       "      <td>China</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>NCT00398879</td>\n",
       "      <td>Perifosine 211</td>\n",
       "      <td>A Randomized Placebo-Controlled Study of Perif...</td>\n",
       "      <td>AEterna Zentaris</td>\n",
       "      <td>AEterna Zentaris</td>\n",
       "      <td>NaN</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>2005-08</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>?</td>\n",
       "      <td>AOI Pharmaceuticals Investigative Site, AOI Ph...</td>\n",
       "      <td>Tucson, Beverly Hills, Deer Park, Monterey, Ne...</td>\n",
       "      <td>Arizona, California, California, California, C...</td>\n",
       "      <td>United States, United States, United States, U...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>10 rows × 45 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "         nctid      orgstudyid  \\\n",
       "0  NCT03878979           J1923   \n",
       "1  NCT04591379    REG-083-2020   \n",
       "2  NCT06671379   SHR-A2009-301   \n",
       "3  NCT04361279      SIBP-02-03   \n",
       "4  NCT05799079     VICCHEM2163   \n",
       "5  NCT04164979        20195426   \n",
       "6  NCT00313079      HEMALL0003   \n",
       "7  NCT00005079    UCLA-9810046   \n",
       "8  NCT05108779    QLF32004-101   \n",
       "9  NCT00398879  Perifosine 211   \n",
       "\n",
       "                                               title  \\\n",
       "0  Preoperative Immune Checkpoint Inhibitor Thera...   \n",
       "1  Intratumoral Influenza Vaccine for Early Color...   \n",
       "2  A Randomized, Open-label, Multicenter, Phase I...   \n",
       "3  A Phase III, Multicenter, Randomized, Double-b...   \n",
       "4  Phase 2 Study of Decitabine and Cedazuridine i...   \n",
       "5  Phase 2 Study of Cabozantinib Combined With Pe...   \n",
       "6  A Phase I Study of mAb 216 With Chemotherapy f...   \n",
       "7  Timing of Breast Cancer Surgery, Menstrual Cyc...   \n",
       "8  Phase Ia Clinical Study of Safety, Tolerabilit...   \n",
       "9  A Randomized Placebo-Controlled Study of Perif...   \n",
       "\n",
       "                               organization_fullname  \\\n",
       "0  Sidney Kimmel Comprehensive Cancer Center at J...   \n",
       "1                        Zealand University Hospital   \n",
       "2       Suzhou Suncadia Biopharmaceuticals Co., Ltd.   \n",
       "3          Shanghai Institute Of Biological Products   \n",
       "4                    Vanderbilt-Ingram Cancer Center   \n",
       "5                   University of California, Irvine   \n",
       "6                                Stanford University   \n",
       "7                    National Cancer Institute (NCI)   \n",
       "8                      Qilu Pharmaceutical Co., Ltd.   \n",
       "9                                   AEterna Zentaris   \n",
       "\n",
       "                                         leadsponsor  \\\n",
       "0  Sidney Kimmel Comprehensive Cancer Center at J...   \n",
       "1                        Zealand University Hospital   \n",
       "2       Suzhou Suncadia Biopharmaceuticals Co., Ltd.   \n",
       "3          Shanghai Institute Of Biological Products   \n",
       "4                                       Sanjay Mohan   \n",
       "5                   University of California, Irvine   \n",
       "6                                   Steven E. Coutre   \n",
       "7                Jonsson Comprehensive Cancer Center   \n",
       "8                      Qilu Pharmaceutical Co., Ltd.   \n",
       "9                                   AEterna Zentaris   \n",
       "\n",
       "                                       collaborators       studytype   phase  \\\n",
       "0                               Bristol-Myers Squibb  INTERVENTIONAL  PHASE2   \n",
       "1                           University of Copenhagen  INTERVENTIONAL  PHASE2   \n",
       "2                                                NaN  INTERVENTIONAL  PHASE3   \n",
       "3                                                NaN  INTERVENTIONAL  PHASE3   \n",
       "4  National Comprehensive Cancer Network, Taiho O...  INTERVENTIONAL  PHASE2   \n",
       "5                                           Exelixis  INTERVENTIONAL  PHASE2   \n",
       "6                                                NaN  INTERVENTIONAL  PHASE1   \n",
       "7                    National Cancer Institute (NCI)  INTERVENTIONAL  PHASE3   \n",
       "8                                                NaN  INTERVENTIONAL  PHASE1   \n",
       "9                                                NaN  INTERVENTIONAL  PHASE2   \n",
       "\n",
       "           overallstatus   startdate  ...  \\\n",
       "0              COMPLETED  2019-07-08  ...   \n",
       "1              COMPLETED  2021-02-26  ...   \n",
       "2             RECRUITING  2024-11-29  ...   \n",
       "3              COMPLETED  2019-07-25  ...   \n",
       "4             RECRUITING  2024-01-29  ...   \n",
       "5  ACTIVE_NOT_RECRUITING  2020-02-04  ...   \n",
       "6              COMPLETED     2006-05  ...   \n",
       "7              COMPLETED     1999-01  ...   \n",
       "8                UNKNOWN  2021-11-09  ...   \n",
       "9              COMPLETED     2005-08  ...   \n",
       "\n",
       "                            centralcontact_name centralcontact_role  \\\n",
       "0                                           NaN                 NaN   \n",
       "1                                           NaN                 NaN   \n",
       "2                                       Fei Qiu             CONTACT   \n",
       "3                                           NaN                 NaN   \n",
       "4  Vanderbilt-Ingram Services for Timely Access             CONTACT   \n",
       "5                                           NaN                 NaN   \n",
       "6                                           NaN                 NaN   \n",
       "7                                           NaN                 NaN   \n",
       "8                                        Jin Li             CONTACT   \n",
       "9                                           NaN                 NaN   \n",
       "\n",
       "  centralcontact_phone centralcontact_phoneext        centralcontact_email  \\\n",
       "0                  NaN                     NaN                         NaN   \n",
       "1                  NaN                     NaN                         NaN   \n",
       "2        0518-82342973                       ?         fei.qiu@hengrui.com   \n",
       "3                  NaN                     NaN                         NaN   \n",
       "4         800-811-8480                       ?                cip@vumc.org   \n",
       "5                  NaN                     NaN                         NaN   \n",
       "6                  NaN                     NaN                         NaN   \n",
       "7                  NaN                     NaN                         NaN   \n",
       "8         021-38804518                       ?  sunypclinicaltrial@163.com   \n",
       "9                  NaN                     NaN                         NaN   \n",
       "\n",
       "  numcentralcontacts                                  location_facility  \\\n",
       "0                  ?  Johns Hopkins Sidney Kimmel Comprehensive Canc...   \n",
       "1                  ?                        Zealand University Hospital   \n",
       "2                  ?             Guangdong Provincial People's Hospital   \n",
       "3                  ?  The First Affiliated Hospital of College of Me...   \n",
       "4                  ?         Vanderbilt University/Ingram Cancer Center   \n",
       "5                  ?  Chao Family Comprehensive Cancer Center, Unive...   \n",
       "6                  ?             Stanford University School of Medicine   \n",
       "7                  ?  Rebecca and John Moores UCSD Cancer Center, Jo...   \n",
       "8                  ?                             Shanghai East Hospital   \n",
       "9                  ?  AOI Pharmaceuticals Investigative Site, AOI Ph...   \n",
       "\n",
       "                                       location_city  \\\n",
       "0                                          Baltimore   \n",
       "1                                               Køge   \n",
       "2                                          Guangzhou   \n",
       "3                                           Hangzhou   \n",
       "4                                          Nashville   \n",
       "5                                             Orange   \n",
       "6                                           Stanford   \n",
       "7                              La Jolla, Los Angeles   \n",
       "8                                           Shanghai   \n",
       "9  Tucson, Beverly Hills, Deer Park, Monterey, Ne...   \n",
       "\n",
       "                                      location_state  \\\n",
       "0                                           Maryland   \n",
       "1                                            Zealand   \n",
       "2                                          Guangdong   \n",
       "3                                                  ?   \n",
       "4                                          Tennessee   \n",
       "5                                         California   \n",
       "6                                         California   \n",
       "7                             California, California   \n",
       "8                                           Shanghai   \n",
       "9  Arizona, California, California, California, C...   \n",
       "\n",
       "                                    location_country  \n",
       "0                                      United States  \n",
       "1                                            Denmark  \n",
       "2                                              China  \n",
       "3                                              China  \n",
       "4                                      United States  \n",
       "5                                      United States  \n",
       "6                                      United States  \n",
       "7                       United States, United States  \n",
       "8                                              China  \n",
       "9  United States, United States, United States, U...  \n",
       "\n",
       "[10 rows x 45 columns]"
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df = pd.read_csv('/home/haider/Desktop/Office/Python/Projects/clinical-trials-analysis/data/updated_cancer_trials.csv')\n",
    "df.head(10)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "496d96b9",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(60687, 45)"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "7c70a28c",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['nctid', 'orgstudyid', 'title', 'organization_fullname', 'leadsponsor',\n",
       "       'collaborators', 'studytype', 'phase', 'overallstatus', 'startdate',\n",
       "       'completiondate', 'primarycompletiondate', 'studyfirstsubmitdate',\n",
       "       'studyfirstpostdate', 'lastupdatepostdate', 'enrollment',\n",
       "       'projectedaccrual', 'eligibilitycriteria', 'designprimarypurpose',\n",
       "       'briefsummary', 'detaileddescription', 'sex', 'minimumage',\n",
       "       'maximumage', 'stdage', 'country', 'conditions', 'keywords',\n",
       "       'interventions_name', 'interventions_description', 'primary_outcomes',\n",
       "       'secondary_outcomes', 'overallofficials_name',\n",
       "       'overallofficials_affiliation', 'oversighthasdmc',\n",
       "       'centralcontact_name', 'centralcontact_role', 'centralcontact_phone',\n",
       "       'centralcontact_phoneext', 'centralcontact_email', 'numcentralcontacts',\n",
       "       'location_facility', 'location_city', 'location_state',\n",
       "       'location_country'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "4f52196e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "nctid                           object\n",
       "orgstudyid                      object\n",
       "title                           object\n",
       "organization_fullname           object\n",
       "leadsponsor                     object\n",
       "collaborators                   object\n",
       "studytype                       object\n",
       "phase                           object\n",
       "overallstatus                   object\n",
       "startdate                       object\n",
       "completiondate                  object\n",
       "primarycompletiondate           object\n",
       "studyfirstsubmitdate            object\n",
       "studyfirstpostdate              object\n",
       "lastupdatepostdate              object\n",
       "enrollment                      object\n",
       "projectedaccrual                object\n",
       "eligibilitycriteria             object\n",
       "designprimarypurpose            object\n",
       "briefsummary                    object\n",
       "detaileddescription             object\n",
       "sex                             object\n",
       "minimumage                      object\n",
       "maximumage                      object\n",
       "stdage                          object\n",
       "country                         object\n",
       "conditions                      object\n",
       "keywords                        object\n",
       "interventions_name              object\n",
       "interventions_description       object\n",
       "primary_outcomes                object\n",
       "secondary_outcomes              object\n",
       "overallofficials_name           object\n",
       "overallofficials_affiliation    object\n",
       "oversighthasdmc                 object\n",
       "centralcontact_name             object\n",
       "centralcontact_role             object\n",
       "centralcontact_phone            object\n",
       "centralcontact_phoneext         object\n",
       "centralcontact_email            object\n",
       "numcentralcontacts              object\n",
       "location_facility               object\n",
       "location_city                   object\n",
       "location_state                  object\n",
       "location_country                object\n",
       "dtype: object"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.dtypes"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "ccf5fe74",
   "metadata": {},
   "source": [
    "### Data Cleaning Phase"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "bb93372e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0         True\n",
       "1         True\n",
       "2            ?\n",
       "3            ?\n",
       "4         True\n",
       "         ...  \n",
       "60682     True\n",
       "60683     True\n",
       "60684    False\n",
       "60685    False\n",
       "60686        ?\n",
       "Name: oversighthasdmc, Length: 60687, dtype: object"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['oversighthasdmc']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "a3dae04f",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0        2023-10-17\n",
       "1        2021-11-01\n",
       "2           2027-06\n",
       "3        2022-05-20\n",
       "4           2029-03\n",
       "            ...    \n",
       "60682    2022-02-21\n",
       "60683    2023-10-11\n",
       "60684       2010-06\n",
       "60685    2020-09-18\n",
       "60686             ?\n",
       "Name: completiondate, Length: 60687, dtype: object"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['completiondate']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "fcd8bc5b",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0        2023-10-17\n",
       "1        2021-09-22\n",
       "2           2026-12\n",
       "3        2022-05-20\n",
       "4           2028-03\n",
       "            ...    \n",
       "60682    2022-02-21\n",
       "60683    2023-10-11\n",
       "60684       2009-11\n",
       "60685    2020-09-18\n",
       "60686       2011-04\n",
       "Name: primarycompletiondate, Length: 60687, dtype: object"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['primarycompletiondate']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "570e7029",
   "metadata": {},
   "outputs": [],
   "source": [
    "df.drop('projectedaccrual',axis=1,inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "5fec18da",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0                   Nivolumab 480mg and surgical resection\n",
       "1                                       Influenza Vaccines\n",
       "2        SHR-A2009 monotherapy, platinum-based dual-age...\n",
       "3                                       SIBP-02, Rituximab\n",
       "4        Venetoclax, Decitabine, Cedazuridine, Bone Mar...\n",
       "                               ...                        \n",
       "60682    Bintrafusp Alfa, Pemetrexed, Carboplatin, Cisp...\n",
       "60683    Extracorporeal Photopheresis, Mogamulizumab, Q...\n",
       "60684                              Ispaghula husk, Placebo\n",
       "60685                                            Alphanate\n",
       "60686    obatoclax mesylate, bortezomib, laboratory bio...\n",
       "Name: interventions_name, Length: 60687, dtype: object"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['interventions_name']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "a6668b28",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0                                   Tanguy Lim-Seiwert, MD\n",
       "1                                Ismail Gögenur, Professor\n",
       "2                                                      NaN\n",
       "3        Shanghai Institute Of Biological Products Co.,...\n",
       "4                                         Sanjay Mohan, MD\n",
       "                               ...                        \n",
       "60682                                           Xiuning Le\n",
       "60683                                       Pamela B Allen\n",
       "60684    Jordi Salas, MD, PhD, Luis Peña, MD, PhD, Marg...\n",
       "60685                                                  NaN\n",
       "60686                                       Joseph Tuscano\n",
       "Name: overallofficials_name, Length: 60687, dtype: object"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['overallofficials_name']"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "607b00b2",
   "metadata": {},
   "source": [
    "#### Renaming Columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "21fbb0e6",
   "metadata": {},
   "outputs": [],
   "source": [
    "df.rename(columns={\n",
    "    'overallstatus': 'overall_status',\n",
    "    'leadsponsor':'lead_sponsor',\n",
    "    'overallofficials_name': 'overall_officials_name',\n",
    "    'overallofficials_affiliation': 'overall_officials_affiliation',\n",
    "    'oversighthasdmc': 'oversight_has_dmc',\n",
    "    'completiondate': 'completion_date',\n",
    "    'primarycompletiondate': 'primary_completion_date',\n",
    "    'studyfirstsubmitdate': 'study_first_submit_date',\n",
    "    'studyfirstpostdate': 'study_first_post_date',\n",
    "    'lastupdatepostdate': 'last_update_post_date',\n",
    "    'eligibilitycriteria': 'eligibility_criteria',\n",
    "    'designprimarypurpose': 'design_primary_purpose',\n",
    "    'briefsummary': 'brief_summary',\n",
    "    'detaileddescription': 'detailed_description',\n",
    "    'startdate': 'start_date',\n",
    "    'studytype': 'study_type',\n",
    "    'minimumage': 'minimum_age',\n",
    "    'maximumage': 'maximum_age',\n",
    "    'numcentralcontacts': 'num_central_contacts'\n",
    "}, inplace=True)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "28a377d9",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nctid</th>\n",
       "      <th>orgstudyid</th>\n",
       "      <th>title</th>\n",
       "      <th>organization_fullname</th>\n",
       "      <th>lead_sponsor</th>\n",
       "      <th>collaborators</th>\n",
       "      <th>study_type</th>\n",
       "      <th>phase</th>\n",
       "      <th>overall_status</th>\n",
       "      <th>start_date</th>\n",
       "      <th>...</th>\n",
       "      <th>centralcontact_name</th>\n",
       "      <th>centralcontact_role</th>\n",
       "      <th>centralcontact_phone</th>\n",
       "      <th>centralcontact_phoneext</th>\n",
       "      <th>centralcontact_email</th>\n",
       "      <th>num_central_contacts</th>\n",
       "      <th>location_facility</th>\n",
       "      <th>location_city</th>\n",
       "      <th>location_state</th>\n",
       "      <th>location_country</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT03878979</td>\n",
       "      <td>J1923</td>\n",
       "      <td>Preoperative Immune Checkpoint Inhibitor Thera...</td>\n",
       "      <td>Sidney Kimmel Comprehensive Cancer Center at J...</td>\n",
       "      <td>Sidney Kimmel Comprehensive Cancer Center at J...</td>\n",
       "      <td>Bristol-Myers Squibb</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>2019-07-08</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>?</td>\n",
       "      <td>Johns Hopkins Sidney Kimmel Comprehensive Canc...</td>\n",
       "      <td>Baltimore</td>\n",
       "      <td>Maryland</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT04591379</td>\n",
       "      <td>REG-083-2020</td>\n",
       "      <td>Intratumoral Influenza Vaccine for Early Color...</td>\n",
       "      <td>Zealand University Hospital</td>\n",
       "      <td>Zealand University Hospital</td>\n",
       "      <td>University of Copenhagen</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>2021-02-26</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>?</td>\n",
       "      <td>Zealand University Hospital</td>\n",
       "      <td>Køge</td>\n",
       "      <td>Zealand</td>\n",
       "      <td>Denmark</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT06671379</td>\n",
       "      <td>SHR-A2009-301</td>\n",
       "      <td>A Randomized, Open-label, Multicenter, Phase I...</td>\n",
       "      <td>Suzhou Suncadia Biopharmaceuticals Co., Ltd.</td>\n",
       "      <td>Suzhou Suncadia Biopharmaceuticals Co., Ltd.</td>\n",
       "      <td>NaN</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>2024-11-29</td>\n",
       "      <td>...</td>\n",
       "      <td>Fei Qiu</td>\n",
       "      <td>CONTACT</td>\n",
       "      <td>0518-82342973</td>\n",
       "      <td>?</td>\n",
       "      <td>fei.qiu@hengrui.com</td>\n",
       "      <td>?</td>\n",
       "      <td>Guangdong Provincial People's Hospital</td>\n",
       "      <td>Guangzhou</td>\n",
       "      <td>Guangdong</td>\n",
       "      <td>China</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT04361279</td>\n",
       "      <td>SIBP-02-03</td>\n",
       "      <td>A Phase III, Multicenter, Randomized, Double-b...</td>\n",
       "      <td>Shanghai Institute Of Biological Products</td>\n",
       "      <td>Shanghai Institute Of Biological Products</td>\n",
       "      <td>NaN</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>2019-07-25</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>?</td>\n",
       "      <td>The First Affiliated Hospital of College of Me...</td>\n",
       "      <td>Hangzhou</td>\n",
       "      <td>?</td>\n",
       "      <td>China</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT05799079</td>\n",
       "      <td>VICCHEM2163</td>\n",
       "      <td>Phase 2 Study of Decitabine and Cedazuridine i...</td>\n",
       "      <td>Vanderbilt-Ingram Cancer Center</td>\n",
       "      <td>Sanjay Mohan</td>\n",
       "      <td>National Comprehensive Cancer Network, Taiho O...</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>2024-01-29</td>\n",
       "      <td>...</td>\n",
       "      <td>Vanderbilt-Ingram Services for Timely Access</td>\n",
       "      <td>CONTACT</td>\n",
       "      <td>800-811-8480</td>\n",
       "      <td>?</td>\n",
       "      <td>cip@vumc.org</td>\n",
       "      <td>?</td>\n",
       "      <td>Vanderbilt University/Ingram Cancer Center</td>\n",
       "      <td>Nashville</td>\n",
       "      <td>Tennessee</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>NCT04164979</td>\n",
       "      <td>20195426</td>\n",
       "      <td>Phase 2 Study of Cabozantinib Combined With Pe...</td>\n",
       "      <td>University of California, Irvine</td>\n",
       "      <td>University of California, Irvine</td>\n",
       "      <td>Exelixis</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>2020-02-04</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>?</td>\n",
       "      <td>Chao Family Comprehensive Cancer Center, Unive...</td>\n",
       "      <td>Orange</td>\n",
       "      <td>California</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>NCT00313079</td>\n",
       "      <td>HEMALL0003</td>\n",
       "      <td>A Phase I Study of mAb 216 With Chemotherapy f...</td>\n",
       "      <td>Stanford University</td>\n",
       "      <td>Steven E. Coutre</td>\n",
       "      <td>NaN</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>2006-05</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>?</td>\n",
       "      <td>Stanford University School of Medicine</td>\n",
       "      <td>Stanford</td>\n",
       "      <td>California</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>NCT00005079</td>\n",
       "      <td>UCLA-9810046</td>\n",
       "      <td>Timing of Breast Cancer Surgery, Menstrual Cyc...</td>\n",
       "      <td>National Cancer Institute (NCI)</td>\n",
       "      <td>Jonsson Comprehensive Cancer Center</td>\n",
       "      <td>National Cancer Institute (NCI)</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>1999-01</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>?</td>\n",
       "      <td>Rebecca and John Moores UCSD Cancer Center, Jo...</td>\n",
       "      <td>La Jolla, Los Angeles</td>\n",
       "      <td>California, California</td>\n",
       "      <td>United States, United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>NCT05108779</td>\n",
       "      <td>QLF32004-101</td>\n",
       "      <td>Phase Ia Clinical Study of Safety, Tolerabilit...</td>\n",
       "      <td>Qilu Pharmaceutical Co., Ltd.</td>\n",
       "      <td>Qilu Pharmaceutical Co., Ltd.</td>\n",
       "      <td>NaN</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>UNKNOWN</td>\n",
       "      <td>2021-11-09</td>\n",
       "      <td>...</td>\n",
       "      <td>Jin Li</td>\n",
       "      <td>CONTACT</td>\n",
       "      <td>021-38804518</td>\n",
       "      <td>?</td>\n",
       "      <td>sunypclinicaltrial@163.com</td>\n",
       "      <td>?</td>\n",
       "      <td>Shanghai East Hospital</td>\n",
       "      <td>Shanghai</td>\n",
       "      <td>Shanghai</td>\n",
       "      <td>China</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>NCT00398879</td>\n",
       "      <td>Perifosine 211</td>\n",
       "      <td>A Randomized Placebo-Controlled Study of Perif...</td>\n",
       "      <td>AEterna Zentaris</td>\n",
       "      <td>AEterna Zentaris</td>\n",
       "      <td>NaN</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>2005-08</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>?</td>\n",
       "      <td>AOI Pharmaceuticals Investigative Site, AOI Ph...</td>\n",
       "      <td>Tucson, Beverly Hills, Deer Park, Monterey, Ne...</td>\n",
       "      <td>Arizona, California, California, California, C...</td>\n",
       "      <td>United States, United States, United States, U...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>10 rows × 44 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "         nctid      orgstudyid  \\\n",
       "0  NCT03878979           J1923   \n",
       "1  NCT04591379    REG-083-2020   \n",
       "2  NCT06671379   SHR-A2009-301   \n",
       "3  NCT04361279      SIBP-02-03   \n",
       "4  NCT05799079     VICCHEM2163   \n",
       "5  NCT04164979        20195426   \n",
       "6  NCT00313079      HEMALL0003   \n",
       "7  NCT00005079    UCLA-9810046   \n",
       "8  NCT05108779    QLF32004-101   \n",
       "9  NCT00398879  Perifosine 211   \n",
       "\n",
       "                                               title  \\\n",
       "0  Preoperative Immune Checkpoint Inhibitor Thera...   \n",
       "1  Intratumoral Influenza Vaccine for Early Color...   \n",
       "2  A Randomized, Open-label, Multicenter, Phase I...   \n",
       "3  A Phase III, Multicenter, Randomized, Double-b...   \n",
       "4  Phase 2 Study of Decitabine and Cedazuridine i...   \n",
       "5  Phase 2 Study of Cabozantinib Combined With Pe...   \n",
       "6  A Phase I Study of mAb 216 With Chemotherapy f...   \n",
       "7  Timing of Breast Cancer Surgery, Menstrual Cyc...   \n",
       "8  Phase Ia Clinical Study of Safety, Tolerabilit...   \n",
       "9  A Randomized Placebo-Controlled Study of Perif...   \n",
       "\n",
       "                               organization_fullname  \\\n",
       "0  Sidney Kimmel Comprehensive Cancer Center at J...   \n",
       "1                        Zealand University Hospital   \n",
       "2       Suzhou Suncadia Biopharmaceuticals Co., Ltd.   \n",
       "3          Shanghai Institute Of Biological Products   \n",
       "4                    Vanderbilt-Ingram Cancer Center   \n",
       "5                   University of California, Irvine   \n",
       "6                                Stanford University   \n",
       "7                    National Cancer Institute (NCI)   \n",
       "8                      Qilu Pharmaceutical Co., Ltd.   \n",
       "9                                   AEterna Zentaris   \n",
       "\n",
       "                                        lead_sponsor  \\\n",
       "0  Sidney Kimmel Comprehensive Cancer Center at J...   \n",
       "1                        Zealand University Hospital   \n",
       "2       Suzhou Suncadia Biopharmaceuticals Co., Ltd.   \n",
       "3          Shanghai Institute Of Biological Products   \n",
       "4                                       Sanjay Mohan   \n",
       "5                   University of California, Irvine   \n",
       "6                                   Steven E. Coutre   \n",
       "7                Jonsson Comprehensive Cancer Center   \n",
       "8                      Qilu Pharmaceutical Co., Ltd.   \n",
       "9                                   AEterna Zentaris   \n",
       "\n",
       "                                       collaborators      study_type   phase  \\\n",
       "0                               Bristol-Myers Squibb  INTERVENTIONAL  PHASE2   \n",
       "1                           University of Copenhagen  INTERVENTIONAL  PHASE2   \n",
       "2                                                NaN  INTERVENTIONAL  PHASE3   \n",
       "3                                                NaN  INTERVENTIONAL  PHASE3   \n",
       "4  National Comprehensive Cancer Network, Taiho O...  INTERVENTIONAL  PHASE2   \n",
       "5                                           Exelixis  INTERVENTIONAL  PHASE2   \n",
       "6                                                NaN  INTERVENTIONAL  PHASE1   \n",
       "7                    National Cancer Institute (NCI)  INTERVENTIONAL  PHASE3   \n",
       "8                                                NaN  INTERVENTIONAL  PHASE1   \n",
       "9                                                NaN  INTERVENTIONAL  PHASE2   \n",
       "\n",
       "          overall_status  start_date  ...  \\\n",
       "0              COMPLETED  2019-07-08  ...   \n",
       "1              COMPLETED  2021-02-26  ...   \n",
       "2             RECRUITING  2024-11-29  ...   \n",
       "3              COMPLETED  2019-07-25  ...   \n",
       "4             RECRUITING  2024-01-29  ...   \n",
       "5  ACTIVE_NOT_RECRUITING  2020-02-04  ...   \n",
       "6              COMPLETED     2006-05  ...   \n",
       "7              COMPLETED     1999-01  ...   \n",
       "8                UNKNOWN  2021-11-09  ...   \n",
       "9              COMPLETED     2005-08  ...   \n",
       "\n",
       "                            centralcontact_name centralcontact_role  \\\n",
       "0                                           NaN                 NaN   \n",
       "1                                           NaN                 NaN   \n",
       "2                                       Fei Qiu             CONTACT   \n",
       "3                                           NaN                 NaN   \n",
       "4  Vanderbilt-Ingram Services for Timely Access             CONTACT   \n",
       "5                                           NaN                 NaN   \n",
       "6                                           NaN                 NaN   \n",
       "7                                           NaN                 NaN   \n",
       "8                                        Jin Li             CONTACT   \n",
       "9                                           NaN                 NaN   \n",
       "\n",
       "  centralcontact_phone centralcontact_phoneext        centralcontact_email  \\\n",
       "0                  NaN                     NaN                         NaN   \n",
       "1                  NaN                     NaN                         NaN   \n",
       "2        0518-82342973                       ?         fei.qiu@hengrui.com   \n",
       "3                  NaN                     NaN                         NaN   \n",
       "4         800-811-8480                       ?                cip@vumc.org   \n",
       "5                  NaN                     NaN                         NaN   \n",
       "6                  NaN                     NaN                         NaN   \n",
       "7                  NaN                     NaN                         NaN   \n",
       "8         021-38804518                       ?  sunypclinicaltrial@163.com   \n",
       "9                  NaN                     NaN                         NaN   \n",
       "\n",
       "  num_central_contacts                                  location_facility  \\\n",
       "0                    ?  Johns Hopkins Sidney Kimmel Comprehensive Canc...   \n",
       "1                    ?                        Zealand University Hospital   \n",
       "2                    ?             Guangdong Provincial People's Hospital   \n",
       "3                    ?  The First Affiliated Hospital of College of Me...   \n",
       "4                    ?         Vanderbilt University/Ingram Cancer Center   \n",
       "5                    ?  Chao Family Comprehensive Cancer Center, Unive...   \n",
       "6                    ?             Stanford University School of Medicine   \n",
       "7                    ?  Rebecca and John Moores UCSD Cancer Center, Jo...   \n",
       "8                    ?                             Shanghai East Hospital   \n",
       "9                    ?  AOI Pharmaceuticals Investigative Site, AOI Ph...   \n",
       "\n",
       "                                       location_city  \\\n",
       "0                                          Baltimore   \n",
       "1                                               Køge   \n",
       "2                                          Guangzhou   \n",
       "3                                           Hangzhou   \n",
       "4                                          Nashville   \n",
       "5                                             Orange   \n",
       "6                                           Stanford   \n",
       "7                              La Jolla, Los Angeles   \n",
       "8                                           Shanghai   \n",
       "9  Tucson, Beverly Hills, Deer Park, Monterey, Ne...   \n",
       "\n",
       "                                      location_state  \\\n",
       "0                                           Maryland   \n",
       "1                                            Zealand   \n",
       "2                                          Guangdong   \n",
       "3                                                  ?   \n",
       "4                                          Tennessee   \n",
       "5                                         California   \n",
       "6                                         California   \n",
       "7                             California, California   \n",
       "8                                           Shanghai   \n",
       "9  Arizona, California, California, California, C...   \n",
       "\n",
       "                                    location_country  \n",
       "0                                      United States  \n",
       "1                                            Denmark  \n",
       "2                                              China  \n",
       "3                                              China  \n",
       "4                                      United States  \n",
       "5                                      United States  \n",
       "6                                      United States  \n",
       "7                       United States, United States  \n",
       "8                                              China  \n",
       "9  United States, United States, United States, U...  \n",
       "\n",
       "[10 rows x 44 columns]"
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.head(10)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "a8e54541",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['nctid', 'orgstudyid', 'title', 'organization_fullname', 'lead_sponsor',\n",
       "       'collaborators', 'study_type', 'phase', 'overall_status', 'start_date',\n",
       "       'completion_date', 'primary_completion_date', 'study_first_submit_date',\n",
       "       'study_first_post_date', 'last_update_post_date', 'enrollment',\n",
       "       'eligibility_criteria', 'design_primary_purpose', 'brief_summary',\n",
       "       'detailed_description', 'sex', 'minimum_age', 'maximum_age', 'stdage',\n",
       "       'country', 'conditions', 'keywords', 'interventions_name',\n",
       "       'interventions_description', 'primary_outcomes', 'secondary_outcomes',\n",
       "       'overall_officials_name', 'overall_officials_affiliation',\n",
       "       'oversight_has_dmc', 'centralcontact_name', 'centralcontact_role',\n",
       "       'centralcontact_phone', 'centralcontact_phoneext',\n",
       "       'centralcontact_email', 'num_central_contacts', 'location_facility',\n",
       "       'location_city', 'location_state', 'location_country'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "512cc5dc",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Number of duplicate rows with same title and phase: 186\n"
     ]
    }
   ],
   "source": [
    "duplicate_count = df.duplicated(subset=['title', 'phase']).sum()\n",
    "print(f\"Number of duplicate rows with same title and phase: {duplicate_count}\")\n",
    "\n",
    "# duplicate_rows.to_csv('duplicate_titles.csv', index=False)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "4e72af34",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Dataframe shape after removing duplicates: (60501, 44)\n"
     ]
    }
   ],
   "source": [
    "df = df.drop_duplicates(subset=['title', 'phase'], keep='first')\n",
    "print(f\"Dataframe shape after removing duplicates: {df.shape}\")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "792e627c",
   "metadata": {},
   "source": [
    "Dropping unnecessary columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "a8ad7392",
   "metadata": {},
   "outputs": [],
   "source": [
    "df.drop(['nctid', 'orgstudyid','title','centralcontact_name','centralcontact_role','centralcontact_phone','centralcontact_phoneext','centralcontact_email','num_central_contacts'], axis=1, inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "5e1df37e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['organization_fullname', 'lead_sponsor', 'collaborators', 'study_type',\n",
       "       'phase', 'overall_status', 'start_date', 'completion_date',\n",
       "       'primary_completion_date', 'study_first_submit_date',\n",
       "       'study_first_post_date', 'last_update_post_date', 'enrollment',\n",
       "       'eligibility_criteria', 'design_primary_purpose', 'brief_summary',\n",
       "       'detailed_description', 'sex', 'minimum_age', 'maximum_age', 'stdage',\n",
       "       'country', 'conditions', 'keywords', 'interventions_name',\n",
       "       'interventions_description', 'primary_outcomes', 'secondary_outcomes',\n",
       "       'overall_officials_name', 'overall_officials_affiliation',\n",
       "       'oversight_has_dmc', 'location_facility', 'location_city',\n",
       "       'location_state', 'location_country'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.columns"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "9bdc7ca0",
   "metadata": {},
   "source": [
    "checking if the location of the organization and the location of the facility are the same to see correlation "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "a48244b2",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>organization_fullname</th>\n",
       "      <th>location_facility</th>\n",
       "      <th>is_same</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Sidney Kimmel Comprehensive Cancer Center at J...</td>\n",
       "      <td>Sidney Kimmel Comprehensive Cancer Center at J...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Zealand University Hospital</td>\n",
       "      <td>Zealand University Hospital</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Suzhou Suncadia Biopharmaceuticals Co., Ltd.</td>\n",
       "      <td>Guangdong Provincial People's Hospital</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Shanghai Institute Of Biological Products</td>\n",
       "      <td>The First Affiliated Hospital of College of Me...</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Vanderbilt-Ingram Cancer Center</td>\n",
       "      <td>Vanderbilt University/Ingram Cancer Center</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Chao Family Comprehensive Cancer Center, Unive...</td>\n",
       "      <td>Chao Family Comprehensive Cancer Center, Unive...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Stanford University School of Medicine</td>\n",
       "      <td>Stanford University School of Medicine</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>National Cancer Institute (NCI)</td>\n",
       "      <td>Rebecca and John Moores UCSD Cancer Center, Jo...</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Qilu Pharmaceutical Co., Ltd.</td>\n",
       "      <td>Shanghai East Hospital</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>AEterna Zentaris</td>\n",
       "      <td>AOI Pharmaceuticals Investigative Site, AOI Ph...</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>Prism Pharma Co., Ltd.</td>\n",
       "      <td>Emory University / Winship Cancer Institute, U...</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Martin-Luther-Universität Halle-Wittenberg</td>\n",
       "      <td>Universitaetsklinikum Halle</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>University of Texas Southwestern Medical Center</td>\n",
       "      <td>University of Texas Southwestern Medical Center</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>Beijing Tsinghua Chang Gung Hospital</td>\n",
       "      <td>Beijing Tsinghua Chang Gung Hospital</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>National Institutes of Health Clinical Center ...</td>\n",
       "      <td>National Naval Medical Center, Warren Grant Ma...</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>University Hospital, Basel, Switzerland</td>\n",
       "      <td>Carsten T. Viehl, MD, Urban Laffer, MD, Markus...</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>St. Jude Children's Research Hospital</td>\n",
       "      <td>St. Jude Children's Research Hospital</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>Emory University Winship Cancer Institute</td>\n",
       "      <td>Emory University Winship Cancer Institute</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>Dana-Farber Cancer Institute</td>\n",
       "      <td>Brigham and Women's Hospital, Dana Farber Canc...</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>Juntendo Urayasu Hospital, St. Marianna Univer...</td>\n",
       "      <td>Juntendo Urayasu Hospital, St. Marianna Univer...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>Sunnybrook Health Sciences Centre</td>\n",
       "      <td>Sunnybrook Health Sciences Centre</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>Aarhus University Hospital</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>University Health Network, Toronto</td>\n",
       "      <td>Princess Margaret Cancer Centre</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>Cure&amp;Sure Biotech Co., LTD</td>\n",
       "      <td>Cancer Insititute and Hospital,Chinese Academy...</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>GOG Foundation</td>\n",
       "      <td>CCOP - Western Regional, Arizona, CCOP - Chris...</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>M.D. Anderson Cancer Center</td>\n",
       "      <td>M.D. Anderson Cancer Center</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>Emory University Winship Cancer Institute, The...</td>\n",
       "      <td>Emory University Winship Cancer Institute, The...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>Shenzhen Yangli Pharmaceutical Technology Co.,...</td>\n",
       "      <td>The 1st Affiliated Hospital of Henan Universit...</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>Dong-A University</td>\n",
       "      <td>Dong-A University</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>Sunshine Guojian Pharmaceutical (Shanghai) Co....</td>\n",
       "      <td>The 307 Hospital of People's Liberation Army, ...</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                organization_fullname  \\\n",
       "0   Sidney Kimmel Comprehensive Cancer Center at J...   \n",
       "1                         Zealand University Hospital   \n",
       "2        Suzhou Suncadia Biopharmaceuticals Co., Ltd.   \n",
       "3           Shanghai Institute Of Biological Products   \n",
       "4                     Vanderbilt-Ingram Cancer Center   \n",
       "5   Chao Family Comprehensive Cancer Center, Unive...   \n",
       "6              Stanford University School of Medicine   \n",
       "7                     National Cancer Institute (NCI)   \n",
       "8                       Qilu Pharmaceutical Co., Ltd.   \n",
       "9                                    AEterna Zentaris   \n",
       "10                             Prism Pharma Co., Ltd.   \n",
       "11         Martin-Luther-Universität Halle-Wittenberg   \n",
       "12    University of Texas Southwestern Medical Center   \n",
       "13               Beijing Tsinghua Chang Gung Hospital   \n",
       "14  National Institutes of Health Clinical Center ...   \n",
       "15            University Hospital, Basel, Switzerland   \n",
       "16              St. Jude Children's Research Hospital   \n",
       "17          Emory University Winship Cancer Institute   \n",
       "18                       Dana-Farber Cancer Institute   \n",
       "19  Juntendo Urayasu Hospital, St. Marianna Univer...   \n",
       "20                  Sunnybrook Health Sciences Centre   \n",
       "21                         Aarhus University Hospital   \n",
       "22                 University Health Network, Toronto   \n",
       "23                         Cure&Sure Biotech Co., LTD   \n",
       "24                                     GOG Foundation   \n",
       "25                        M.D. Anderson Cancer Center   \n",
       "26  Emory University Winship Cancer Institute, The...   \n",
       "27  Shenzhen Yangli Pharmaceutical Technology Co.,...   \n",
       "28                                  Dong-A University   \n",
       "29  Sunshine Guojian Pharmaceutical (Shanghai) Co....   \n",
       "\n",
       "                                    location_facility is_same  \n",
       "0   Sidney Kimmel Comprehensive Cancer Center at J...    True  \n",
       "1                         Zealand University Hospital    True  \n",
       "2              Guangdong Provincial People's Hospital   False  \n",
       "3   The First Affiliated Hospital of College of Me...   False  \n",
       "4          Vanderbilt University/Ingram Cancer Center   False  \n",
       "5   Chao Family Comprehensive Cancer Center, Unive...    True  \n",
       "6              Stanford University School of Medicine    True  \n",
       "7   Rebecca and John Moores UCSD Cancer Center, Jo...   False  \n",
       "8                              Shanghai East Hospital   False  \n",
       "9   AOI Pharmaceuticals Investigative Site, AOI Ph...   False  \n",
       "10  Emory University / Winship Cancer Institute, U...   False  \n",
       "11                        Universitaetsklinikum Halle   False  \n",
       "12    University of Texas Southwestern Medical Center    True  \n",
       "13               Beijing Tsinghua Chang Gung Hospital    True  \n",
       "14  National Naval Medical Center, Warren Grant Ma...   False  \n",
       "15  Carsten T. Viehl, MD, Urban Laffer, MD, Markus...   False  \n",
       "16              St. Jude Children's Research Hospital    True  \n",
       "17          Emory University Winship Cancer Institute    True  \n",
       "18  Brigham and Women's Hospital, Dana Farber Canc...   False  \n",
       "19  Juntendo Urayasu Hospital, St. Marianna Univer...    True  \n",
       "20                  Sunnybrook Health Sciences Centre    True  \n",
       "21                                                NaN     NaN  \n",
       "22                    Princess Margaret Cancer Centre   False  \n",
       "23  Cancer Insititute and Hospital,Chinese Academy...   False  \n",
       "24  CCOP - Western Regional, Arizona, CCOP - Chris...   False  \n",
       "25                        M.D. Anderson Cancer Center    True  \n",
       "26  Emory University Winship Cancer Institute, The...    True  \n",
       "27  The 1st Affiliated Hospital of Henan Universit...   False  \n",
       "28                                  Dong-A University    True  \n",
       "29  The 307 Hospital of People's Liberation Army, ...   False  "
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from rapidfuzz import fuzz\n",
    "import re\n",
    "import pandas as pd\n",
    "\n",
    "# Cleaning function\n",
    "def clean_text(text):\n",
    "    if not isinstance(text, str):\n",
    "        return \"\"\n",
    "    text = text.lower()\n",
    "    text = re.sub(r'[^a-z0-9\\s]', '', text)  # remove punctuation\n",
    "    text = re.sub(r'\\s+', ' ', text).strip()  # normalize spaces\n",
    "    return text\n",
    "\n",
    "\n",
    "def fuzzy_match_and_replace(row, threshold=85):\n",
    "    org = row['organization_fullname']\n",
    "    loc = row['location_facility']\n",
    "    \n",
    "    if pd.isna(org) or pd.isna(loc):\n",
    "        return row  # skip if any is NaN\n",
    "\n",
    "    org_clean = clean_text(org)\n",
    "    loc_clean = clean_text(loc)\n",
    "    \n",
    "    score = fuzz.token_set_ratio(org_clean, loc_clean)\n",
    "    \n",
    "    if score >= threshold:\n",
    "        # Choose the longer original string (not cleaned)\n",
    "        unified_name = org if len(org) >= len(loc) else loc\n",
    "        row['organization_fullname'] = unified_name\n",
    "        row['location_facility'] = unified_name\n",
    "        row['is_same'] = True\n",
    "    else:\n",
    "        row['is_same'] = False\n",
    "\n",
    "    return row\n",
    "\n",
    "# Apply to the whole DataFrame\n",
    "df = df.apply(fuzzy_match_and_replace, axis=1)\n",
    "\n",
    "# View subset\n",
    "subset = df[['organization_fullname', 'location_facility', 'is_same']]\n",
    "subset.head(30)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "9f1d03fc",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "is_same\n",
       "False    34611\n",
       "True     22636\n",
       "Name: count, dtype: int64"
      ]
     },
     "execution_count": 20,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['is_same'].value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "0c18d87e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "collaborators                    37279\n",
       "keywords                         21735\n",
       "detailed_description             19041\n",
       "secondary_outcomes               10606\n",
       "overall_officials_affiliation    10358\n",
       "overall_officials_name           10235\n",
       "interventions_description         8944\n",
       "location_city                     3254\n",
       "location_state                    3254\n",
       "location_facility                 3254\n",
       "location_country                  3254\n",
       "is_same                           3254\n",
       "country                           3254\n",
       "primary_outcomes                  2680\n",
       "conditions                           1\n",
       "brief_summary                        0\n",
       "completion_date                      0\n",
       "enrollment                           0\n",
       "design_primary_purpose               0\n",
       "eligibility_criteria                 0\n",
       "maximum_age                          0\n",
       "lead_sponsor                         0\n",
       "last_update_post_date                0\n",
       "interventions_name                   0\n",
       "overall_status                       0\n",
       "oversight_has_dmc                    0\n",
       "organization_fullname                0\n",
       "minimum_age                          0\n",
       "primary_completion_date              0\n",
       "phase                                0\n",
       "sex                                  0\n",
       "start_date                           0\n",
       "stdage                               0\n",
       "study_first_post_date                0\n",
       "study_first_submit_date              0\n",
       "study_type                           0\n",
       "dtype: int64"
      ]
     },
     "execution_count": 21,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.isnull().sum().sort_values(ascending=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "31ebca20",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "overall_status\n",
       "COMPLETED                  22111\n",
       "TERMINATED                 17935\n",
       "RECRUITING                  7898\n",
       "UNKNOWN                     6175\n",
       "ACTIVE_NOT_RECRUITING       4293\n",
       "NOT_YET_RECRUITING          1995\n",
       "ENROLLING_BY_INVITATION       94\n",
       "Name: count, dtype: int64"
      ]
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['overall_status'].value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "id": "7126ada5",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['brief_summary', 'collaborators', 'completion_date', 'conditions',\n",
       "       'country', 'design_primary_purpose', 'detailed_description',\n",
       "       'eligibility_criteria', 'enrollment', 'interventions_description',\n",
       "       'interventions_name', 'is_same', 'keywords', 'last_update_post_date',\n",
       "       'lead_sponsor', 'location_city', 'location_country',\n",
       "       'location_facility', 'location_state', 'maximum_age', 'minimum_age',\n",
       "       'organization_fullname', 'overall_officials_affiliation',\n",
       "       'overall_officials_name', 'overall_status', 'oversight_has_dmc',\n",
       "       'phase', 'primary_completion_date', 'primary_outcomes',\n",
       "       'secondary_outcomes', 'sex', 'start_date', 'stdage',\n",
       "       'study_first_post_date', 'study_first_submit_date', 'study_type'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 23,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.columns"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "d5842b44",
   "metadata": {},
   "source": [
    "Checking what influence does collaborators have on completed/terminated"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "id": "eae71127",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "When 'collaborators' is NULL:\n",
      "overall_status\n",
      "COMPLETED     12657\n",
      "TERMINATED    11701\n",
      "Name: count, dtype: int64\n",
      "Total: 24358\n",
      "\n",
      "When 'collaborators' is NOT NULL:\n",
      "overall_status\n",
      "COMPLETED     9454\n",
      "TERMINATED    6234\n",
      "Name: count, dtype: int64\n",
      "Total: 15688\n"
     ]
    }
   ],
   "source": [
    "# Case 1: collaborators is NULL and status is COMPLETED or TERMINATED\n",
    "null_mask = df['collaborators'].isnull()\n",
    "null_and_status = df[null_mask & df['overall_status'].isin(['COMPLETED', 'TERMINATED'])]\n",
    "print(\"When 'collaborators' is NULL:\")\n",
    "print(null_and_status['overall_status'].value_counts())\n",
    "print(f\"Total: {null_and_status.shape[0]}\\n\")\n",
    "\n",
    "# Case 2: collaborators is NOT NULL and status is COMPLETED or TERMINATED\n",
    "not_null_mask = df['collaborators'].notnull()\n",
    "not_null_and_status = df[not_null_mask & df['overall_status'].isin(['COMPLETED', 'TERMINATED'])]\n",
    "print(\"When 'collaborators' is NOT NULL:\")\n",
    "print(not_null_and_status['overall_status'].value_counts())\n",
    "print(f\"Total: {not_null_and_status.shape[0]}\")\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "79e74313",
   "metadata": {},
   "source": [
    "The general data distribution shows no such trend as having an influence on the overall status as compeleted/terminated, so we can drop it"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "id": "07441ab7",
   "metadata": {},
   "outputs": [],
   "source": [
    "df.drop('collaborators', axis=1, inplace=True)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "fa3b11a3",
   "metadata": {},
   "source": [
    "Checking for data types and their conversion (dates). Some fields have missing days, so I am manually setting day as 15\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "id": "9dd4bf9d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(60501, 35)"
      ]
     },
     "execution_count": 26,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "id": "ed026f27",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>brief_summary</th>\n",
       "      <th>completion_date</th>\n",
       "      <th>conditions</th>\n",
       "      <th>country</th>\n",
       "      <th>design_primary_purpose</th>\n",
       "      <th>detailed_description</th>\n",
       "      <th>eligibility_criteria</th>\n",
       "      <th>enrollment</th>\n",
       "      <th>interventions_description</th>\n",
       "      <th>interventions_name</th>\n",
       "      <th>...</th>\n",
       "      <th>phase</th>\n",
       "      <th>primary_completion_date</th>\n",
       "      <th>primary_outcomes</th>\n",
       "      <th>secondary_outcomes</th>\n",
       "      <th>sex</th>\n",
       "      <th>start_date</th>\n",
       "      <th>stdage</th>\n",
       "      <th>study_first_post_date</th>\n",
       "      <th>study_first_submit_date</th>\n",
       "      <th>study_type</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Nivolumab, also known as (Bristol Myers Squibb...</td>\n",
       "      <td>2023-10-17</td>\n",
       "      <td>Head and Neck Squamous Cell Carcinoma, Head an...</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This research is being done to see if it is sa...</td>\n",
       "      <td>Inclusion:\\n\\nCohort 1: Subjects must have his...</td>\n",
       "      <td>26</td>\n",
       "      <td>One dose of Nivolumab 480mg given four weeks p...</td>\n",
       "      <td>Nivolumab 480mg and surgical resection</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2023-10-17</td>\n",
       "      <td>Safety as Measured by Number of Participants W...</td>\n",
       "      <td>Major Pathologic Response Rate; Progression Fr...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2019-07-08</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2019-03-18</td>\n",
       "      <td>2019-03-15</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>The aim of this explorative phase II clinical ...</td>\n",
       "      <td>2021-11-01</td>\n",
       "      <td>Colorectal Cancer</td>\n",
       "      <td>Denmark</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This is an explorative phase 2 clinical trial ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Patients must be ment...</td>\n",
       "      <td>10</td>\n",
       "      <td>Intratumoral application of an unattenuated in...</td>\n",
       "      <td>Influenza Vaccines</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2021-09-22</td>\n",
       "      <td>Safety - Adverse reactions are classified acco...</td>\n",
       "      <td>Efficacy - local immunological changes</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2021-02-26</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2020-10-19</td>\n",
       "      <td>2020-09-07</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>This study was a randomized, controlled, open-...</td>\n",
       "      <td>2027-06</td>\n",
       "      <td>Non-small Cell Lung Cancer</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Age 18 to 75 years o...</td>\n",
       "      <td>500</td>\n",
       "      <td>SHR-A2009 monotherapy ，SHR-A2009 will be admin...</td>\n",
       "      <td>SHR-A2009 monotherapy, platinum-based dual-age...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>2026-12</td>\n",
       "      <td>Progression-free survival (PFS) assessed by BI...</td>\n",
       "      <td>overall survival (OS); Progression Free Surviv...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2024-11-29</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2024-11-04</td>\n",
       "      <td>2024-11-01</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>This is a randomised, double-blind, positive d...</td>\n",
       "      <td>2022-05-20</td>\n",
       "      <td>Diffuse Large B-Cell Lymphoma</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* 18-75 years old, male...</td>\n",
       "      <td>421</td>\n",
       "      <td>Injection，100mg/10ml; Injection，100mg/10ml</td>\n",
       "      <td>SIBP-02, Rituximab</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>2022-05-20</td>\n",
       "      <td>Overall Response Rate (ORR)</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2019-07-25</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2020-04-24</td>\n",
       "      <td>2020-04-22</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>This phase II trial tests how well decitabine ...</td>\n",
       "      <td>2029-03</td>\n",
       "      <td>Recurrent Acute Myeloid Leukemia</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>PRIMARY OBJECTIVE:\\n\\nI. To assess the effect ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Age \\&gt;= 18 years at t...</td>\n",
       "      <td>51</td>\n",
       "      <td>Given by mouth; Given by mouth; Given by mouth...</td>\n",
       "      <td>Venetoclax, Decitabine, Cedazuridine, Bone Mar...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2028-03</td>\n",
       "      <td>Composite complete response (CR) rate (CR/comp...</td>\n",
       "      <td>Rate of partial response (PR) following treatm...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2024-01-29</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2023-04-05</td>\n",
       "      <td>2023-03-22</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>This is a phase 2 single-arm, open-label clini...</td>\n",
       "      <td>2024-12-30</td>\n",
       "      <td>Gastric Adenocarcinoma, GastroEsophageal Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Treatment on study will be administered in 21 ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Patients must have hi...</td>\n",
       "      <td>20</td>\n",
       "      <td>Given PO; Given IV</td>\n",
       "      <td>Cabozantinib, Pembrolizumab</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2023-11-25</td>\n",
       "      <td>Percentage of Participants with Progression-fr...</td>\n",
       "      <td>Percentage of Grade 3-5 Adverse Events; Overal...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2020-02-04</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2019-11-15</td>\n",
       "      <td>2019-11-13</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>A phase I trial in patients with relapsed or r...</td>\n",
       "      <td>2009-07</td>\n",
       "      <td>Leukemia, Lymphocytic, Leukemia, Acute Lymphoc...</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n3.1.1 Age Patients must...</td>\n",
       "      <td>9</td>\n",
       "      <td>Dosage: 1.25mg/kg intravenous with dose escala...</td>\n",
       "      <td>MAb 216, Vincristine</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2009-02</td>\n",
       "      <td>In this phase I study the endpoint is the dete...</td>\n",
       "      <td>A decrease in leukemic blasts. The study will ...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2006-05</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2006-04-11</td>\n",
       "      <td>2006-04-07</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>RATIONALE: The timing of breast cancer surgery...</td>\n",
       "      <td>2004-10</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>OBJECTIVES:\\n\\n* Determine if the timing of br...</td>\n",
       "      <td>DISEASE CHARACTERISTICS:\\n\\n* Histologically c...</td>\n",
       "      <td>?</td>\n",
       "      <td>NaN</td>\n",
       "      <td>conventional surgery</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>?</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>FEMALE</td>\n",
       "      <td>1999-01</td>\n",
       "      <td>CHILD, ADULT, OLDER_ADULT</td>\n",
       "      <td>2003-01-27</td>\n",
       "      <td>2000-04-06</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>To determine the safety, tolerability, and rec...</td>\n",
       "      <td>2024-12-30</td>\n",
       "      <td>Advanced Tumor</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Age: 18-75 years old...</td>\n",
       "      <td>40</td>\n",
       "      <td>In the phase, five dose groups were proposed.T...</td>\n",
       "      <td>QLF32004</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2024-12-30</td>\n",
       "      <td>Dose-Limiting Toxicity (DLT); Maximum Tolerate...</td>\n",
       "      <td>Treatment-Emergent Adverse Event (TEAE); Maxim...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2021-11-09</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2021-11-05</td>\n",
       "      <td>2021-10-22</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>This is an exploratory phase 2, randomized pla...</td>\n",
       "      <td>2011-10</td>\n",
       "      <td>Colon Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This is an exploratory phase 2, randomized pla...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. In the opinion of th...</td>\n",
       "      <td>381</td>\n",
       "      <td>Perifosine 50 mg/d qd; Capecitabine 825 mg/m\\^...</td>\n",
       "      <td>Perifosine, Capecitabine, Perifosine Placebo</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2010-12</td>\n",
       "      <td>Effects of perifosine on time to progression</td>\n",
       "      <td>Toxicity; Comparison of time to progression to...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2005-08</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2006-11-14</td>\n",
       "      <td>2006-11-06</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>PRI-724 is a new investigational drug being st...</td>\n",
       "      <td>2016-12-30</td>\n",
       "      <td>Acute Myeloid Leukemia, Chronic Myeloid Leukemia</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>PRI-724 is a new investigational drug being st...</td>\n",
       "      <td>Inclusion Criteria\\n\\n1. Patients 18 years or ...</td>\n",
       "      <td>49</td>\n",
       "      <td>PRI-724; PRI-724 in combination with dasatinib...</td>\n",
       "      <td>PRI-724, PRI-724, PRI-724</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2016-12-30</td>\n",
       "      <td>DLT (Dose Limiting Toxicity)</td>\n",
       "      <td>Preliminary Efficacy Endpoints</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2012-07</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2012-05-25</td>\n",
       "      <td>2012-05-16</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Longterm disease-free survival (DFS) of older ...</td>\n",
       "      <td>2017-09</td>\n",
       "      <td>AML</td>\n",
       "      <td>Germany</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Subjects must provid...</td>\n",
       "      <td>16</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tranylcypromine, Tretinoin</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2017-09</td>\n",
       "      <td>Analysis of the cumulative response rate (CR,C...</td>\n",
       "      <td>number of participants with adverse events as ...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2014-09</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2014-10-10</td>\n",
       "      <td>2014-09-23</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>RATIONALE: Combinations of biological substanc...</td>\n",
       "      <td>2017-07-27</td>\n",
       "      <td>Leukemia, Myelodysplastic Syndromes, Blastic P...</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>OBJECTIVES:\\n\\n* Determine the maximum tolerat...</td>\n",
       "      <td>DISEASE CHARACTERISTICS:\\n\\n* Diagnosis of 1 o...</td>\n",
       "      <td>11</td>\n",
       "      <td>Intravenously via a 3 cc plastic syringe as a ...</td>\n",
       "      <td>DT388IL3</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2017-07-27</td>\n",
       "      <td>Overall Response Rate (CR+PR+SD): Percentage o...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2013-05</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2006-11-09</td>\n",
       "      <td>2006-11-08</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>The purpose of this conversion therapy study i...</td>\n",
       "      <td>2024-04-30</td>\n",
       "      <td>NSCLC, Stage III</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Written informed cons...</td>\n",
       "      <td>30</td>\n",
       "      <td>Tislelizumab: 200mg, IV, day 1 of each 21-day ...</td>\n",
       "      <td>Tislelizumab, Pemetrexed (Nonsquamous NSCLC) o...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2024-02-29</td>\n",
       "      <td>Resectability rate</td>\n",
       "      <td>Major pathological response rate (MPR); Pathol...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2023-03-12</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2022-11-10</td>\n",
       "      <td>2022-11-04</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>RATIONALE: MS-275 may stop the growth of cance...</td>\n",
       "      <td>2008-10</td>\n",
       "      <td>Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>OBJECTIVES:\\n\\n* Determine the dose-limiting t...</td>\n",
       "      <td>DISEASE CHARACTERISTICS:\\n\\n* Histologically c...</td>\n",
       "      <td>75</td>\n",
       "      <td>NaN</td>\n",
       "      <td>entinostat</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2008-04</td>\n",
       "      <td>Dose-limiting toxicities and maximum tolerated...</td>\n",
       "      <td>Acetylation of histones in peripheral blood; T...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2001-03</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2003-01-27</td>\n",
       "      <td>2001-07-11</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>The study is a feasibility and validation stud...</td>\n",
       "      <td>2009-01</td>\n",
       "      <td>Colonic Neoplasms</td>\n",
       "      <td>Switzerland</td>\n",
       "      <td>DIAGNOSTIC</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Colon cancer at any s...</td>\n",
       "      <td>192</td>\n",
       "      <td>After careful mobilization of the affected col...</td>\n",
       "      <td>Sentinel lymph node procedure, Bone marrow asp...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2009-01</td>\n",
       "      <td>To assess the extent of upstaging due to the S...</td>\n",
       "      <td>To evaluate the accuracy of the SLN procedure ...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2000-05</td>\n",
       "      <td>CHILD, ADULT, OLDER_ADULT</td>\n",
       "      <td>2009-01-22</td>\n",
       "      <td>2009-01-13</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>This study is a phase I study designed to eval...</td>\n",
       "      <td>2031-01</td>\n",
       "      <td>Acute Lymphoblastic Leukemia, Recurrent Acute ...</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Treatment will include a single course of lymp...</td>\n",
       "      <td>Collection and Manufacturing Eligibility\\n\\nIn...</td>\n",
       "      <td>30</td>\n",
       "      <td>IV; IV; IV; CAR T cell infusion will be given ...</td>\n",
       "      <td>Fludarabine, Cyclophosphamide, Mesna, CD19-CD2...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2030-01</td>\n",
       "      <td>Recommended phase 2 dose (RP2D) of CD19-CD22-C...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2025-05</td>\n",
       "      <td>CHILD, ADULT</td>\n",
       "      <td>2025-01-16</td>\n",
       "      <td>2025-01-10</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>This is an open-label (doctors and patients kn...</td>\n",
       "      <td>2015-11</td>\n",
       "      <td>Lymphoma, B-Cell, Follicular Lymphoma</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This study will assess whether adding bortezom...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Tissue diagnosis of a...</td>\n",
       "      <td>37</td>\n",
       "      <td>Bortezomib 1.6 mg/m² given on days 1 and 8; Ri...</td>\n",
       "      <td>Bortezomib, Rituximab, Doxorubicin, Cyclophosp...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2015-11</td>\n",
       "      <td>Maximal Tolerated Doses of Bortezomib and Vinc...</td>\n",
       "      <td>An Estimate of the Overall Response Rate (ORR)...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2008-02</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2008-03-12</td>\n",
       "      <td>2008-02-11</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>This research is being done to compare rates o...</td>\n",
       "      <td>2028-06-01</td>\n",
       "      <td>Metastatic Breast Cancer, Chemotherapy-induced...</td>\n",
       "      <td>United States</td>\n",
       "      <td>SUPPORTIVE_CARE</td>\n",
       "      <td>This study is a prospective, controlled, pivot...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Men and women with a ...</td>\n",
       "      <td>120</td>\n",
       "      <td>Cap attached to coolant lines connected to a r...</td>\n",
       "      <td>Paxman Scalp Cooling System, Eribulin, Sacituz...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2026-06-01</td>\n",
       "      <td>Hair Loss Rate</td>\n",
       "      <td>Change in Patient Reported Quality of Life; Ch...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2021-10-07</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2021-08-03</td>\n",
       "      <td>2021-07-20</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>The purpose of this study is to assess the saf...</td>\n",
       "      <td>2024-10</td>\n",
       "      <td>Non-squamous Non-small-cell Lung Cancer, EGFR ...</td>\n",
       "      <td>Japan</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Have a histologicall...</td>\n",
       "      <td>30</td>\n",
       "      <td>IV infusion Q3W; Oral capsule once daily; IV i...</td>\n",
       "      <td>Pembrolizumab, Lenvatinib, Carboplatin, Pemetr...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2023-10-31</td>\n",
       "      <td>Objective Response Rate (ORR) as Assessed by B...</td>\n",
       "      <td>Objective Response Rate (ORR) as Assessed by i...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2022-07-01</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2022-02-28</td>\n",
       "      <td>2022-02-17</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>This is a single-center, single-arm, open-labe...</td>\n",
       "      <td>2023-07-06</td>\n",
       "      <td>Neuroendocrine Tumors</td>\n",
       "      <td>Canada</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Adults (males or fema...</td>\n",
       "      <td>17</td>\n",
       "      <td>Avelumab will be administered intravenously as...</td>\n",
       "      <td>Avelumab</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2021-07-26</td>\n",
       "      <td>Overall response rate (ORR)</td>\n",
       "      <td>Disease control rate (DCR); Duration of respon...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2017-11-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2017-09-11</td>\n",
       "      <td>2017-08-23</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>The investigartors will conduct a randomized, ...</td>\n",
       "      <td>2032-02-01</td>\n",
       "      <td>Non-Muscle Invasive Bladder Cancer</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Tumour recurrence aft...</td>\n",
       "      <td>272</td>\n",
       "      <td>Chemoablation</td>\n",
       "      <td>Mitomycin c</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE4</td>\n",
       "      <td>2029-02-01</td>\n",
       "      <td>Two-year Recurrence Free Survival</td>\n",
       "      <td>Five-year RFS; Number of patients in need of a...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2025-02-24</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2025-01-17</td>\n",
       "      <td>2025-01-14</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>The purpose of this study is to see if using P...</td>\n",
       "      <td>2028-02-17</td>\n",
       "      <td>Pancreatic Ductal Carcinoma, Advanced Cancer, ...</td>\n",
       "      <td>Canada</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>PDO is a three-dimensional experimental model ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Age 18 years or over...</td>\n",
       "      <td>25</td>\n",
       "      <td>Cobimetinib is an antineoplastic agent and sel...</td>\n",
       "      <td>Cobimetinib, Ponatinib, Brigatinib, Colchicine...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2028-02-17</td>\n",
       "      <td>Objective response rate (ORR)</td>\n",
       "      <td>Disease control rate (DCR); Duration of respon...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2025-02-17</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2025-02-06</td>\n",
       "      <td>2025-02-03</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>To evaluate the safety and effectiveness of au...</td>\n",
       "      <td>2019-11</td>\n",
       "      <td>Liver Cancer, Pancreatic Adenocarcinoma</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Able to read and und...</td>\n",
       "      <td>20</td>\n",
       "      <td>vaccination of autologous gp96 derived from tu...</td>\n",
       "      <td>autologous gp96 vaccination</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2016-11</td>\n",
       "      <td>blood count; blood count; blood count; blood c...</td>\n",
       "      <td>Disease-free survival; overall survive; change...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2012-03</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2014-05-07</td>\n",
       "      <td>2014-05-03</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>RATIONALE: Radiation therapy uses high-energy ...</td>\n",
       "      <td>?</td>\n",
       "      <td>Cervical Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>OBJECTIVES:\\n\\n* Determine the toxicity of rad...</td>\n",
       "      <td>DISEASE CHARACTERISTICS:\\n\\n* Histologically p...</td>\n",
       "      <td>40</td>\n",
       "      <td>NaN</td>\n",
       "      <td>cisplatin, paclitaxel, brachytherapy, radiatio...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2007-01</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>FEMALE</td>\n",
       "      <td>1999-11</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2003-01-27</td>\n",
       "      <td>1999-11-01</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>To learn if sacituzumab govitecan and pembroli...</td>\n",
       "      <td>2026-12-31</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Primary Objective:\\n\\n• To determine the effic...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Female or male patie...</td>\n",
       "      <td>25</td>\n",
       "      <td>Given by IV (vein); Given by IV (vein)</td>\n",
       "      <td>Sacituzumab Govitecan, Pembrolizumab</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2026-12-31</td>\n",
       "      <td>Incidence of Adverse Events, Graded According ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2023-05-23</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2023-01-09</td>\n",
       "      <td>2022-12-22</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>The goal of this clinical research study is to...</td>\n",
       "      <td>2018-06-04</td>\n",
       "      <td>Oral Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>PREVENTION</td>\n",
       "      <td>Erlotinib hydrochloride is designed to block t...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Male or female patie...</td>\n",
       "      <td>303</td>\n",
       "      <td>150 mg by mouth daily; Tablet by mouth daily</td>\n",
       "      <td>Erlotinib, Placebo</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>2018-06-04</td>\n",
       "      <td>Oral Cancer-free Survival in Participants Rece...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2006-11-03</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2006-11-22</td>\n",
       "      <td>2006-11-20</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>A Phase 1/2 Dose Escalation and Expansion Stud...</td>\n",
       "      <td>2025-04-30</td>\n",
       "      <td>ER+, HER2- Advanced Breast Cancer, Metastatic ...</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This is a phase Ⅰ/Ⅱ, open-label study of TFX06...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. voluntary participat...</td>\n",
       "      <td>74</td>\n",
       "      <td>TFX06 tablet taken orally</td>\n",
       "      <td>TFX06 tablet</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2024-12-30</td>\n",
       "      <td>Recommended phase 2 Dose (RP2D); Disease Contr...</td>\n",
       "      <td>Incidence of Treatment-Emergent Adverse Events...</td>\n",
       "      <td>FEMALE</td>\n",
       "      <td>2023-04-17</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2023-07-03</td>\n",
       "      <td>2023-06-03</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>Topical photodynamic therapy with methyl-amino...</td>\n",
       "      <td>2013-09</td>\n",
       "      <td>Nodular Basal Cell Carcinoma</td>\n",
       "      <td>Korea, Republic of</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Basal cell carcinoma (BCC) is the most common ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* patient's request for...</td>\n",
       "      <td>34</td>\n",
       "      <td>AFL was performed using a 2940-nm Er:YAG ablat...</td>\n",
       "      <td>Er:YAG AFL-PDT, MAL-PDT</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2013-02</td>\n",
       "      <td>Difference the efficacy between Er:YAG AFL-PDT...</td>\n",
       "      <td>Difference of the cosmetic outcomes between Er...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2011-03</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2013-12-23</td>\n",
       "      <td>2013-11-29</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>The purpose of this study is to evaluate the p...</td>\n",
       "      <td>2019-10-31</td>\n",
       "      <td>CD20 Positive B Cell NHL</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This is a multi-center, randomized, double-bli...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Histological examinat...</td>\n",
       "      <td>60</td>\n",
       "      <td>Monoclonal antibodies, 100mg/10ml per injectio...</td>\n",
       "      <td>304 injection, rituximab injection</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2019-06-30</td>\n",
       "      <td>AUC [0-t]; AUC [0-∞]; Cmax</td>\n",
       "      <td>tmax; t1/2; MRT; Vz; CLz; ADA; Adverse events</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2018-12-18</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2019-06-10</td>\n",
       "      <td>2019-06-06</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>The purpose of the study is to address the fol...</td>\n",
       "      <td>2024-03</td>\n",
       "      <td>Triple Negative Breast Cancer</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Newly diagnosed histo...</td>\n",
       "      <td>49</td>\n",
       "      <td>The PD-1 inhibitor Sintilimab 200mg for intrav...</td>\n",
       "      <td>Sintilimab</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2023-12</td>\n",
       "      <td>Pathologic Complete Response (pCR)</td>\n",
       "      <td>NaN</td>\n",
       "      <td>FEMALE</td>\n",
       "      <td>2021-03</td>\n",
       "      <td>ADULT</td>\n",
       "      <td>2021-03-22</td>\n",
       "      <td>2021-03-19</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>Study of elotuzumab in combination with pomali...</td>\n",
       "      <td>2020-06-12</td>\n",
       "      <td>Multiple Myeloma</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>For more information regarding BMS clinical tr...</td>\n",
       "      <td>74</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Elotuzumab, Pomalidomide, Dexamethasone, Nivol...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2019-07-29</td>\n",
       "      <td>Progression Free Survival (PFS); Objective Res...</td>\n",
       "      <td>Objective Response Rate (ORR); Progression Fre...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2016-02-09</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2015-11-24</td>\n",
       "      <td>2015-11-20</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>RATIONALE: CT-322 may stop the growth of solid...</td>\n",
       "      <td>2009-02</td>\n",
       "      <td>Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>DISEASE CHARACTERISTICS\\n\\n* Histologically pr...</td>\n",
       "      <td>40</td>\n",
       "      <td>IV solution, weekly or bi-weekly</td>\n",
       "      <td>CT-322</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2008-11</td>\n",
       "      <td>Safety and tolerability of CT-322</td>\n",
       "      <td>To evaluate the pharmacokinetics of CT-322 in ...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2006-08</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2006-09-11</td>\n",
       "      <td>2006-09-08</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>This is a single-arm, single-center, open-labe...</td>\n",
       "      <td>2025-12-31</td>\n",
       "      <td>B-cell Acute Lymphoblastic Leukemia, B-ALL</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Although the anti-CD19 CAR-T cell therapies ha...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Male or female, aged...</td>\n",
       "      <td>30</td>\n",
       "      <td>UCAR-T Cellswill be administered by vein. The ...</td>\n",
       "      <td>UCAR-T Cells</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2024-12-31</td>\n",
       "      <td>Dose-limiting toxicity (DLT); Incidence of Tre...</td>\n",
       "      <td>Persistence of CAR-T cells; Objective response...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2022-12-05</td>\n",
       "      <td>CHILD, ADULT, OLDER_ADULT</td>\n",
       "      <td>2022-12-06</td>\n",
       "      <td>2022-11-25</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>The purpose of this study is to determine if t...</td>\n",
       "      <td>2024-08-07</td>\n",
       "      <td>Multiple Myeloma</td>\n",
       "      <td>Croatia, Greece, United States, Argentina, Jap...</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>The study consists of 3 phases: Screening Phas...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Participant must have...</td>\n",
       "      <td>706</td>\n",
       "      <td>Participants will receive velcade 1.3 mg/m\\^2,...</td>\n",
       "      <td>Velcade, Melphalan, Prednisone, Daratumumab IV...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>2017-11-21</td>\n",
       "      <td>Progression Free Survival (PFS)</td>\n",
       "      <td>Overall Response Rate (ORR); Percentage of Par...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2014-12-09</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2014-07-21</td>\n",
       "      <td>2014-07-18</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>This study is examining a chemotherapy regimen...</td>\n",
       "      <td>2022-02-11</td>\n",
       "      <td>Leukemia, Lymphoid, Leukemia, Myeloid, Myelody...</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Age less than or equ...</td>\n",
       "      <td>20</td>\n",
       "      <td>Fludarabine: 30 mg/m2 daily for 5 days; Busulf...</td>\n",
       "      <td>Fludarabine, Busulfan, Rabbit ATG, Methotrexate</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2019-06-07</td>\n",
       "      <td>Number of patients who are surviving at 100-Da...</td>\n",
       "      <td>Time to marrow engraftment; Assessing all subj...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2016-09-06</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2016-09-28</td>\n",
       "      <td>2016-08-15</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>This is a single-center, single-arm, phase Ib/...</td>\n",
       "      <td>2027-10-01</td>\n",
       "      <td>NMIBC</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Age ≥18 years old, b...</td>\n",
       "      <td>58</td>\n",
       "      <td>SHR-1501, instillation；SHR-2005, instillation</td>\n",
       "      <td>SHR-1501+SHR-2005</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2027-10-01</td>\n",
       "      <td>Phase I : Incidence of dose limiting toxicitie...</td>\n",
       "      <td>Phase I : CR rate at 3 months; Phase II : Inci...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2024-10-01</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2024-09-19</td>\n",
       "      <td>2024-09-05</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>This is an open-label, multicenter, dose-escal...</td>\n",
       "      <td>2019-03</td>\n",
       "      <td>Acute Myeloid Leukemia, Acute Myelogenous Leuk...</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Key Inclusion Criteria:\\n\\n* Single agent (SA)...</td>\n",
       "      <td>94</td>\n",
       "      <td>FT-1101 will be supplied as 5 mg, 20 mg or 100...</td>\n",
       "      <td>FT-1101, Azacitidine</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2019-03</td>\n",
       "      <td>Maximum Tolerated Dose (MTD); Dose Limiting To...</td>\n",
       "      <td>Area under the plasma concentration versus tim...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2015-09</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2015-09-07</td>\n",
       "      <td>2015-09-01</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>Dual center, single arm, two-stage, non-blinde...</td>\n",
       "      <td>2019-12-04</td>\n",
       "      <td>Glioblastoma</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* At least 18 years of ...</td>\n",
       "      <td>35</td>\n",
       "      <td>10mg/kg; 670mg/m2</td>\n",
       "      <td>Bevacizumab, TH-302</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2019-01-04</td>\n",
       "      <td>Number of Patients With Adverse Events</td>\n",
       "      <td>Progression Free Survival</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2015-05</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2015-01-19</td>\n",
       "      <td>2015-01-14</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>RATIONALE: Drugs used in chemotherapy, such as...</td>\n",
       "      <td>2009-02-10</td>\n",
       "      <td>Head and Neck Cancer</td>\n",
       "      <td>Canada</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>OBJECTIVES:\\n\\nPrimary\\n\\n* Determine the acti...</td>\n",
       "      <td>DISEASE CHARACTERISTICS:\\n\\n* Histologically o...</td>\n",
       "      <td>34</td>\n",
       "      <td>NaN</td>\n",
       "      <td>carboplatin, cisplatin, gemcitabine hydrochloride</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2008-09-29</td>\n",
       "      <td>Objective response measured by RECIST criteria...</td>\n",
       "      <td>Toxicity assessed by NCI CTC v2.0; Overall sur...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2003-10-27</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2004-03-09</td>\n",
       "      <td>2004-03-08</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>The purposes of this study are to determine th...</td>\n",
       "      <td>?</td>\n",
       "      <td>Carcinoma, Non-Small-Cell Lung, Pulmonary Neop...</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Definition: The phase 2 study will provide imp...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Diagnosis of Non-Smal...</td>\n",
       "      <td>?</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Gemcitabine, Carboplatin, LY900003</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>?</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2002-06</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2002-08-06</td>\n",
       "      <td>2002-08-02</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41</th>\n",
       "      <td>The main purpose of this Phase 1/2 study is to...</td>\n",
       "      <td>2021-01-01</td>\n",
       "      <td>Small-cell Lung Cancer</td>\n",
       "      <td>Puerto Rico, United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Key Inclusion Criteria:\\n\\n1. Patient is able ...</td>\n",
       "      <td>68</td>\n",
       "      <td>Administered IV; Administered IV</td>\n",
       "      <td>Pegzilarginase, Pembrolizumab</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2021-01-01</td>\n",
       "      <td>1. Phase 1: Incidence of treatment-related adv...</td>\n",
       "      <td>Objective Response Rate; Clinical Benefit Rate...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2017-12-21</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2017-12-13</td>\n",
       "      <td>2017-11-20</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>42</th>\n",
       "      <td>The purpose of this study is to evaluate the e...</td>\n",
       "      <td>2013-09</td>\n",
       "      <td>Colorectal Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>HEALTH_SERVICES_RESEARCH</td>\n",
       "      <td>This study will test the separate and combined...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Patients aged 50-75 y...</td>\n",
       "      <td>569</td>\n",
       "      <td>Physicians at these clinics will participate i...</td>\n",
       "      <td>Physician Intervention, Physician and Patient ...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2, PHASE3</td>\n",
       "      <td>2013-07</td>\n",
       "      <td>Colorectal Cancer (CRC) Screening Completion; ...</td>\n",
       "      <td>Provider Recommendation of CRC Screening</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2010-04</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2010-04-14</td>\n",
       "      <td>2010-04-12</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>43</th>\n",
       "      <td>Maintenance durvalumab (MEDI4736) and olaparib...</td>\n",
       "      <td>2026-12</td>\n",
       "      <td>Small Cell Lung Carcinoma</td>\n",
       "      <td>Germany</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria Pre-Screening:\\n\\n* Newly d...</td>\n",
       "      <td>29</td>\n",
       "      <td>1500 mg i.v. Q4W; 300 mg BID orally</td>\n",
       "      <td>Durvalumab, Olaparib</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2026-09</td>\n",
       "      <td>Progression-free survival (PFS)</td>\n",
       "      <td>Incidence, severity and grading of adverse eve...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2024-10-09</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2024-05-17</td>\n",
       "      <td>2024-05-03</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>44</th>\n",
       "      <td>There is no muture method to treat EGFR 20 ins...</td>\n",
       "      <td>2024-12-31</td>\n",
       "      <td>Carcinoma, Non-Small-Cell Lung</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Lung cancer is one of the most common types of...</td>\n",
       "      <td>Inclusion Criteria:\\n\\nParticipant must have h...</td>\n",
       "      <td>20</td>\n",
       "      <td>Osimertinib, 80mg, oral daily; bevacizumab (av...</td>\n",
       "      <td>Osimertinib Oral Tablet</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2024-07-31</td>\n",
       "      <td>Progression free survival</td>\n",
       "      <td>Objective Response Rate (ORR); Overall Surviva...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2021-07-01</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2021-07-23</td>\n",
       "      <td>2021-07-16</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>45</th>\n",
       "      <td>This is a randomized, open-label, phase 2 stud...</td>\n",
       "      <td>2027-02</td>\n",
       "      <td>Glioblastoma, IDH-wildtype</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This is a randomized, open-label phase 2 study...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Written informed cons...</td>\n",
       "      <td>54</td>\n",
       "      <td>Ropidoxuridine is administered daily, 5 days a...</td>\n",
       "      <td>Ropidoxuridine</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2026-08</td>\n",
       "      <td>Number of patients treated with oral ropidoxur...</td>\n",
       "      <td>Overall survival at 12 months; Radiographic Re...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2024-09-02</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2024-04-11</td>\n",
       "      <td>2024-03-24</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>46</th>\n",
       "      <td>From Protocol v3.0 dated 16Jun2022. This is an...</td>\n",
       "      <td>2024-10-31</td>\n",
       "      <td>Melanoma (Skin), Non-Small-Cell Lung Carcinoma</td>\n",
       "      <td>Spain, Belgium, United Kingdom</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Overall Study Design:\\n\\n• This is an open-lab...</td>\n",
       "      <td>Inclusion Criteria:\\n\\nMain Inclusion Criteria...</td>\n",
       "      <td>34</td>\n",
       "      <td>Priming phase including 1 GAd-PEV administrati...</td>\n",
       "      <td>GAd-PEV, MVA-PEV</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2024-10-31</td>\n",
       "      <td>Safety and tolerability: incidence of treatmen...</td>\n",
       "      <td>RP2D confirmation 2. Clinical efficacy:; Clini...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2021-06-11</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2021-08-04</td>\n",
       "      <td>2021-07-15</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>47</th>\n",
       "      <td>The proposed study will evaluate whether the c...</td>\n",
       "      <td>2014-07</td>\n",
       "      <td>Multiple Myeloma</td>\n",
       "      <td>Italy</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This phase III study represents a prospective ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Age \\&gt; 65 year old an...</td>\n",
       "      <td>511</td>\n",
       "      <td>Induction therapy:\\n\\n9 courses with weekly VE...</td>\n",
       "      <td>Bortezomib, Melphalan, Prednisone, Thalidomide...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>2014-07</td>\n",
       "      <td>Determine whether the V-MPT combination improv...</td>\n",
       "      <td>Determine whether the VMPT combination improve...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2006-05</td>\n",
       "      <td>OLDER_ADULT</td>\n",
       "      <td>2010-02-05</td>\n",
       "      <td>2010-02-04</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>48</th>\n",
       "      <td>The purpose of this study is to evaluate the e...</td>\n",
       "      <td>2022-12-31</td>\n",
       "      <td>Extranodal NK/T-cell Lymphoma</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Previous study has confirmed the efficacy of a...</td>\n",
       "      <td>Inclusion Criteria:\\n\\nHistopathology and immu...</td>\n",
       "      <td>20</td>\n",
       "      <td>200mg d1,ivdrip, repeated every 3 weeks; 10mg ...</td>\n",
       "      <td>Sintilimab, Decitabine</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2022-12-31</td>\n",
       "      <td>complete response rate</td>\n",
       "      <td>overall response rate; 1-year progression free...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2020-04-01</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2020-02-21</td>\n",
       "      <td>2020-02-19</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>49</th>\n",
       "      <td>The purpose of this study is to evaluate the i...</td>\n",
       "      <td>2013-08</td>\n",
       "      <td>Esophageal Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>DIAGNOSTIC</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Newly diagnosed or re...</td>\n",
       "      <td>22</td>\n",
       "      <td>15 mCi 11C-choline will be administered intrav...</td>\n",
       "      <td>C11-Choline</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2013-08</td>\n",
       "      <td>To evaluate our ability to obtain reliable and...</td>\n",
       "      <td>Perform semi-quantitative analysis of tracer u...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2010-03</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2010-01-18</td>\n",
       "      <td>2010-01-15</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>50 rows × 35 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                        brief_summary completion_date  \\\n",
       "0   Nivolumab, also known as (Bristol Myers Squibb...      2023-10-17   \n",
       "1   The aim of this explorative phase II clinical ...      2021-11-01   \n",
       "2   This study was a randomized, controlled, open-...         2027-06   \n",
       "3   This is a randomised, double-blind, positive d...      2022-05-20   \n",
       "4   This phase II trial tests how well decitabine ...         2029-03   \n",
       "5   This is a phase 2 single-arm, open-label clini...      2024-12-30   \n",
       "6   A phase I trial in patients with relapsed or r...         2009-07   \n",
       "7   RATIONALE: The timing of breast cancer surgery...         2004-10   \n",
       "8   To determine the safety, tolerability, and rec...      2024-12-30   \n",
       "9   This is an exploratory phase 2, randomized pla...         2011-10   \n",
       "10  PRI-724 is a new investigational drug being st...      2016-12-30   \n",
       "11  Longterm disease-free survival (DFS) of older ...         2017-09   \n",
       "12  RATIONALE: Combinations of biological substanc...      2017-07-27   \n",
       "13  The purpose of this conversion therapy study i...      2024-04-30   \n",
       "14  RATIONALE: MS-275 may stop the growth of cance...         2008-10   \n",
       "15  The study is a feasibility and validation stud...         2009-01   \n",
       "16  This study is a phase I study designed to eval...         2031-01   \n",
       "17  This is an open-label (doctors and patients kn...         2015-11   \n",
       "18  This research is being done to compare rates o...      2028-06-01   \n",
       "19  The purpose of this study is to assess the saf...         2024-10   \n",
       "20  This is a single-center, single-arm, open-labe...      2023-07-06   \n",
       "21  The investigartors will conduct a randomized, ...      2032-02-01   \n",
       "22  The purpose of this study is to see if using P...      2028-02-17   \n",
       "23  To evaluate the safety and effectiveness of au...         2019-11   \n",
       "24  RATIONALE: Radiation therapy uses high-energy ...               ?   \n",
       "25  To learn if sacituzumab govitecan and pembroli...      2026-12-31   \n",
       "26  The goal of this clinical research study is to...      2018-06-04   \n",
       "27  A Phase 1/2 Dose Escalation and Expansion Stud...      2025-04-30   \n",
       "28  Topical photodynamic therapy with methyl-amino...         2013-09   \n",
       "29  The purpose of this study is to evaluate the p...      2019-10-31   \n",
       "30  The purpose of the study is to address the fol...         2024-03   \n",
       "31  Study of elotuzumab in combination with pomali...      2020-06-12   \n",
       "32  RATIONALE: CT-322 may stop the growth of solid...         2009-02   \n",
       "33  This is a single-arm, single-center, open-labe...      2025-12-31   \n",
       "34  The purpose of this study is to determine if t...      2024-08-07   \n",
       "35  This study is examining a chemotherapy regimen...      2022-02-11   \n",
       "36  This is a single-center, single-arm, phase Ib/...      2027-10-01   \n",
       "37  This is an open-label, multicenter, dose-escal...         2019-03   \n",
       "38  Dual center, single arm, two-stage, non-blinde...      2019-12-04   \n",
       "39  RATIONALE: Drugs used in chemotherapy, such as...      2009-02-10   \n",
       "40  The purposes of this study are to determine th...               ?   \n",
       "41  The main purpose of this Phase 1/2 study is to...      2021-01-01   \n",
       "42  The purpose of this study is to evaluate the e...         2013-09   \n",
       "43  Maintenance durvalumab (MEDI4736) and olaparib...         2026-12   \n",
       "44  There is no muture method to treat EGFR 20 ins...      2024-12-31   \n",
       "45  This is a randomized, open-label, phase 2 stud...         2027-02   \n",
       "46  From Protocol v3.0 dated 16Jun2022. This is an...      2024-10-31   \n",
       "47  The proposed study will evaluate whether the c...         2014-07   \n",
       "48  The purpose of this study is to evaluate the e...      2022-12-31   \n",
       "49  The purpose of this study is to evaluate the i...         2013-08   \n",
       "\n",
       "                                           conditions  \\\n",
       "0   Head and Neck Squamous Cell Carcinoma, Head an...   \n",
       "1                                   Colorectal Cancer   \n",
       "2                          Non-small Cell Lung Cancer   \n",
       "3                       Diffuse Large B-Cell Lymphoma   \n",
       "4                    Recurrent Acute Myeloid Leukemia   \n",
       "5     Gastric Adenocarcinoma, GastroEsophageal Cancer   \n",
       "6   Leukemia, Lymphocytic, Leukemia, Acute Lymphoc...   \n",
       "7                                       Breast Cancer   \n",
       "8                                      Advanced Tumor   \n",
       "9                                        Colon Cancer   \n",
       "10   Acute Myeloid Leukemia, Chronic Myeloid Leukemia   \n",
       "11                                                AML   \n",
       "12  Leukemia, Myelodysplastic Syndromes, Blastic P...   \n",
       "13                                   NSCLC, Stage III   \n",
       "14                                             Cancer   \n",
       "15                                  Colonic Neoplasms   \n",
       "16  Acute Lymphoblastic Leukemia, Recurrent Acute ...   \n",
       "17              Lymphoma, B-Cell, Follicular Lymphoma   \n",
       "18  Metastatic Breast Cancer, Chemotherapy-induced...   \n",
       "19  Non-squamous Non-small-cell Lung Cancer, EGFR ...   \n",
       "20                              Neuroendocrine Tumors   \n",
       "21                 Non-Muscle Invasive Bladder Cancer   \n",
       "22  Pancreatic Ductal Carcinoma, Advanced Cancer, ...   \n",
       "23            Liver Cancer, Pancreatic Adenocarcinoma   \n",
       "24                                    Cervical Cancer   \n",
       "25                                      Breast Cancer   \n",
       "26                                        Oral Cancer   \n",
       "27  ER+, HER2- Advanced Breast Cancer, Metastatic ...   \n",
       "28                       Nodular Basal Cell Carcinoma   \n",
       "29                           CD20 Positive B Cell NHL   \n",
       "30                      Triple Negative Breast Cancer   \n",
       "31                                   Multiple Myeloma   \n",
       "32                                             Cancer   \n",
       "33         B-cell Acute Lymphoblastic Leukemia, B-ALL   \n",
       "34                                   Multiple Myeloma   \n",
       "35  Leukemia, Lymphoid, Leukemia, Myeloid, Myelody...   \n",
       "36                                              NMIBC   \n",
       "37  Acute Myeloid Leukemia, Acute Myelogenous Leuk...   \n",
       "38                                       Glioblastoma   \n",
       "39                               Head and Neck Cancer   \n",
       "40  Carcinoma, Non-Small-Cell Lung, Pulmonary Neop...   \n",
       "41                             Small-cell Lung Cancer   \n",
       "42                                  Colorectal Cancer   \n",
       "43                          Small Cell Lung Carcinoma   \n",
       "44                     Carcinoma, Non-Small-Cell Lung   \n",
       "45                         Glioblastoma, IDH-wildtype   \n",
       "46     Melanoma (Skin), Non-Small-Cell Lung Carcinoma   \n",
       "47                                   Multiple Myeloma   \n",
       "48                      Extranodal NK/T-cell Lymphoma   \n",
       "49                                  Esophageal Cancer   \n",
       "\n",
       "                                              country  \\\n",
       "0                                       United States   \n",
       "1                                             Denmark   \n",
       "2                                               China   \n",
       "3                                               China   \n",
       "4                                       United States   \n",
       "5                                       United States   \n",
       "6                                       United States   \n",
       "7                                       United States   \n",
       "8                                               China   \n",
       "9                                       United States   \n",
       "10                                      United States   \n",
       "11                                            Germany   \n",
       "12                                      United States   \n",
       "13                                              China   \n",
       "14                                      United States   \n",
       "15                                        Switzerland   \n",
       "16                                      United States   \n",
       "17                                      United States   \n",
       "18                                      United States   \n",
       "19                                              Japan   \n",
       "20                                             Canada   \n",
       "21                                                NaN   \n",
       "22                                             Canada   \n",
       "23                                              China   \n",
       "24                                      United States   \n",
       "25                                      United States   \n",
       "26                                      United States   \n",
       "27                                              China   \n",
       "28                                 Korea, Republic of   \n",
       "29                                              China   \n",
       "30                                              China   \n",
       "31                                      United States   \n",
       "32                                      United States   \n",
       "33                                              China   \n",
       "34  Croatia, Greece, United States, Argentina, Jap...   \n",
       "35                                      United States   \n",
       "36                                              China   \n",
       "37                                      United States   \n",
       "38                                      United States   \n",
       "39                                             Canada   \n",
       "40                                      United States   \n",
       "41                         Puerto Rico, United States   \n",
       "42                                      United States   \n",
       "43                                            Germany   \n",
       "44                                              China   \n",
       "45                                      United States   \n",
       "46                     Spain, Belgium, United Kingdom   \n",
       "47                                              Italy   \n",
       "48                                              China   \n",
       "49                                      United States   \n",
       "\n",
       "      design_primary_purpose  \\\n",
       "0                  TREATMENT   \n",
       "1                  TREATMENT   \n",
       "2                  TREATMENT   \n",
       "3                  TREATMENT   \n",
       "4                  TREATMENT   \n",
       "5                  TREATMENT   \n",
       "6                  TREATMENT   \n",
       "7                  TREATMENT   \n",
       "8                  TREATMENT   \n",
       "9                  TREATMENT   \n",
       "10                 TREATMENT   \n",
       "11                 TREATMENT   \n",
       "12                 TREATMENT   \n",
       "13                 TREATMENT   \n",
       "14                 TREATMENT   \n",
       "15                DIAGNOSTIC   \n",
       "16                 TREATMENT   \n",
       "17                 TREATMENT   \n",
       "18           SUPPORTIVE_CARE   \n",
       "19                 TREATMENT   \n",
       "20                 TREATMENT   \n",
       "21                 TREATMENT   \n",
       "22                 TREATMENT   \n",
       "23                 TREATMENT   \n",
       "24                 TREATMENT   \n",
       "25                 TREATMENT   \n",
       "26                PREVENTION   \n",
       "27                 TREATMENT   \n",
       "28                 TREATMENT   \n",
       "29                 TREATMENT   \n",
       "30                 TREATMENT   \n",
       "31                 TREATMENT   \n",
       "32                 TREATMENT   \n",
       "33                 TREATMENT   \n",
       "34                 TREATMENT   \n",
       "35                 TREATMENT   \n",
       "36                 TREATMENT   \n",
       "37                 TREATMENT   \n",
       "38                 TREATMENT   \n",
       "39                 TREATMENT   \n",
       "40                 TREATMENT   \n",
       "41                 TREATMENT   \n",
       "42  HEALTH_SERVICES_RESEARCH   \n",
       "43                 TREATMENT   \n",
       "44                 TREATMENT   \n",
       "45                 TREATMENT   \n",
       "46                 TREATMENT   \n",
       "47                 TREATMENT   \n",
       "48                 TREATMENT   \n",
       "49                DIAGNOSTIC   \n",
       "\n",
       "                                 detailed_description  \\\n",
       "0   This research is being done to see if it is sa...   \n",
       "1   This is an explorative phase 2 clinical trial ...   \n",
       "2                                                 NaN   \n",
       "3                                                 NaN   \n",
       "4   PRIMARY OBJECTIVE:\\n\\nI. To assess the effect ...   \n",
       "5   Treatment on study will be administered in 21 ...   \n",
       "6                                                 NaN   \n",
       "7   OBJECTIVES:\\n\\n* Determine if the timing of br...   \n",
       "8                                                 NaN   \n",
       "9   This is an exploratory phase 2, randomized pla...   \n",
       "10  PRI-724 is a new investigational drug being st...   \n",
       "11                                                NaN   \n",
       "12  OBJECTIVES:\\n\\n* Determine the maximum tolerat...   \n",
       "13                                                NaN   \n",
       "14  OBJECTIVES:\\n\\n* Determine the dose-limiting t...   \n",
       "15                                                NaN   \n",
       "16  Treatment will include a single course of lymp...   \n",
       "17  This study will assess whether adding bortezom...   \n",
       "18  This study is a prospective, controlled, pivot...   \n",
       "19                                                NaN   \n",
       "20                                                NaN   \n",
       "21                                                NaN   \n",
       "22  PDO is a three-dimensional experimental model ...   \n",
       "23                                                NaN   \n",
       "24  OBJECTIVES:\\n\\n* Determine the toxicity of rad...   \n",
       "25  Primary Objective:\\n\\n• To determine the effic...   \n",
       "26  Erlotinib hydrochloride is designed to block t...   \n",
       "27  This is a phase Ⅰ/Ⅱ, open-label study of TFX06...   \n",
       "28  Basal cell carcinoma (BCC) is the most common ...   \n",
       "29  This is a multi-center, randomized, double-bli...   \n",
       "30                                                NaN   \n",
       "31                                                NaN   \n",
       "32                                                NaN   \n",
       "33  Although the anti-CD19 CAR-T cell therapies ha...   \n",
       "34  The study consists of 3 phases: Screening Phas...   \n",
       "35                                                NaN   \n",
       "36                                                NaN   \n",
       "37                                                NaN   \n",
       "38                                                NaN   \n",
       "39  OBJECTIVES:\\n\\nPrimary\\n\\n* Determine the acti...   \n",
       "40  Definition: The phase 2 study will provide imp...   \n",
       "41                                                NaN   \n",
       "42  This study will test the separate and combined...   \n",
       "43                                                NaN   \n",
       "44  Lung cancer is one of the most common types of...   \n",
       "45  This is a randomized, open-label phase 2 study...   \n",
       "46  Overall Study Design:\\n\\n• This is an open-lab...   \n",
       "47  This phase III study represents a prospective ...   \n",
       "48  Previous study has confirmed the efficacy of a...   \n",
       "49                                                NaN   \n",
       "\n",
       "                                 eligibility_criteria enrollment  \\\n",
       "0   Inclusion:\\n\\nCohort 1: Subjects must have his...         26   \n",
       "1   Inclusion Criteria:\\n\\n* Patients must be ment...         10   \n",
       "2   Inclusion Criteria:\\n\\n1. Age 18 to 75 years o...        500   \n",
       "3   Inclusion Criteria:\\n\\n* 18-75 years old, male...        421   \n",
       "4   Inclusion Criteria:\\n\\n* Age \\>= 18 years at t...         51   \n",
       "5   Inclusion Criteria:\\n\\n* Patients must have hi...         20   \n",
       "6   Inclusion Criteria:\\n\\n3.1.1 Age Patients must...          9   \n",
       "7   DISEASE CHARACTERISTICS:\\n\\n* Histologically c...          ?   \n",
       "8   Inclusion Criteria:\\n\\n1. Age: 18-75 years old...         40   \n",
       "9   Inclusion Criteria:\\n\\n1. In the opinion of th...        381   \n",
       "10  Inclusion Criteria\\n\\n1. Patients 18 years or ...         49   \n",
       "11  Inclusion Criteria:\\n\\n1. Subjects must provid...         16   \n",
       "12  DISEASE CHARACTERISTICS:\\n\\n* Diagnosis of 1 o...         11   \n",
       "13  Inclusion Criteria:\\n\\n* Written informed cons...         30   \n",
       "14  DISEASE CHARACTERISTICS:\\n\\n* Histologically c...         75   \n",
       "15  Inclusion Criteria:\\n\\n* Colon cancer at any s...        192   \n",
       "16  Collection and Manufacturing Eligibility\\n\\nIn...         30   \n",
       "17  Inclusion Criteria:\\n\\n* Tissue diagnosis of a...         37   \n",
       "18  Inclusion Criteria:\\n\\n* Men and women with a ...        120   \n",
       "19  Inclusion Criteria:\\n\\n1. Have a histologicall...         30   \n",
       "20  Inclusion Criteria:\\n\\n* Adults (males or fema...         17   \n",
       "21  Inclusion Criteria:\\n\\n* Tumour recurrence aft...        272   \n",
       "22  Inclusion Criteria:\\n\\n1. Age 18 years or over...         25   \n",
       "23  Inclusion Criteria:\\n\\n1. Able to read and und...         20   \n",
       "24  DISEASE CHARACTERISTICS:\\n\\n* Histologically p...         40   \n",
       "25  Inclusion Criteria:\\n\\n1. Female or male patie...         25   \n",
       "26  Inclusion Criteria:\\n\\n1. Male or female patie...        303   \n",
       "27  Inclusion Criteria:\\n\\n1. voluntary participat...         74   \n",
       "28  Inclusion Criteria:\\n\\n* patient's request for...         34   \n",
       "29  Inclusion Criteria:\\n\\n* Histological examinat...         60   \n",
       "30  Inclusion Criteria:\\n\\n* Newly diagnosed histo...         49   \n",
       "31  For more information regarding BMS clinical tr...         74   \n",
       "32  DISEASE CHARACTERISTICS\\n\\n* Histologically pr...         40   \n",
       "33  Inclusion Criteria:\\n\\n1. Male or female, aged...         30   \n",
       "34  Inclusion Criteria:\\n\\n* Participant must have...        706   \n",
       "35  Inclusion Criteria:\\n\\n1. Age less than or equ...         20   \n",
       "36  Inclusion Criteria:\\n\\n1. Age ≥18 years old, b...         58   \n",
       "37  Key Inclusion Criteria:\\n\\n* Single agent (SA)...         94   \n",
       "38  Inclusion Criteria:\\n\\n* At least 18 years of ...         35   \n",
       "39  DISEASE CHARACTERISTICS:\\n\\n* Histologically o...         34   \n",
       "40  Inclusion Criteria:\\n\\n* Diagnosis of Non-Smal...          ?   \n",
       "41  Key Inclusion Criteria:\\n\\n1. Patient is able ...         68   \n",
       "42  Inclusion Criteria:\\n\\n* Patients aged 50-75 y...        569   \n",
       "43  Inclusion Criteria Pre-Screening:\\n\\n* Newly d...         29   \n",
       "44  Inclusion Criteria:\\n\\nParticipant must have h...         20   \n",
       "45  Inclusion Criteria:\\n\\n* Written informed cons...         54   \n",
       "46  Inclusion Criteria:\\n\\nMain Inclusion Criteria...         34   \n",
       "47  Inclusion Criteria:\\n\\n* Age \\> 65 year old an...        511   \n",
       "48  Inclusion Criteria:\\n\\nHistopathology and immu...         20   \n",
       "49  Inclusion Criteria:\\n\\n* Newly diagnosed or re...         22   \n",
       "\n",
       "                            interventions_description  \\\n",
       "0   One dose of Nivolumab 480mg given four weeks p...   \n",
       "1   Intratumoral application of an unattenuated in...   \n",
       "2   SHR-A2009 monotherapy ，SHR-A2009 will be admin...   \n",
       "3          Injection，100mg/10ml; Injection，100mg/10ml   \n",
       "4   Given by mouth; Given by mouth; Given by mouth...   \n",
       "5                                  Given PO; Given IV   \n",
       "6   Dosage: 1.25mg/kg intravenous with dose escala...   \n",
       "7                                                 NaN   \n",
       "8   In the phase, five dose groups were proposed.T...   \n",
       "9   Perifosine 50 mg/d qd; Capecitabine 825 mg/m\\^...   \n",
       "10  PRI-724; PRI-724 in combination with dasatinib...   \n",
       "11                                                NaN   \n",
       "12  Intravenously via a 3 cc plastic syringe as a ...   \n",
       "13  Tislelizumab: 200mg, IV, day 1 of each 21-day ...   \n",
       "14                                                NaN   \n",
       "15  After careful mobilization of the affected col...   \n",
       "16  IV; IV; IV; CAR T cell infusion will be given ...   \n",
       "17  Bortezomib 1.6 mg/m² given on days 1 and 8; Ri...   \n",
       "18  Cap attached to coolant lines connected to a r...   \n",
       "19  IV infusion Q3W; Oral capsule once daily; IV i...   \n",
       "20  Avelumab will be administered intravenously as...   \n",
       "21                                      Chemoablation   \n",
       "22  Cobimetinib is an antineoplastic agent and sel...   \n",
       "23  vaccination of autologous gp96 derived from tu...   \n",
       "24                                                NaN   \n",
       "25             Given by IV (vein); Given by IV (vein)   \n",
       "26       150 mg by mouth daily; Tablet by mouth daily   \n",
       "27                          TFX06 tablet taken orally   \n",
       "28  AFL was performed using a 2940-nm Er:YAG ablat...   \n",
       "29  Monoclonal antibodies, 100mg/10ml per injectio...   \n",
       "30  The PD-1 inhibitor Sintilimab 200mg for intrav...   \n",
       "31                                                NaN   \n",
       "32                   IV solution, weekly or bi-weekly   \n",
       "33  UCAR-T Cellswill be administered by vein. The ...   \n",
       "34  Participants will receive velcade 1.3 mg/m\\^2,...   \n",
       "35  Fludarabine: 30 mg/m2 daily for 5 days; Busulf...   \n",
       "36      SHR-1501, instillation；SHR-2005, instillation   \n",
       "37  FT-1101 will be supplied as 5 mg, 20 mg or 100...   \n",
       "38                                  10mg/kg; 670mg/m2   \n",
       "39                                                NaN   \n",
       "40                                                NaN   \n",
       "41                   Administered IV; Administered IV   \n",
       "42  Physicians at these clinics will participate i...   \n",
       "43                1500 mg i.v. Q4W; 300 mg BID orally   \n",
       "44  Osimertinib, 80mg, oral daily; bevacizumab (av...   \n",
       "45  Ropidoxuridine is administered daily, 5 days a...   \n",
       "46  Priming phase including 1 GAd-PEV administrati...   \n",
       "47  Induction therapy:\\n\\n9 courses with weekly VE...   \n",
       "48  200mg d1,ivdrip, repeated every 3 weeks; 10mg ...   \n",
       "49  15 mCi 11C-choline will be administered intrav...   \n",
       "\n",
       "                                   interventions_name  ...           phase  \\\n",
       "0              Nivolumab 480mg and surgical resection  ...          PHASE2   \n",
       "1                                  Influenza Vaccines  ...          PHASE2   \n",
       "2   SHR-A2009 monotherapy, platinum-based dual-age...  ...          PHASE3   \n",
       "3                                  SIBP-02, Rituximab  ...          PHASE3   \n",
       "4   Venetoclax, Decitabine, Cedazuridine, Bone Mar...  ...          PHASE2   \n",
       "5                         Cabozantinib, Pembrolizumab  ...          PHASE2   \n",
       "6                                MAb 216, Vincristine  ...          PHASE1   \n",
       "7                                conventional surgery  ...          PHASE3   \n",
       "8                                            QLF32004  ...          PHASE1   \n",
       "9        Perifosine, Capecitabine, Perifosine Placebo  ...          PHASE2   \n",
       "10                          PRI-724, PRI-724, PRI-724  ...  PHASE1, PHASE2   \n",
       "11                         Tranylcypromine, Tretinoin  ...  PHASE1, PHASE2   \n",
       "12                                           DT388IL3  ...  PHASE1, PHASE2   \n",
       "13  Tislelizumab, Pemetrexed (Nonsquamous NSCLC) o...  ...          PHASE2   \n",
       "14                                         entinostat  ...          PHASE1   \n",
       "15  Sentinel lymph node procedure, Bone marrow asp...  ...  PHASE1, PHASE2   \n",
       "16  Fludarabine, Cyclophosphamide, Mesna, CD19-CD2...  ...          PHASE1   \n",
       "17  Bortezomib, Rituximab, Doxorubicin, Cyclophosp...  ...  PHASE1, PHASE2   \n",
       "18  Paxman Scalp Cooling System, Eribulin, Sacituz...  ...          PHASE2   \n",
       "19  Pembrolizumab, Lenvatinib, Carboplatin, Pemetr...  ...          PHASE2   \n",
       "20                                           Avelumab  ...          PHASE2   \n",
       "21                                        Mitomycin c  ...          PHASE4   \n",
       "22  Cobimetinib, Ponatinib, Brigatinib, Colchicine...  ...          PHASE2   \n",
       "23                        autologous gp96 vaccination  ...  PHASE1, PHASE2   \n",
       "24  cisplatin, paclitaxel, brachytherapy, radiatio...  ...  PHASE1, PHASE2   \n",
       "25               Sacituzumab Govitecan, Pembrolizumab  ...          PHASE2   \n",
       "26                                 Erlotinib, Placebo  ...          PHASE3   \n",
       "27                                       TFX06 tablet  ...  PHASE1, PHASE2   \n",
       "28                            Er:YAG AFL-PDT, MAL-PDT  ...          PHASE1   \n",
       "29                 304 injection, rituximab injection  ...          PHASE1   \n",
       "30                                         Sintilimab  ...          PHASE2   \n",
       "31  Elotuzumab, Pomalidomide, Dexamethasone, Nivol...  ...          PHASE2   \n",
       "32                                             CT-322  ...          PHASE1   \n",
       "33                                       UCAR-T Cells  ...  PHASE1, PHASE2   \n",
       "34  Velcade, Melphalan, Prednisone, Daratumumab IV...  ...          PHASE3   \n",
       "35    Fludarabine, Busulfan, Rabbit ATG, Methotrexate  ...          PHASE1   \n",
       "36                                  SHR-1501+SHR-2005  ...  PHASE1, PHASE2   \n",
       "37                               FT-1101, Azacitidine  ...          PHASE1   \n",
       "38                                Bevacizumab, TH-302  ...          PHASE2   \n",
       "39  carboplatin, cisplatin, gemcitabine hydrochloride  ...          PHASE2   \n",
       "40                 Gemcitabine, Carboplatin, LY900003  ...          PHASE2   \n",
       "41                      Pegzilarginase, Pembrolizumab  ...  PHASE1, PHASE2   \n",
       "42  Physician Intervention, Physician and Patient ...  ...  PHASE2, PHASE3   \n",
       "43                               Durvalumab, Olaparib  ...          PHASE2   \n",
       "44                            Osimertinib Oral Tablet  ...          PHASE2   \n",
       "45                                     Ropidoxuridine  ...          PHASE2   \n",
       "46                                   GAd-PEV, MVA-PEV  ...          PHASE1   \n",
       "47  Bortezomib, Melphalan, Prednisone, Thalidomide...  ...          PHASE3   \n",
       "48                             Sintilimab, Decitabine  ...          PHASE2   \n",
       "49                                        C11-Choline  ...          PHASE1   \n",
       "\n",
       "   primary_completion_date                                   primary_outcomes  \\\n",
       "0               2023-10-17  Safety as Measured by Number of Participants W...   \n",
       "1               2021-09-22  Safety - Adverse reactions are classified acco...   \n",
       "2                  2026-12  Progression-free survival (PFS) assessed by BI...   \n",
       "3               2022-05-20                        Overall Response Rate (ORR)   \n",
       "4                  2028-03  Composite complete response (CR) rate (CR/comp...   \n",
       "5               2023-11-25  Percentage of Participants with Progression-fr...   \n",
       "6                  2009-02  In this phase I study the endpoint is the dete...   \n",
       "7                        ?                                                NaN   \n",
       "8               2024-12-30  Dose-Limiting Toxicity (DLT); Maximum Tolerate...   \n",
       "9                  2010-12       Effects of perifosine on time to progression   \n",
       "10              2016-12-30                       DLT (Dose Limiting Toxicity)   \n",
       "11                 2017-09  Analysis of the cumulative response rate (CR,C...   \n",
       "12              2017-07-27  Overall Response Rate (CR+PR+SD): Percentage o...   \n",
       "13              2024-02-29                                 Resectability rate   \n",
       "14                 2008-04  Dose-limiting toxicities and maximum tolerated...   \n",
       "15                 2009-01  To assess the extent of upstaging due to the S...   \n",
       "16                 2030-01  Recommended phase 2 dose (RP2D) of CD19-CD22-C...   \n",
       "17                 2015-11  Maximal Tolerated Doses of Bortezomib and Vinc...   \n",
       "18              2026-06-01                                     Hair Loss Rate   \n",
       "19              2023-10-31  Objective Response Rate (ORR) as Assessed by B...   \n",
       "20              2021-07-26                        Overall response rate (ORR)   \n",
       "21              2029-02-01                  Two-year Recurrence Free Survival   \n",
       "22              2028-02-17                      Objective response rate (ORR)   \n",
       "23                 2016-11  blood count; blood count; blood count; blood c...   \n",
       "24                 2007-01                                                NaN   \n",
       "25              2026-12-31  Incidence of Adverse Events, Graded According ...   \n",
       "26              2018-06-04  Oral Cancer-free Survival in Participants Rece...   \n",
       "27              2024-12-30  Recommended phase 2 Dose (RP2D); Disease Contr...   \n",
       "28                 2013-02  Difference the efficacy between Er:YAG AFL-PDT...   \n",
       "29              2019-06-30                         AUC [0-t]; AUC [0-∞]; Cmax   \n",
       "30                 2023-12                 Pathologic Complete Response (pCR)   \n",
       "31              2019-07-29  Progression Free Survival (PFS); Objective Res...   \n",
       "32                 2008-11                  Safety and tolerability of CT-322   \n",
       "33              2024-12-31  Dose-limiting toxicity (DLT); Incidence of Tre...   \n",
       "34              2017-11-21                    Progression Free Survival (PFS)   \n",
       "35              2019-06-07  Number of patients who are surviving at 100-Da...   \n",
       "36              2027-10-01  Phase I : Incidence of dose limiting toxicitie...   \n",
       "37                 2019-03  Maximum Tolerated Dose (MTD); Dose Limiting To...   \n",
       "38              2019-01-04             Number of Patients With Adverse Events   \n",
       "39              2008-09-29  Objective response measured by RECIST criteria...   \n",
       "40                       ?                                                NaN   \n",
       "41              2021-01-01  1. Phase 1: Incidence of treatment-related adv...   \n",
       "42                 2013-07  Colorectal Cancer (CRC) Screening Completion; ...   \n",
       "43                 2026-09                    Progression-free survival (PFS)   \n",
       "44              2024-07-31                          Progression free survival   \n",
       "45                 2026-08  Number of patients treated with oral ropidoxur...   \n",
       "46              2024-10-31  Safety and tolerability: incidence of treatmen...   \n",
       "47                 2014-07  Determine whether the V-MPT combination improv...   \n",
       "48              2022-12-31                             complete response rate   \n",
       "49                 2013-08  To evaluate our ability to obtain reliable and...   \n",
       "\n",
       "                                   secondary_outcomes     sex  start_date  \\\n",
       "0   Major Pathologic Response Rate; Progression Fr...     ALL  2019-07-08   \n",
       "1              Efficacy - local immunological changes     ALL  2021-02-26   \n",
       "2   overall survival (OS); Progression Free Surviv...     ALL  2024-11-29   \n",
       "3                                                 NaN     ALL  2019-07-25   \n",
       "4   Rate of partial response (PR) following treatm...     ALL  2024-01-29   \n",
       "5   Percentage of Grade 3-5 Adverse Events; Overal...     ALL  2020-02-04   \n",
       "6   A decrease in leukemic blasts. The study will ...     ALL     2006-05   \n",
       "7                                                 NaN  FEMALE     1999-01   \n",
       "8   Treatment-Emergent Adverse Event (TEAE); Maxim...     ALL  2021-11-09   \n",
       "9   Toxicity; Comparison of time to progression to...     ALL     2005-08   \n",
       "10                     Preliminary Efficacy Endpoints     ALL     2012-07   \n",
       "11  number of participants with adverse events as ...     ALL     2014-09   \n",
       "12                                                NaN     ALL     2013-05   \n",
       "13  Major pathological response rate (MPR); Pathol...     ALL  2023-03-12   \n",
       "14  Acetylation of histones in peripheral blood; T...     ALL     2001-03   \n",
       "15  To evaluate the accuracy of the SLN procedure ...     ALL     2000-05   \n",
       "16                                                NaN     ALL     2025-05   \n",
       "17  An Estimate of the Overall Response Rate (ORR)...     ALL     2008-02   \n",
       "18  Change in Patient Reported Quality of Life; Ch...     ALL  2021-10-07   \n",
       "19  Objective Response Rate (ORR) as Assessed by i...     ALL  2022-07-01   \n",
       "20  Disease control rate (DCR); Duration of respon...     ALL  2017-11-15   \n",
       "21  Five-year RFS; Number of patients in need of a...     ALL  2025-02-24   \n",
       "22  Disease control rate (DCR); Duration of respon...     ALL  2025-02-17   \n",
       "23  Disease-free survival; overall survive; change...     ALL     2012-03   \n",
       "24                                                NaN  FEMALE     1999-11   \n",
       "25                                                NaN     ALL  2023-05-23   \n",
       "26                                                NaN     ALL  2006-11-03   \n",
       "27  Incidence of Treatment-Emergent Adverse Events...  FEMALE  2023-04-17   \n",
       "28  Difference of the cosmetic outcomes between Er...     ALL     2011-03   \n",
       "29      tmax; t1/2; MRT; Vz; CLz; ADA; Adverse events     ALL  2018-12-18   \n",
       "30                                                NaN  FEMALE     2021-03   \n",
       "31  Objective Response Rate (ORR); Progression Fre...     ALL  2016-02-09   \n",
       "32  To evaluate the pharmacokinetics of CT-322 in ...     ALL     2006-08   \n",
       "33  Persistence of CAR-T cells; Objective response...     ALL  2022-12-05   \n",
       "34  Overall Response Rate (ORR); Percentage of Par...     ALL  2014-12-09   \n",
       "35  Time to marrow engraftment; Assessing all subj...     ALL  2016-09-06   \n",
       "36  Phase I : CR rate at 3 months; Phase II : Inci...     ALL  2024-10-01   \n",
       "37  Area under the plasma concentration versus tim...     ALL     2015-09   \n",
       "38                          Progression Free Survival     ALL     2015-05   \n",
       "39  Toxicity assessed by NCI CTC v2.0; Overall sur...     ALL  2003-10-27   \n",
       "40                                                NaN     ALL     2002-06   \n",
       "41  Objective Response Rate; Clinical Benefit Rate...     ALL  2017-12-21   \n",
       "42           Provider Recommendation of CRC Screening     ALL     2010-04   \n",
       "43  Incidence, severity and grading of adverse eve...     ALL  2024-10-09   \n",
       "44  Objective Response Rate (ORR); Overall Surviva...     ALL  2021-07-01   \n",
       "45  Overall survival at 12 months; Radiographic Re...     ALL  2024-09-02   \n",
       "46  RP2D confirmation 2. Clinical efficacy:; Clini...     ALL  2021-06-11   \n",
       "47  Determine whether the VMPT combination improve...     ALL     2006-05   \n",
       "48  overall response rate; 1-year progression free...     ALL  2020-04-01   \n",
       "49  Perform semi-quantitative analysis of tracer u...     ALL     2010-03   \n",
       "\n",
       "                       stdage study_first_post_date study_first_submit_date  \\\n",
       "0          ADULT, OLDER_ADULT            2019-03-18              2019-03-15   \n",
       "1          ADULT, OLDER_ADULT            2020-10-19              2020-09-07   \n",
       "2          ADULT, OLDER_ADULT            2024-11-04              2024-11-01   \n",
       "3          ADULT, OLDER_ADULT            2020-04-24              2020-04-22   \n",
       "4          ADULT, OLDER_ADULT            2023-04-05              2023-03-22   \n",
       "5          ADULT, OLDER_ADULT            2019-11-15              2019-11-13   \n",
       "6          ADULT, OLDER_ADULT            2006-04-11              2006-04-07   \n",
       "7   CHILD, ADULT, OLDER_ADULT            2003-01-27              2000-04-06   \n",
       "8          ADULT, OLDER_ADULT            2021-11-05              2021-10-22   \n",
       "9          ADULT, OLDER_ADULT            2006-11-14              2006-11-06   \n",
       "10         ADULT, OLDER_ADULT            2012-05-25              2012-05-16   \n",
       "11         ADULT, OLDER_ADULT            2014-10-10              2014-09-23   \n",
       "12         ADULT, OLDER_ADULT            2006-11-09              2006-11-08   \n",
       "13         ADULT, OLDER_ADULT            2022-11-10              2022-11-04   \n",
       "14         ADULT, OLDER_ADULT            2003-01-27              2001-07-11   \n",
       "15  CHILD, ADULT, OLDER_ADULT            2009-01-22              2009-01-13   \n",
       "16               CHILD, ADULT            2025-01-16              2025-01-10   \n",
       "17         ADULT, OLDER_ADULT            2008-03-12              2008-02-11   \n",
       "18         ADULT, OLDER_ADULT            2021-08-03              2021-07-20   \n",
       "19         ADULT, OLDER_ADULT            2022-02-28              2022-02-17   \n",
       "20         ADULT, OLDER_ADULT            2017-09-11              2017-08-23   \n",
       "21         ADULT, OLDER_ADULT            2025-01-17              2025-01-14   \n",
       "22         ADULT, OLDER_ADULT            2025-02-06              2025-02-03   \n",
       "23         ADULT, OLDER_ADULT            2014-05-07              2014-05-03   \n",
       "24         ADULT, OLDER_ADULT            2003-01-27              1999-11-01   \n",
       "25         ADULT, OLDER_ADULT            2023-01-09              2022-12-22   \n",
       "26         ADULT, OLDER_ADULT            2006-11-22              2006-11-20   \n",
       "27         ADULT, OLDER_ADULT            2023-07-03              2023-06-03   \n",
       "28         ADULT, OLDER_ADULT            2013-12-23              2013-11-29   \n",
       "29         ADULT, OLDER_ADULT            2019-06-10              2019-06-06   \n",
       "30                      ADULT            2021-03-22              2021-03-19   \n",
       "31         ADULT, OLDER_ADULT            2015-11-24              2015-11-20   \n",
       "32         ADULT, OLDER_ADULT            2006-09-11              2006-09-08   \n",
       "33  CHILD, ADULT, OLDER_ADULT            2022-12-06              2022-11-25   \n",
       "34         ADULT, OLDER_ADULT            2014-07-21              2014-07-18   \n",
       "35         ADULT, OLDER_ADULT            2016-09-28              2016-08-15   \n",
       "36         ADULT, OLDER_ADULT            2024-09-19              2024-09-05   \n",
       "37         ADULT, OLDER_ADULT            2015-09-07              2015-09-01   \n",
       "38         ADULT, OLDER_ADULT            2015-01-19              2015-01-14   \n",
       "39         ADULT, OLDER_ADULT            2004-03-09              2004-03-08   \n",
       "40         ADULT, OLDER_ADULT            2002-08-06              2002-08-02   \n",
       "41         ADULT, OLDER_ADULT            2017-12-13              2017-11-20   \n",
       "42         ADULT, OLDER_ADULT            2010-04-14              2010-04-12   \n",
       "43         ADULT, OLDER_ADULT            2024-05-17              2024-05-03   \n",
       "44         ADULT, OLDER_ADULT            2021-07-23              2021-07-16   \n",
       "45         ADULT, OLDER_ADULT            2024-04-11              2024-03-24   \n",
       "46         ADULT, OLDER_ADULT            2021-08-04              2021-07-15   \n",
       "47                OLDER_ADULT            2010-02-05              2010-02-04   \n",
       "48         ADULT, OLDER_ADULT            2020-02-21              2020-02-19   \n",
       "49         ADULT, OLDER_ADULT            2010-01-18              2010-01-15   \n",
       "\n",
       "        study_type  \n",
       "0   INTERVENTIONAL  \n",
       "1   INTERVENTIONAL  \n",
       "2   INTERVENTIONAL  \n",
       "3   INTERVENTIONAL  \n",
       "4   INTERVENTIONAL  \n",
       "5   INTERVENTIONAL  \n",
       "6   INTERVENTIONAL  \n",
       "7   INTERVENTIONAL  \n",
       "8   INTERVENTIONAL  \n",
       "9   INTERVENTIONAL  \n",
       "10  INTERVENTIONAL  \n",
       "11  INTERVENTIONAL  \n",
       "12  INTERVENTIONAL  \n",
       "13  INTERVENTIONAL  \n",
       "14  INTERVENTIONAL  \n",
       "15  INTERVENTIONAL  \n",
       "16  INTERVENTIONAL  \n",
       "17  INTERVENTIONAL  \n",
       "18  INTERVENTIONAL  \n",
       "19  INTERVENTIONAL  \n",
       "20  INTERVENTIONAL  \n",
       "21  INTERVENTIONAL  \n",
       "22  INTERVENTIONAL  \n",
       "23  INTERVENTIONAL  \n",
       "24  INTERVENTIONAL  \n",
       "25  INTERVENTIONAL  \n",
       "26  INTERVENTIONAL  \n",
       "27  INTERVENTIONAL  \n",
       "28  INTERVENTIONAL  \n",
       "29  INTERVENTIONAL  \n",
       "30  INTERVENTIONAL  \n",
       "31  INTERVENTIONAL  \n",
       "32  INTERVENTIONAL  \n",
       "33  INTERVENTIONAL  \n",
       "34  INTERVENTIONAL  \n",
       "35  INTERVENTIONAL  \n",
       "36  INTERVENTIONAL  \n",
       "37  INTERVENTIONAL  \n",
       "38  INTERVENTIONAL  \n",
       "39  INTERVENTIONAL  \n",
       "40  INTERVENTIONAL  \n",
       "41  INTERVENTIONAL  \n",
       "42  INTERVENTIONAL  \n",
       "43  INTERVENTIONAL  \n",
       "44  INTERVENTIONAL  \n",
       "45  INTERVENTIONAL  \n",
       "46  INTERVENTIONAL  \n",
       "47  INTERVENTIONAL  \n",
       "48  INTERVENTIONAL  \n",
       "49  INTERVENTIONAL  \n",
       "\n",
       "[50 rows x 35 columns]"
      ]
     },
     "execution_count": 27,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.head(50)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "id": "9388472b",
   "metadata": {},
   "outputs": [],
   "source": [
    "import re\n",
    "\n",
    "# Your date columns\n",
    "date_cols = [\n",
    "    'completion_date',\n",
    "    'last_update_post_date',\n",
    "    'primary_completion_date',\n",
    "    'start_date',\n",
    "    'study_first_post_date',\n",
    "    'study_first_submit_date'\n",
    "]\n",
    "\n",
    "# Function to insert day=15 if day is missing\n",
    "def fill_day_15(date_str):\n",
    "    if pd.isna(date_str):\n",
    "        return np.nan\n",
    "    date_str = str(date_str).strip()\n",
    "    \n",
    "    # Check if format is like \"Jan 2023\" or \"2023-01\"\n",
    "    if re.fullmatch(r'[A-Za-z]{3,9}\\s+\\d{4}', date_str):  # e.g., \"March 2021\"\n",
    "        return f'15 {date_str}'\n",
    "    elif re.fullmatch(r'\\d{4}-\\d{2}', date_str):  # e.g., \"2023-01\"\n",
    "        return f'{date_str}-15'\n",
    "    return date_str  # return unchanged if full date is already present\n",
    "\n",
    "# Apply transformation and convert to datetime\n",
    "for col in date_cols:\n",
    "    df[col] = df[col].apply(fill_day_15)  # Fill in day if needed\n",
    "    df[col] = pd.to_datetime(df[col], errors='coerce')  # Convert to datetime"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "id": "2d671049",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>brief_summary</th>\n",
       "      <th>completion_date</th>\n",
       "      <th>conditions</th>\n",
       "      <th>country</th>\n",
       "      <th>design_primary_purpose</th>\n",
       "      <th>detailed_description</th>\n",
       "      <th>eligibility_criteria</th>\n",
       "      <th>enrollment</th>\n",
       "      <th>interventions_description</th>\n",
       "      <th>interventions_name</th>\n",
       "      <th>...</th>\n",
       "      <th>phase</th>\n",
       "      <th>primary_completion_date</th>\n",
       "      <th>primary_outcomes</th>\n",
       "      <th>secondary_outcomes</th>\n",
       "      <th>sex</th>\n",
       "      <th>start_date</th>\n",
       "      <th>stdage</th>\n",
       "      <th>study_first_post_date</th>\n",
       "      <th>study_first_submit_date</th>\n",
       "      <th>study_type</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Nivolumab, also known as (Bristol Myers Squibb...</td>\n",
       "      <td>2023-10-17</td>\n",
       "      <td>Head and Neck Squamous Cell Carcinoma, Head an...</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This research is being done to see if it is sa...</td>\n",
       "      <td>Inclusion:\\n\\nCohort 1: Subjects must have his...</td>\n",
       "      <td>26</td>\n",
       "      <td>One dose of Nivolumab 480mg given four weeks p...</td>\n",
       "      <td>Nivolumab 480mg and surgical resection</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2023-10-17</td>\n",
       "      <td>Safety as Measured by Number of Participants W...</td>\n",
       "      <td>Major Pathologic Response Rate; Progression Fr...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2019-07-08</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2019-03-18</td>\n",
       "      <td>2019-03-15</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>The aim of this explorative phase II clinical ...</td>\n",
       "      <td>2021-11-01</td>\n",
       "      <td>Colorectal Cancer</td>\n",
       "      <td>Denmark</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This is an explorative phase 2 clinical trial ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Patients must be ment...</td>\n",
       "      <td>10</td>\n",
       "      <td>Intratumoral application of an unattenuated in...</td>\n",
       "      <td>Influenza Vaccines</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2021-09-22</td>\n",
       "      <td>Safety - Adverse reactions are classified acco...</td>\n",
       "      <td>Efficacy - local immunological changes</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2021-02-26</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2020-10-19</td>\n",
       "      <td>2020-09-07</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>This study was a randomized, controlled, open-...</td>\n",
       "      <td>2027-06-15</td>\n",
       "      <td>Non-small Cell Lung Cancer</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Age 18 to 75 years o...</td>\n",
       "      <td>500</td>\n",
       "      <td>SHR-A2009 monotherapy ，SHR-A2009 will be admin...</td>\n",
       "      <td>SHR-A2009 monotherapy, platinum-based dual-age...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>2026-12-15</td>\n",
       "      <td>Progression-free survival (PFS) assessed by BI...</td>\n",
       "      <td>overall survival (OS); Progression Free Surviv...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2024-11-29</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2024-11-04</td>\n",
       "      <td>2024-11-01</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>This is a randomised, double-blind, positive d...</td>\n",
       "      <td>2022-05-20</td>\n",
       "      <td>Diffuse Large B-Cell Lymphoma</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* 18-75 years old, male...</td>\n",
       "      <td>421</td>\n",
       "      <td>Injection，100mg/10ml; Injection，100mg/10ml</td>\n",
       "      <td>SIBP-02, Rituximab</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>2022-05-20</td>\n",
       "      <td>Overall Response Rate (ORR)</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2019-07-25</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2020-04-24</td>\n",
       "      <td>2020-04-22</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>This phase II trial tests how well decitabine ...</td>\n",
       "      <td>2029-03-15</td>\n",
       "      <td>Recurrent Acute Myeloid Leukemia</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>PRIMARY OBJECTIVE:\\n\\nI. To assess the effect ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Age \\&gt;= 18 years at t...</td>\n",
       "      <td>51</td>\n",
       "      <td>Given by mouth; Given by mouth; Given by mouth...</td>\n",
       "      <td>Venetoclax, Decitabine, Cedazuridine, Bone Mar...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2028-03-15</td>\n",
       "      <td>Composite complete response (CR) rate (CR/comp...</td>\n",
       "      <td>Rate of partial response (PR) following treatm...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2024-01-29</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2023-04-05</td>\n",
       "      <td>2023-03-22</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>This is a phase 2 single-arm, open-label clini...</td>\n",
       "      <td>2024-12-30</td>\n",
       "      <td>Gastric Adenocarcinoma, GastroEsophageal Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Treatment on study will be administered in 21 ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Patients must have hi...</td>\n",
       "      <td>20</td>\n",
       "      <td>Given PO; Given IV</td>\n",
       "      <td>Cabozantinib, Pembrolizumab</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2023-11-25</td>\n",
       "      <td>Percentage of Participants with Progression-fr...</td>\n",
       "      <td>Percentage of Grade 3-5 Adverse Events; Overal...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2020-02-04</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2019-11-15</td>\n",
       "      <td>2019-11-13</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>A phase I trial in patients with relapsed or r...</td>\n",
       "      <td>2009-07-15</td>\n",
       "      <td>Leukemia, Lymphocytic, Leukemia, Acute Lymphoc...</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n3.1.1 Age Patients must...</td>\n",
       "      <td>9</td>\n",
       "      <td>Dosage: 1.25mg/kg intravenous with dose escala...</td>\n",
       "      <td>MAb 216, Vincristine</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2009-02-15</td>\n",
       "      <td>In this phase I study the endpoint is the dete...</td>\n",
       "      <td>A decrease in leukemic blasts. The study will ...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2006-05-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2006-04-11</td>\n",
       "      <td>2006-04-07</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>RATIONALE: The timing of breast cancer surgery...</td>\n",
       "      <td>2004-10-15</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>OBJECTIVES:\\n\\n* Determine if the timing of br...</td>\n",
       "      <td>DISEASE CHARACTERISTICS:\\n\\n* Histologically c...</td>\n",
       "      <td>?</td>\n",
       "      <td>NaN</td>\n",
       "      <td>conventional surgery</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>NaT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>FEMALE</td>\n",
       "      <td>1999-01-15</td>\n",
       "      <td>CHILD, ADULT, OLDER_ADULT</td>\n",
       "      <td>2003-01-27</td>\n",
       "      <td>2000-04-06</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>To determine the safety, tolerability, and rec...</td>\n",
       "      <td>2024-12-30</td>\n",
       "      <td>Advanced Tumor</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Age: 18-75 years old...</td>\n",
       "      <td>40</td>\n",
       "      <td>In the phase, five dose groups were proposed.T...</td>\n",
       "      <td>QLF32004</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2024-12-30</td>\n",
       "      <td>Dose-Limiting Toxicity (DLT); Maximum Tolerate...</td>\n",
       "      <td>Treatment-Emergent Adverse Event (TEAE); Maxim...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2021-11-09</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2021-11-05</td>\n",
       "      <td>2021-10-22</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>This is an exploratory phase 2, randomized pla...</td>\n",
       "      <td>2011-10-15</td>\n",
       "      <td>Colon Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This is an exploratory phase 2, randomized pla...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. In the opinion of th...</td>\n",
       "      <td>381</td>\n",
       "      <td>Perifosine 50 mg/d qd; Capecitabine 825 mg/m\\^...</td>\n",
       "      <td>Perifosine, Capecitabine, Perifosine Placebo</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2010-12-15</td>\n",
       "      <td>Effects of perifosine on time to progression</td>\n",
       "      <td>Toxicity; Comparison of time to progression to...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2005-08-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2006-11-14</td>\n",
       "      <td>2006-11-06</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>PRI-724 is a new investigational drug being st...</td>\n",
       "      <td>2016-12-30</td>\n",
       "      <td>Acute Myeloid Leukemia, Chronic Myeloid Leukemia</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>PRI-724 is a new investigational drug being st...</td>\n",
       "      <td>Inclusion Criteria\\n\\n1. Patients 18 years or ...</td>\n",
       "      <td>49</td>\n",
       "      <td>PRI-724; PRI-724 in combination with dasatinib...</td>\n",
       "      <td>PRI-724, PRI-724, PRI-724</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2016-12-30</td>\n",
       "      <td>DLT (Dose Limiting Toxicity)</td>\n",
       "      <td>Preliminary Efficacy Endpoints</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2012-07-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2012-05-25</td>\n",
       "      <td>2012-05-16</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Longterm disease-free survival (DFS) of older ...</td>\n",
       "      <td>2017-09-15</td>\n",
       "      <td>AML</td>\n",
       "      <td>Germany</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Subjects must provid...</td>\n",
       "      <td>16</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tranylcypromine, Tretinoin</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2017-09-15</td>\n",
       "      <td>Analysis of the cumulative response rate (CR,C...</td>\n",
       "      <td>number of participants with adverse events as ...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2014-09-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2014-10-10</td>\n",
       "      <td>2014-09-23</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>RATIONALE: Combinations of biological substanc...</td>\n",
       "      <td>2017-07-27</td>\n",
       "      <td>Leukemia, Myelodysplastic Syndromes, Blastic P...</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>OBJECTIVES:\\n\\n* Determine the maximum tolerat...</td>\n",
       "      <td>DISEASE CHARACTERISTICS:\\n\\n* Diagnosis of 1 o...</td>\n",
       "      <td>11</td>\n",
       "      <td>Intravenously via a 3 cc plastic syringe as a ...</td>\n",
       "      <td>DT388IL3</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2017-07-27</td>\n",
       "      <td>Overall Response Rate (CR+PR+SD): Percentage o...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2013-05-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2006-11-09</td>\n",
       "      <td>2006-11-08</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>The purpose of this conversion therapy study i...</td>\n",
       "      <td>2024-04-30</td>\n",
       "      <td>NSCLC, Stage III</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Written informed cons...</td>\n",
       "      <td>30</td>\n",
       "      <td>Tislelizumab: 200mg, IV, day 1 of each 21-day ...</td>\n",
       "      <td>Tislelizumab, Pemetrexed (Nonsquamous NSCLC) o...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2024-02-29</td>\n",
       "      <td>Resectability rate</td>\n",
       "      <td>Major pathological response rate (MPR); Pathol...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2023-03-12</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2022-11-10</td>\n",
       "      <td>2022-11-04</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>RATIONALE: MS-275 may stop the growth of cance...</td>\n",
       "      <td>2008-10-15</td>\n",
       "      <td>Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>OBJECTIVES:\\n\\n* Determine the dose-limiting t...</td>\n",
       "      <td>DISEASE CHARACTERISTICS:\\n\\n* Histologically c...</td>\n",
       "      <td>75</td>\n",
       "      <td>NaN</td>\n",
       "      <td>entinostat</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2008-04-15</td>\n",
       "      <td>Dose-limiting toxicities and maximum tolerated...</td>\n",
       "      <td>Acetylation of histones in peripheral blood; T...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2001-03-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2003-01-27</td>\n",
       "      <td>2001-07-11</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>The study is a feasibility and validation stud...</td>\n",
       "      <td>2009-01-15</td>\n",
       "      <td>Colonic Neoplasms</td>\n",
       "      <td>Switzerland</td>\n",
       "      <td>DIAGNOSTIC</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Colon cancer at any s...</td>\n",
       "      <td>192</td>\n",
       "      <td>After careful mobilization of the affected col...</td>\n",
       "      <td>Sentinel lymph node procedure, Bone marrow asp...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2009-01-15</td>\n",
       "      <td>To assess the extent of upstaging due to the S...</td>\n",
       "      <td>To evaluate the accuracy of the SLN procedure ...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2000-05-15</td>\n",
       "      <td>CHILD, ADULT, OLDER_ADULT</td>\n",
       "      <td>2009-01-22</td>\n",
       "      <td>2009-01-13</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>This study is a phase I study designed to eval...</td>\n",
       "      <td>2031-01-15</td>\n",
       "      <td>Acute Lymphoblastic Leukemia, Recurrent Acute ...</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Treatment will include a single course of lymp...</td>\n",
       "      <td>Collection and Manufacturing Eligibility\\n\\nIn...</td>\n",
       "      <td>30</td>\n",
       "      <td>IV; IV; IV; CAR T cell infusion will be given ...</td>\n",
       "      <td>Fludarabine, Cyclophosphamide, Mesna, CD19-CD2...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2030-01-15</td>\n",
       "      <td>Recommended phase 2 dose (RP2D) of CD19-CD22-C...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2025-05-15</td>\n",
       "      <td>CHILD, ADULT</td>\n",
       "      <td>2025-01-16</td>\n",
       "      <td>2025-01-10</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>This is an open-label (doctors and patients kn...</td>\n",
       "      <td>2015-11-15</td>\n",
       "      <td>Lymphoma, B-Cell, Follicular Lymphoma</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This study will assess whether adding bortezom...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Tissue diagnosis of a...</td>\n",
       "      <td>37</td>\n",
       "      <td>Bortezomib 1.6 mg/m² given on days 1 and 8; Ri...</td>\n",
       "      <td>Bortezomib, Rituximab, Doxorubicin, Cyclophosp...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2015-11-15</td>\n",
       "      <td>Maximal Tolerated Doses of Bortezomib and Vinc...</td>\n",
       "      <td>An Estimate of the Overall Response Rate (ORR)...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2008-02-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2008-03-12</td>\n",
       "      <td>2008-02-11</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>This research is being done to compare rates o...</td>\n",
       "      <td>2028-06-01</td>\n",
       "      <td>Metastatic Breast Cancer, Chemotherapy-induced...</td>\n",
       "      <td>United States</td>\n",
       "      <td>SUPPORTIVE_CARE</td>\n",
       "      <td>This study is a prospective, controlled, pivot...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Men and women with a ...</td>\n",
       "      <td>120</td>\n",
       "      <td>Cap attached to coolant lines connected to a r...</td>\n",
       "      <td>Paxman Scalp Cooling System, Eribulin, Sacituz...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2026-06-01</td>\n",
       "      <td>Hair Loss Rate</td>\n",
       "      <td>Change in Patient Reported Quality of Life; Ch...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2021-10-07</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2021-08-03</td>\n",
       "      <td>2021-07-20</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>The purpose of this study is to assess the saf...</td>\n",
       "      <td>2024-10-15</td>\n",
       "      <td>Non-squamous Non-small-cell Lung Cancer, EGFR ...</td>\n",
       "      <td>Japan</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Have a histologicall...</td>\n",
       "      <td>30</td>\n",
       "      <td>IV infusion Q3W; Oral capsule once daily; IV i...</td>\n",
       "      <td>Pembrolizumab, Lenvatinib, Carboplatin, Pemetr...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2023-10-31</td>\n",
       "      <td>Objective Response Rate (ORR) as Assessed by B...</td>\n",
       "      <td>Objective Response Rate (ORR) as Assessed by i...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2022-07-01</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2022-02-28</td>\n",
       "      <td>2022-02-17</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>This is a single-center, single-arm, open-labe...</td>\n",
       "      <td>2023-07-06</td>\n",
       "      <td>Neuroendocrine Tumors</td>\n",
       "      <td>Canada</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Adults (males or fema...</td>\n",
       "      <td>17</td>\n",
       "      <td>Avelumab will be administered intravenously as...</td>\n",
       "      <td>Avelumab</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2021-07-26</td>\n",
       "      <td>Overall response rate (ORR)</td>\n",
       "      <td>Disease control rate (DCR); Duration of respon...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2017-11-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2017-09-11</td>\n",
       "      <td>2017-08-23</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>The investigartors will conduct a randomized, ...</td>\n",
       "      <td>2032-02-01</td>\n",
       "      <td>Non-Muscle Invasive Bladder Cancer</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Tumour recurrence aft...</td>\n",
       "      <td>272</td>\n",
       "      <td>Chemoablation</td>\n",
       "      <td>Mitomycin c</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE4</td>\n",
       "      <td>2029-02-01</td>\n",
       "      <td>Two-year Recurrence Free Survival</td>\n",
       "      <td>Five-year RFS; Number of patients in need of a...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2025-02-24</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2025-01-17</td>\n",
       "      <td>2025-01-14</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>The purpose of this study is to see if using P...</td>\n",
       "      <td>2028-02-17</td>\n",
       "      <td>Pancreatic Ductal Carcinoma, Advanced Cancer, ...</td>\n",
       "      <td>Canada</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>PDO is a three-dimensional experimental model ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Age 18 years or over...</td>\n",
       "      <td>25</td>\n",
       "      <td>Cobimetinib is an antineoplastic agent and sel...</td>\n",
       "      <td>Cobimetinib, Ponatinib, Brigatinib, Colchicine...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2028-02-17</td>\n",
       "      <td>Objective response rate (ORR)</td>\n",
       "      <td>Disease control rate (DCR); Duration of respon...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2025-02-17</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2025-02-06</td>\n",
       "      <td>2025-02-03</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>To evaluate the safety and effectiveness of au...</td>\n",
       "      <td>2019-11-15</td>\n",
       "      <td>Liver Cancer, Pancreatic Adenocarcinoma</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Able to read and und...</td>\n",
       "      <td>20</td>\n",
       "      <td>vaccination of autologous gp96 derived from tu...</td>\n",
       "      <td>autologous gp96 vaccination</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2016-11-15</td>\n",
       "      <td>blood count; blood count; blood count; blood c...</td>\n",
       "      <td>Disease-free survival; overall survive; change...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2012-03-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2014-05-07</td>\n",
       "      <td>2014-05-03</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>RATIONALE: Radiation therapy uses high-energy ...</td>\n",
       "      <td>NaT</td>\n",
       "      <td>Cervical Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>OBJECTIVES:\\n\\n* Determine the toxicity of rad...</td>\n",
       "      <td>DISEASE CHARACTERISTICS:\\n\\n* Histologically p...</td>\n",
       "      <td>40</td>\n",
       "      <td>NaN</td>\n",
       "      <td>cisplatin, paclitaxel, brachytherapy, radiatio...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2007-01-15</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>FEMALE</td>\n",
       "      <td>1999-11-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2003-01-27</td>\n",
       "      <td>1999-11-01</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>To learn if sacituzumab govitecan and pembroli...</td>\n",
       "      <td>2026-12-31</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Primary Objective:\\n\\n• To determine the effic...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Female or male patie...</td>\n",
       "      <td>25</td>\n",
       "      <td>Given by IV (vein); Given by IV (vein)</td>\n",
       "      <td>Sacituzumab Govitecan, Pembrolizumab</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2026-12-31</td>\n",
       "      <td>Incidence of Adverse Events, Graded According ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2023-05-23</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2023-01-09</td>\n",
       "      <td>2022-12-22</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>The goal of this clinical research study is to...</td>\n",
       "      <td>2018-06-04</td>\n",
       "      <td>Oral Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>PREVENTION</td>\n",
       "      <td>Erlotinib hydrochloride is designed to block t...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Male or female patie...</td>\n",
       "      <td>303</td>\n",
       "      <td>150 mg by mouth daily; Tablet by mouth daily</td>\n",
       "      <td>Erlotinib, Placebo</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>2018-06-04</td>\n",
       "      <td>Oral Cancer-free Survival in Participants Rece...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2006-11-03</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2006-11-22</td>\n",
       "      <td>2006-11-20</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>A Phase 1/2 Dose Escalation and Expansion Stud...</td>\n",
       "      <td>2025-04-30</td>\n",
       "      <td>ER+, HER2- Advanced Breast Cancer, Metastatic ...</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This is a phase Ⅰ/Ⅱ, open-label study of TFX06...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. voluntary participat...</td>\n",
       "      <td>74</td>\n",
       "      <td>TFX06 tablet taken orally</td>\n",
       "      <td>TFX06 tablet</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2024-12-30</td>\n",
       "      <td>Recommended phase 2 Dose (RP2D); Disease Contr...</td>\n",
       "      <td>Incidence of Treatment-Emergent Adverse Events...</td>\n",
       "      <td>FEMALE</td>\n",
       "      <td>2023-04-17</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2023-07-03</td>\n",
       "      <td>2023-06-03</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>Topical photodynamic therapy with methyl-amino...</td>\n",
       "      <td>2013-09-15</td>\n",
       "      <td>Nodular Basal Cell Carcinoma</td>\n",
       "      <td>Korea, Republic of</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Basal cell carcinoma (BCC) is the most common ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* patient's request for...</td>\n",
       "      <td>34</td>\n",
       "      <td>AFL was performed using a 2940-nm Er:YAG ablat...</td>\n",
       "      <td>Er:YAG AFL-PDT, MAL-PDT</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2013-02-15</td>\n",
       "      <td>Difference the efficacy between Er:YAG AFL-PDT...</td>\n",
       "      <td>Difference of the cosmetic outcomes between Er...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2011-03-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2013-12-23</td>\n",
       "      <td>2013-11-29</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>The purpose of this study is to evaluate the p...</td>\n",
       "      <td>2019-10-31</td>\n",
       "      <td>CD20 Positive B Cell NHL</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This is a multi-center, randomized, double-bli...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Histological examinat...</td>\n",
       "      <td>60</td>\n",
       "      <td>Monoclonal antibodies, 100mg/10ml per injectio...</td>\n",
       "      <td>304 injection, rituximab injection</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2019-06-30</td>\n",
       "      <td>AUC [0-t]; AUC [0-∞]; Cmax</td>\n",
       "      <td>tmax; t1/2; MRT; Vz; CLz; ADA; Adverse events</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2018-12-18</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2019-06-10</td>\n",
       "      <td>2019-06-06</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>The purpose of the study is to address the fol...</td>\n",
       "      <td>2024-03-15</td>\n",
       "      <td>Triple Negative Breast Cancer</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Newly diagnosed histo...</td>\n",
       "      <td>49</td>\n",
       "      <td>The PD-1 inhibitor Sintilimab 200mg for intrav...</td>\n",
       "      <td>Sintilimab</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2023-12-15</td>\n",
       "      <td>Pathologic Complete Response (pCR)</td>\n",
       "      <td>NaN</td>\n",
       "      <td>FEMALE</td>\n",
       "      <td>2021-03-15</td>\n",
       "      <td>ADULT</td>\n",
       "      <td>2021-03-22</td>\n",
       "      <td>2021-03-19</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>Study of elotuzumab in combination with pomali...</td>\n",
       "      <td>2020-06-12</td>\n",
       "      <td>Multiple Myeloma</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>For more information regarding BMS clinical tr...</td>\n",
       "      <td>74</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Elotuzumab, Pomalidomide, Dexamethasone, Nivol...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2019-07-29</td>\n",
       "      <td>Progression Free Survival (PFS); Objective Res...</td>\n",
       "      <td>Objective Response Rate (ORR); Progression Fre...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2016-02-09</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2015-11-24</td>\n",
       "      <td>2015-11-20</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>RATIONALE: CT-322 may stop the growth of solid...</td>\n",
       "      <td>2009-02-15</td>\n",
       "      <td>Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>DISEASE CHARACTERISTICS\\n\\n* Histologically pr...</td>\n",
       "      <td>40</td>\n",
       "      <td>IV solution, weekly or bi-weekly</td>\n",
       "      <td>CT-322</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2008-11-15</td>\n",
       "      <td>Safety and tolerability of CT-322</td>\n",
       "      <td>To evaluate the pharmacokinetics of CT-322 in ...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2006-08-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2006-09-11</td>\n",
       "      <td>2006-09-08</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>This is a single-arm, single-center, open-labe...</td>\n",
       "      <td>2025-12-31</td>\n",
       "      <td>B-cell Acute Lymphoblastic Leukemia, B-ALL</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Although the anti-CD19 CAR-T cell therapies ha...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Male or female, aged...</td>\n",
       "      <td>30</td>\n",
       "      <td>UCAR-T Cellswill be administered by vein. The ...</td>\n",
       "      <td>UCAR-T Cells</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2024-12-31</td>\n",
       "      <td>Dose-limiting toxicity (DLT); Incidence of Tre...</td>\n",
       "      <td>Persistence of CAR-T cells; Objective response...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2022-12-05</td>\n",
       "      <td>CHILD, ADULT, OLDER_ADULT</td>\n",
       "      <td>2022-12-06</td>\n",
       "      <td>2022-11-25</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>The purpose of this study is to determine if t...</td>\n",
       "      <td>2024-08-07</td>\n",
       "      <td>Multiple Myeloma</td>\n",
       "      <td>Croatia, Greece, United States, Argentina, Jap...</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>The study consists of 3 phases: Screening Phas...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Participant must have...</td>\n",
       "      <td>706</td>\n",
       "      <td>Participants will receive velcade 1.3 mg/m\\^2,...</td>\n",
       "      <td>Velcade, Melphalan, Prednisone, Daratumumab IV...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>2017-11-21</td>\n",
       "      <td>Progression Free Survival (PFS)</td>\n",
       "      <td>Overall Response Rate (ORR); Percentage of Par...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2014-12-09</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2014-07-21</td>\n",
       "      <td>2014-07-18</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>This study is examining a chemotherapy regimen...</td>\n",
       "      <td>2022-02-11</td>\n",
       "      <td>Leukemia, Lymphoid, Leukemia, Myeloid, Myelody...</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Age less than or equ...</td>\n",
       "      <td>20</td>\n",
       "      <td>Fludarabine: 30 mg/m2 daily for 5 days; Busulf...</td>\n",
       "      <td>Fludarabine, Busulfan, Rabbit ATG, Methotrexate</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2019-06-07</td>\n",
       "      <td>Number of patients who are surviving at 100-Da...</td>\n",
       "      <td>Time to marrow engraftment; Assessing all subj...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2016-09-06</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2016-09-28</td>\n",
       "      <td>2016-08-15</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>This is a single-center, single-arm, phase Ib/...</td>\n",
       "      <td>2027-10-01</td>\n",
       "      <td>NMIBC</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Age ≥18 years old, b...</td>\n",
       "      <td>58</td>\n",
       "      <td>SHR-1501, instillation；SHR-2005, instillation</td>\n",
       "      <td>SHR-1501+SHR-2005</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2027-10-01</td>\n",
       "      <td>Phase I : Incidence of dose limiting toxicitie...</td>\n",
       "      <td>Phase I : CR rate at 3 months; Phase II : Inci...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2024-10-01</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2024-09-19</td>\n",
       "      <td>2024-09-05</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>This is an open-label, multicenter, dose-escal...</td>\n",
       "      <td>2019-03-15</td>\n",
       "      <td>Acute Myeloid Leukemia, Acute Myelogenous Leuk...</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Key Inclusion Criteria:\\n\\n* Single agent (SA)...</td>\n",
       "      <td>94</td>\n",
       "      <td>FT-1101 will be supplied as 5 mg, 20 mg or 100...</td>\n",
       "      <td>FT-1101, Azacitidine</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2019-03-15</td>\n",
       "      <td>Maximum Tolerated Dose (MTD); Dose Limiting To...</td>\n",
       "      <td>Area under the plasma concentration versus tim...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2015-09-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2015-09-07</td>\n",
       "      <td>2015-09-01</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>Dual center, single arm, two-stage, non-blinde...</td>\n",
       "      <td>2019-12-04</td>\n",
       "      <td>Glioblastoma</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* At least 18 years of ...</td>\n",
       "      <td>35</td>\n",
       "      <td>10mg/kg; 670mg/m2</td>\n",
       "      <td>Bevacizumab, TH-302</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2019-01-04</td>\n",
       "      <td>Number of Patients With Adverse Events</td>\n",
       "      <td>Progression Free Survival</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2015-05-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2015-01-19</td>\n",
       "      <td>2015-01-14</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>RATIONALE: Drugs used in chemotherapy, such as...</td>\n",
       "      <td>2009-02-10</td>\n",
       "      <td>Head and Neck Cancer</td>\n",
       "      <td>Canada</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>OBJECTIVES:\\n\\nPrimary\\n\\n* Determine the acti...</td>\n",
       "      <td>DISEASE CHARACTERISTICS:\\n\\n* Histologically o...</td>\n",
       "      <td>34</td>\n",
       "      <td>NaN</td>\n",
       "      <td>carboplatin, cisplatin, gemcitabine hydrochloride</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2008-09-29</td>\n",
       "      <td>Objective response measured by RECIST criteria...</td>\n",
       "      <td>Toxicity assessed by NCI CTC v2.0; Overall sur...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2003-10-27</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2004-03-09</td>\n",
       "      <td>2004-03-08</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>The purposes of this study are to determine th...</td>\n",
       "      <td>NaT</td>\n",
       "      <td>Carcinoma, Non-Small-Cell Lung, Pulmonary Neop...</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Definition: The phase 2 study will provide imp...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Diagnosis of Non-Smal...</td>\n",
       "      <td>?</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Gemcitabine, Carboplatin, LY900003</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>NaT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2002-06-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2002-08-06</td>\n",
       "      <td>2002-08-02</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41</th>\n",
       "      <td>The main purpose of this Phase 1/2 study is to...</td>\n",
       "      <td>2021-01-01</td>\n",
       "      <td>Small-cell Lung Cancer</td>\n",
       "      <td>Puerto Rico, United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Key Inclusion Criteria:\\n\\n1. Patient is able ...</td>\n",
       "      <td>68</td>\n",
       "      <td>Administered IV; Administered IV</td>\n",
       "      <td>Pegzilarginase, Pembrolizumab</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2021-01-01</td>\n",
       "      <td>1. Phase 1: Incidence of treatment-related adv...</td>\n",
       "      <td>Objective Response Rate; Clinical Benefit Rate...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2017-12-21</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2017-12-13</td>\n",
       "      <td>2017-11-20</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>42</th>\n",
       "      <td>The purpose of this study is to evaluate the e...</td>\n",
       "      <td>2013-09-15</td>\n",
       "      <td>Colorectal Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>HEALTH_SERVICES_RESEARCH</td>\n",
       "      <td>This study will test the separate and combined...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Patients aged 50-75 y...</td>\n",
       "      <td>569</td>\n",
       "      <td>Physicians at these clinics will participate i...</td>\n",
       "      <td>Physician Intervention, Physician and Patient ...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2, PHASE3</td>\n",
       "      <td>2013-07-15</td>\n",
       "      <td>Colorectal Cancer (CRC) Screening Completion; ...</td>\n",
       "      <td>Provider Recommendation of CRC Screening</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2010-04-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2010-04-14</td>\n",
       "      <td>2010-04-12</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>43</th>\n",
       "      <td>Maintenance durvalumab (MEDI4736) and olaparib...</td>\n",
       "      <td>2026-12-15</td>\n",
       "      <td>Small Cell Lung Carcinoma</td>\n",
       "      <td>Germany</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria Pre-Screening:\\n\\n* Newly d...</td>\n",
       "      <td>29</td>\n",
       "      <td>1500 mg i.v. Q4W; 300 mg BID orally</td>\n",
       "      <td>Durvalumab, Olaparib</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2026-09-15</td>\n",
       "      <td>Progression-free survival (PFS)</td>\n",
       "      <td>Incidence, severity and grading of adverse eve...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2024-10-09</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2024-05-17</td>\n",
       "      <td>2024-05-03</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>44</th>\n",
       "      <td>There is no muture method to treat EGFR 20 ins...</td>\n",
       "      <td>2024-12-31</td>\n",
       "      <td>Carcinoma, Non-Small-Cell Lung</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Lung cancer is one of the most common types of...</td>\n",
       "      <td>Inclusion Criteria:\\n\\nParticipant must have h...</td>\n",
       "      <td>20</td>\n",
       "      <td>Osimertinib, 80mg, oral daily; bevacizumab (av...</td>\n",
       "      <td>Osimertinib Oral Tablet</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2024-07-31</td>\n",
       "      <td>Progression free survival</td>\n",
       "      <td>Objective Response Rate (ORR); Overall Surviva...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2021-07-01</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2021-07-23</td>\n",
       "      <td>2021-07-16</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>45</th>\n",
       "      <td>This is a randomized, open-label, phase 2 stud...</td>\n",
       "      <td>2027-02-15</td>\n",
       "      <td>Glioblastoma, IDH-wildtype</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This is a randomized, open-label phase 2 study...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Written informed cons...</td>\n",
       "      <td>54</td>\n",
       "      <td>Ropidoxuridine is administered daily, 5 days a...</td>\n",
       "      <td>Ropidoxuridine</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2026-08-15</td>\n",
       "      <td>Number of patients treated with oral ropidoxur...</td>\n",
       "      <td>Overall survival at 12 months; Radiographic Re...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2024-09-02</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2024-04-11</td>\n",
       "      <td>2024-03-24</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>46</th>\n",
       "      <td>From Protocol v3.0 dated 16Jun2022. This is an...</td>\n",
       "      <td>2024-10-31</td>\n",
       "      <td>Melanoma (Skin), Non-Small-Cell Lung Carcinoma</td>\n",
       "      <td>Spain, Belgium, United Kingdom</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Overall Study Design:\\n\\n• This is an open-lab...</td>\n",
       "      <td>Inclusion Criteria:\\n\\nMain Inclusion Criteria...</td>\n",
       "      <td>34</td>\n",
       "      <td>Priming phase including 1 GAd-PEV administrati...</td>\n",
       "      <td>GAd-PEV, MVA-PEV</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2024-10-31</td>\n",
       "      <td>Safety and tolerability: incidence of treatmen...</td>\n",
       "      <td>RP2D confirmation 2. Clinical efficacy:; Clini...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2021-06-11</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2021-08-04</td>\n",
       "      <td>2021-07-15</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>47</th>\n",
       "      <td>The proposed study will evaluate whether the c...</td>\n",
       "      <td>2014-07-15</td>\n",
       "      <td>Multiple Myeloma</td>\n",
       "      <td>Italy</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This phase III study represents a prospective ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Age \\&gt; 65 year old an...</td>\n",
       "      <td>511</td>\n",
       "      <td>Induction therapy:\\n\\n9 courses with weekly VE...</td>\n",
       "      <td>Bortezomib, Melphalan, Prednisone, Thalidomide...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>2014-07-15</td>\n",
       "      <td>Determine whether the V-MPT combination improv...</td>\n",
       "      <td>Determine whether the VMPT combination improve...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2006-05-15</td>\n",
       "      <td>OLDER_ADULT</td>\n",
       "      <td>2010-02-05</td>\n",
       "      <td>2010-02-04</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>48</th>\n",
       "      <td>The purpose of this study is to evaluate the e...</td>\n",
       "      <td>2022-12-31</td>\n",
       "      <td>Extranodal NK/T-cell Lymphoma</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Previous study has confirmed the efficacy of a...</td>\n",
       "      <td>Inclusion Criteria:\\n\\nHistopathology and immu...</td>\n",
       "      <td>20</td>\n",
       "      <td>200mg d1,ivdrip, repeated every 3 weeks; 10mg ...</td>\n",
       "      <td>Sintilimab, Decitabine</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2022-12-31</td>\n",
       "      <td>complete response rate</td>\n",
       "      <td>overall response rate; 1-year progression free...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2020-04-01</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2020-02-21</td>\n",
       "      <td>2020-02-19</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>49</th>\n",
       "      <td>The purpose of this study is to evaluate the i...</td>\n",
       "      <td>2013-08-15</td>\n",
       "      <td>Esophageal Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>DIAGNOSTIC</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Newly diagnosed or re...</td>\n",
       "      <td>22</td>\n",
       "      <td>15 mCi 11C-choline will be administered intrav...</td>\n",
       "      <td>C11-Choline</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2013-08-15</td>\n",
       "      <td>To evaluate our ability to obtain reliable and...</td>\n",
       "      <td>Perform semi-quantitative analysis of tracer u...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2010-03-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2010-01-18</td>\n",
       "      <td>2010-01-15</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>50 rows × 35 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                        brief_summary completion_date  \\\n",
       "0   Nivolumab, also known as (Bristol Myers Squibb...      2023-10-17   \n",
       "1   The aim of this explorative phase II clinical ...      2021-11-01   \n",
       "2   This study was a randomized, controlled, open-...      2027-06-15   \n",
       "3   This is a randomised, double-blind, positive d...      2022-05-20   \n",
       "4   This phase II trial tests how well decitabine ...      2029-03-15   \n",
       "5   This is a phase 2 single-arm, open-label clini...      2024-12-30   \n",
       "6   A phase I trial in patients with relapsed or r...      2009-07-15   \n",
       "7   RATIONALE: The timing of breast cancer surgery...      2004-10-15   \n",
       "8   To determine the safety, tolerability, and rec...      2024-12-30   \n",
       "9   This is an exploratory phase 2, randomized pla...      2011-10-15   \n",
       "10  PRI-724 is a new investigational drug being st...      2016-12-30   \n",
       "11  Longterm disease-free survival (DFS) of older ...      2017-09-15   \n",
       "12  RATIONALE: Combinations of biological substanc...      2017-07-27   \n",
       "13  The purpose of this conversion therapy study i...      2024-04-30   \n",
       "14  RATIONALE: MS-275 may stop the growth of cance...      2008-10-15   \n",
       "15  The study is a feasibility and validation stud...      2009-01-15   \n",
       "16  This study is a phase I study designed to eval...      2031-01-15   \n",
       "17  This is an open-label (doctors and patients kn...      2015-11-15   \n",
       "18  This research is being done to compare rates o...      2028-06-01   \n",
       "19  The purpose of this study is to assess the saf...      2024-10-15   \n",
       "20  This is a single-center, single-arm, open-labe...      2023-07-06   \n",
       "21  The investigartors will conduct a randomized, ...      2032-02-01   \n",
       "22  The purpose of this study is to see if using P...      2028-02-17   \n",
       "23  To evaluate the safety and effectiveness of au...      2019-11-15   \n",
       "24  RATIONALE: Radiation therapy uses high-energy ...             NaT   \n",
       "25  To learn if sacituzumab govitecan and pembroli...      2026-12-31   \n",
       "26  The goal of this clinical research study is to...      2018-06-04   \n",
       "27  A Phase 1/2 Dose Escalation and Expansion Stud...      2025-04-30   \n",
       "28  Topical photodynamic therapy with methyl-amino...      2013-09-15   \n",
       "29  The purpose of this study is to evaluate the p...      2019-10-31   \n",
       "30  The purpose of the study is to address the fol...      2024-03-15   \n",
       "31  Study of elotuzumab in combination with pomali...      2020-06-12   \n",
       "32  RATIONALE: CT-322 may stop the growth of solid...      2009-02-15   \n",
       "33  This is a single-arm, single-center, open-labe...      2025-12-31   \n",
       "34  The purpose of this study is to determine if t...      2024-08-07   \n",
       "35  This study is examining a chemotherapy regimen...      2022-02-11   \n",
       "36  This is a single-center, single-arm, phase Ib/...      2027-10-01   \n",
       "37  This is an open-label, multicenter, dose-escal...      2019-03-15   \n",
       "38  Dual center, single arm, two-stage, non-blinde...      2019-12-04   \n",
       "39  RATIONALE: Drugs used in chemotherapy, such as...      2009-02-10   \n",
       "40  The purposes of this study are to determine th...             NaT   \n",
       "41  The main purpose of this Phase 1/2 study is to...      2021-01-01   \n",
       "42  The purpose of this study is to evaluate the e...      2013-09-15   \n",
       "43  Maintenance durvalumab (MEDI4736) and olaparib...      2026-12-15   \n",
       "44  There is no muture method to treat EGFR 20 ins...      2024-12-31   \n",
       "45  This is a randomized, open-label, phase 2 stud...      2027-02-15   \n",
       "46  From Protocol v3.0 dated 16Jun2022. This is an...      2024-10-31   \n",
       "47  The proposed study will evaluate whether the c...      2014-07-15   \n",
       "48  The purpose of this study is to evaluate the e...      2022-12-31   \n",
       "49  The purpose of this study is to evaluate the i...      2013-08-15   \n",
       "\n",
       "                                           conditions  \\\n",
       "0   Head and Neck Squamous Cell Carcinoma, Head an...   \n",
       "1                                   Colorectal Cancer   \n",
       "2                          Non-small Cell Lung Cancer   \n",
       "3                       Diffuse Large B-Cell Lymphoma   \n",
       "4                    Recurrent Acute Myeloid Leukemia   \n",
       "5     Gastric Adenocarcinoma, GastroEsophageal Cancer   \n",
       "6   Leukemia, Lymphocytic, Leukemia, Acute Lymphoc...   \n",
       "7                                       Breast Cancer   \n",
       "8                                      Advanced Tumor   \n",
       "9                                        Colon Cancer   \n",
       "10   Acute Myeloid Leukemia, Chronic Myeloid Leukemia   \n",
       "11                                                AML   \n",
       "12  Leukemia, Myelodysplastic Syndromes, Blastic P...   \n",
       "13                                   NSCLC, Stage III   \n",
       "14                                             Cancer   \n",
       "15                                  Colonic Neoplasms   \n",
       "16  Acute Lymphoblastic Leukemia, Recurrent Acute ...   \n",
       "17              Lymphoma, B-Cell, Follicular Lymphoma   \n",
       "18  Metastatic Breast Cancer, Chemotherapy-induced...   \n",
       "19  Non-squamous Non-small-cell Lung Cancer, EGFR ...   \n",
       "20                              Neuroendocrine Tumors   \n",
       "21                 Non-Muscle Invasive Bladder Cancer   \n",
       "22  Pancreatic Ductal Carcinoma, Advanced Cancer, ...   \n",
       "23            Liver Cancer, Pancreatic Adenocarcinoma   \n",
       "24                                    Cervical Cancer   \n",
       "25                                      Breast Cancer   \n",
       "26                                        Oral Cancer   \n",
       "27  ER+, HER2- Advanced Breast Cancer, Metastatic ...   \n",
       "28                       Nodular Basal Cell Carcinoma   \n",
       "29                           CD20 Positive B Cell NHL   \n",
       "30                      Triple Negative Breast Cancer   \n",
       "31                                   Multiple Myeloma   \n",
       "32                                             Cancer   \n",
       "33         B-cell Acute Lymphoblastic Leukemia, B-ALL   \n",
       "34                                   Multiple Myeloma   \n",
       "35  Leukemia, Lymphoid, Leukemia, Myeloid, Myelody...   \n",
       "36                                              NMIBC   \n",
       "37  Acute Myeloid Leukemia, Acute Myelogenous Leuk...   \n",
       "38                                       Glioblastoma   \n",
       "39                               Head and Neck Cancer   \n",
       "40  Carcinoma, Non-Small-Cell Lung, Pulmonary Neop...   \n",
       "41                             Small-cell Lung Cancer   \n",
       "42                                  Colorectal Cancer   \n",
       "43                          Small Cell Lung Carcinoma   \n",
       "44                     Carcinoma, Non-Small-Cell Lung   \n",
       "45                         Glioblastoma, IDH-wildtype   \n",
       "46     Melanoma (Skin), Non-Small-Cell Lung Carcinoma   \n",
       "47                                   Multiple Myeloma   \n",
       "48                      Extranodal NK/T-cell Lymphoma   \n",
       "49                                  Esophageal Cancer   \n",
       "\n",
       "                                              country  \\\n",
       "0                                       United States   \n",
       "1                                             Denmark   \n",
       "2                                               China   \n",
       "3                                               China   \n",
       "4                                       United States   \n",
       "5                                       United States   \n",
       "6                                       United States   \n",
       "7                                       United States   \n",
       "8                                               China   \n",
       "9                                       United States   \n",
       "10                                      United States   \n",
       "11                                            Germany   \n",
       "12                                      United States   \n",
       "13                                              China   \n",
       "14                                      United States   \n",
       "15                                        Switzerland   \n",
       "16                                      United States   \n",
       "17                                      United States   \n",
       "18                                      United States   \n",
       "19                                              Japan   \n",
       "20                                             Canada   \n",
       "21                                                NaN   \n",
       "22                                             Canada   \n",
       "23                                              China   \n",
       "24                                      United States   \n",
       "25                                      United States   \n",
       "26                                      United States   \n",
       "27                                              China   \n",
       "28                                 Korea, Republic of   \n",
       "29                                              China   \n",
       "30                                              China   \n",
       "31                                      United States   \n",
       "32                                      United States   \n",
       "33                                              China   \n",
       "34  Croatia, Greece, United States, Argentina, Jap...   \n",
       "35                                      United States   \n",
       "36                                              China   \n",
       "37                                      United States   \n",
       "38                                      United States   \n",
       "39                                             Canada   \n",
       "40                                      United States   \n",
       "41                         Puerto Rico, United States   \n",
       "42                                      United States   \n",
       "43                                            Germany   \n",
       "44                                              China   \n",
       "45                                      United States   \n",
       "46                     Spain, Belgium, United Kingdom   \n",
       "47                                              Italy   \n",
       "48                                              China   \n",
       "49                                      United States   \n",
       "\n",
       "      design_primary_purpose  \\\n",
       "0                  TREATMENT   \n",
       "1                  TREATMENT   \n",
       "2                  TREATMENT   \n",
       "3                  TREATMENT   \n",
       "4                  TREATMENT   \n",
       "5                  TREATMENT   \n",
       "6                  TREATMENT   \n",
       "7                  TREATMENT   \n",
       "8                  TREATMENT   \n",
       "9                  TREATMENT   \n",
       "10                 TREATMENT   \n",
       "11                 TREATMENT   \n",
       "12                 TREATMENT   \n",
       "13                 TREATMENT   \n",
       "14                 TREATMENT   \n",
       "15                DIAGNOSTIC   \n",
       "16                 TREATMENT   \n",
       "17                 TREATMENT   \n",
       "18           SUPPORTIVE_CARE   \n",
       "19                 TREATMENT   \n",
       "20                 TREATMENT   \n",
       "21                 TREATMENT   \n",
       "22                 TREATMENT   \n",
       "23                 TREATMENT   \n",
       "24                 TREATMENT   \n",
       "25                 TREATMENT   \n",
       "26                PREVENTION   \n",
       "27                 TREATMENT   \n",
       "28                 TREATMENT   \n",
       "29                 TREATMENT   \n",
       "30                 TREATMENT   \n",
       "31                 TREATMENT   \n",
       "32                 TREATMENT   \n",
       "33                 TREATMENT   \n",
       "34                 TREATMENT   \n",
       "35                 TREATMENT   \n",
       "36                 TREATMENT   \n",
       "37                 TREATMENT   \n",
       "38                 TREATMENT   \n",
       "39                 TREATMENT   \n",
       "40                 TREATMENT   \n",
       "41                 TREATMENT   \n",
       "42  HEALTH_SERVICES_RESEARCH   \n",
       "43                 TREATMENT   \n",
       "44                 TREATMENT   \n",
       "45                 TREATMENT   \n",
       "46                 TREATMENT   \n",
       "47                 TREATMENT   \n",
       "48                 TREATMENT   \n",
       "49                DIAGNOSTIC   \n",
       "\n",
       "                                 detailed_description  \\\n",
       "0   This research is being done to see if it is sa...   \n",
       "1   This is an explorative phase 2 clinical trial ...   \n",
       "2                                                 NaN   \n",
       "3                                                 NaN   \n",
       "4   PRIMARY OBJECTIVE:\\n\\nI. To assess the effect ...   \n",
       "5   Treatment on study will be administered in 21 ...   \n",
       "6                                                 NaN   \n",
       "7   OBJECTIVES:\\n\\n* Determine if the timing of br...   \n",
       "8                                                 NaN   \n",
       "9   This is an exploratory phase 2, randomized pla...   \n",
       "10  PRI-724 is a new investigational drug being st...   \n",
       "11                                                NaN   \n",
       "12  OBJECTIVES:\\n\\n* Determine the maximum tolerat...   \n",
       "13                                                NaN   \n",
       "14  OBJECTIVES:\\n\\n* Determine the dose-limiting t...   \n",
       "15                                                NaN   \n",
       "16  Treatment will include a single course of lymp...   \n",
       "17  This study will assess whether adding bortezom...   \n",
       "18  This study is a prospective, controlled, pivot...   \n",
       "19                                                NaN   \n",
       "20                                                NaN   \n",
       "21                                                NaN   \n",
       "22  PDO is a three-dimensional experimental model ...   \n",
       "23                                                NaN   \n",
       "24  OBJECTIVES:\\n\\n* Determine the toxicity of rad...   \n",
       "25  Primary Objective:\\n\\n• To determine the effic...   \n",
       "26  Erlotinib hydrochloride is designed to block t...   \n",
       "27  This is a phase Ⅰ/Ⅱ, open-label study of TFX06...   \n",
       "28  Basal cell carcinoma (BCC) is the most common ...   \n",
       "29  This is a multi-center, randomized, double-bli...   \n",
       "30                                                NaN   \n",
       "31                                                NaN   \n",
       "32                                                NaN   \n",
       "33  Although the anti-CD19 CAR-T cell therapies ha...   \n",
       "34  The study consists of 3 phases: Screening Phas...   \n",
       "35                                                NaN   \n",
       "36                                                NaN   \n",
       "37                                                NaN   \n",
       "38                                                NaN   \n",
       "39  OBJECTIVES:\\n\\nPrimary\\n\\n* Determine the acti...   \n",
       "40  Definition: The phase 2 study will provide imp...   \n",
       "41                                                NaN   \n",
       "42  This study will test the separate and combined...   \n",
       "43                                                NaN   \n",
       "44  Lung cancer is one of the most common types of...   \n",
       "45  This is a randomized, open-label phase 2 study...   \n",
       "46  Overall Study Design:\\n\\n• This is an open-lab...   \n",
       "47  This phase III study represents a prospective ...   \n",
       "48  Previous study has confirmed the efficacy of a...   \n",
       "49                                                NaN   \n",
       "\n",
       "                                 eligibility_criteria enrollment  \\\n",
       "0   Inclusion:\\n\\nCohort 1: Subjects must have his...         26   \n",
       "1   Inclusion Criteria:\\n\\n* Patients must be ment...         10   \n",
       "2   Inclusion Criteria:\\n\\n1. Age 18 to 75 years o...        500   \n",
       "3   Inclusion Criteria:\\n\\n* 18-75 years old, male...        421   \n",
       "4   Inclusion Criteria:\\n\\n* Age \\>= 18 years at t...         51   \n",
       "5   Inclusion Criteria:\\n\\n* Patients must have hi...         20   \n",
       "6   Inclusion Criteria:\\n\\n3.1.1 Age Patients must...          9   \n",
       "7   DISEASE CHARACTERISTICS:\\n\\n* Histologically c...          ?   \n",
       "8   Inclusion Criteria:\\n\\n1. Age: 18-75 years old...         40   \n",
       "9   Inclusion Criteria:\\n\\n1. In the opinion of th...        381   \n",
       "10  Inclusion Criteria\\n\\n1. Patients 18 years or ...         49   \n",
       "11  Inclusion Criteria:\\n\\n1. Subjects must provid...         16   \n",
       "12  DISEASE CHARACTERISTICS:\\n\\n* Diagnosis of 1 o...         11   \n",
       "13  Inclusion Criteria:\\n\\n* Written informed cons...         30   \n",
       "14  DISEASE CHARACTERISTICS:\\n\\n* Histologically c...         75   \n",
       "15  Inclusion Criteria:\\n\\n* Colon cancer at any s...        192   \n",
       "16  Collection and Manufacturing Eligibility\\n\\nIn...         30   \n",
       "17  Inclusion Criteria:\\n\\n* Tissue diagnosis of a...         37   \n",
       "18  Inclusion Criteria:\\n\\n* Men and women with a ...        120   \n",
       "19  Inclusion Criteria:\\n\\n1. Have a histologicall...         30   \n",
       "20  Inclusion Criteria:\\n\\n* Adults (males or fema...         17   \n",
       "21  Inclusion Criteria:\\n\\n* Tumour recurrence aft...        272   \n",
       "22  Inclusion Criteria:\\n\\n1. Age 18 years or over...         25   \n",
       "23  Inclusion Criteria:\\n\\n1. Able to read and und...         20   \n",
       "24  DISEASE CHARACTERISTICS:\\n\\n* Histologically p...         40   \n",
       "25  Inclusion Criteria:\\n\\n1. Female or male patie...         25   \n",
       "26  Inclusion Criteria:\\n\\n1. Male or female patie...        303   \n",
       "27  Inclusion Criteria:\\n\\n1. voluntary participat...         74   \n",
       "28  Inclusion Criteria:\\n\\n* patient's request for...         34   \n",
       "29  Inclusion Criteria:\\n\\n* Histological examinat...         60   \n",
       "30  Inclusion Criteria:\\n\\n* Newly diagnosed histo...         49   \n",
       "31  For more information regarding BMS clinical tr...         74   \n",
       "32  DISEASE CHARACTERISTICS\\n\\n* Histologically pr...         40   \n",
       "33  Inclusion Criteria:\\n\\n1. Male or female, aged...         30   \n",
       "34  Inclusion Criteria:\\n\\n* Participant must have...        706   \n",
       "35  Inclusion Criteria:\\n\\n1. Age less than or equ...         20   \n",
       "36  Inclusion Criteria:\\n\\n1. Age ≥18 years old, b...         58   \n",
       "37  Key Inclusion Criteria:\\n\\n* Single agent (SA)...         94   \n",
       "38  Inclusion Criteria:\\n\\n* At least 18 years of ...         35   \n",
       "39  DISEASE CHARACTERISTICS:\\n\\n* Histologically o...         34   \n",
       "40  Inclusion Criteria:\\n\\n* Diagnosis of Non-Smal...          ?   \n",
       "41  Key Inclusion Criteria:\\n\\n1. Patient is able ...         68   \n",
       "42  Inclusion Criteria:\\n\\n* Patients aged 50-75 y...        569   \n",
       "43  Inclusion Criteria Pre-Screening:\\n\\n* Newly d...         29   \n",
       "44  Inclusion Criteria:\\n\\nParticipant must have h...         20   \n",
       "45  Inclusion Criteria:\\n\\n* Written informed cons...         54   \n",
       "46  Inclusion Criteria:\\n\\nMain Inclusion Criteria...         34   \n",
       "47  Inclusion Criteria:\\n\\n* Age \\> 65 year old an...        511   \n",
       "48  Inclusion Criteria:\\n\\nHistopathology and immu...         20   \n",
       "49  Inclusion Criteria:\\n\\n* Newly diagnosed or re...         22   \n",
       "\n",
       "                            interventions_description  \\\n",
       "0   One dose of Nivolumab 480mg given four weeks p...   \n",
       "1   Intratumoral application of an unattenuated in...   \n",
       "2   SHR-A2009 monotherapy ，SHR-A2009 will be admin...   \n",
       "3          Injection，100mg/10ml; Injection，100mg/10ml   \n",
       "4   Given by mouth; Given by mouth; Given by mouth...   \n",
       "5                                  Given PO; Given IV   \n",
       "6   Dosage: 1.25mg/kg intravenous with dose escala...   \n",
       "7                                                 NaN   \n",
       "8   In the phase, five dose groups were proposed.T...   \n",
       "9   Perifosine 50 mg/d qd; Capecitabine 825 mg/m\\^...   \n",
       "10  PRI-724; PRI-724 in combination with dasatinib...   \n",
       "11                                                NaN   \n",
       "12  Intravenously via a 3 cc plastic syringe as a ...   \n",
       "13  Tislelizumab: 200mg, IV, day 1 of each 21-day ...   \n",
       "14                                                NaN   \n",
       "15  After careful mobilization of the affected col...   \n",
       "16  IV; IV; IV; CAR T cell infusion will be given ...   \n",
       "17  Bortezomib 1.6 mg/m² given on days 1 and 8; Ri...   \n",
       "18  Cap attached to coolant lines connected to a r...   \n",
       "19  IV infusion Q3W; Oral capsule once daily; IV i...   \n",
       "20  Avelumab will be administered intravenously as...   \n",
       "21                                      Chemoablation   \n",
       "22  Cobimetinib is an antineoplastic agent and sel...   \n",
       "23  vaccination of autologous gp96 derived from tu...   \n",
       "24                                                NaN   \n",
       "25             Given by IV (vein); Given by IV (vein)   \n",
       "26       150 mg by mouth daily; Tablet by mouth daily   \n",
       "27                          TFX06 tablet taken orally   \n",
       "28  AFL was performed using a 2940-nm Er:YAG ablat...   \n",
       "29  Monoclonal antibodies, 100mg/10ml per injectio...   \n",
       "30  The PD-1 inhibitor Sintilimab 200mg for intrav...   \n",
       "31                                                NaN   \n",
       "32                   IV solution, weekly or bi-weekly   \n",
       "33  UCAR-T Cellswill be administered by vein. The ...   \n",
       "34  Participants will receive velcade 1.3 mg/m\\^2,...   \n",
       "35  Fludarabine: 30 mg/m2 daily for 5 days; Busulf...   \n",
       "36      SHR-1501, instillation；SHR-2005, instillation   \n",
       "37  FT-1101 will be supplied as 5 mg, 20 mg or 100...   \n",
       "38                                  10mg/kg; 670mg/m2   \n",
       "39                                                NaN   \n",
       "40                                                NaN   \n",
       "41                   Administered IV; Administered IV   \n",
       "42  Physicians at these clinics will participate i...   \n",
       "43                1500 mg i.v. Q4W; 300 mg BID orally   \n",
       "44  Osimertinib, 80mg, oral daily; bevacizumab (av...   \n",
       "45  Ropidoxuridine is administered daily, 5 days a...   \n",
       "46  Priming phase including 1 GAd-PEV administrati...   \n",
       "47  Induction therapy:\\n\\n9 courses with weekly VE...   \n",
       "48  200mg d1,ivdrip, repeated every 3 weeks; 10mg ...   \n",
       "49  15 mCi 11C-choline will be administered intrav...   \n",
       "\n",
       "                                   interventions_name  ...           phase  \\\n",
       "0              Nivolumab 480mg and surgical resection  ...          PHASE2   \n",
       "1                                  Influenza Vaccines  ...          PHASE2   \n",
       "2   SHR-A2009 monotherapy, platinum-based dual-age...  ...          PHASE3   \n",
       "3                                  SIBP-02, Rituximab  ...          PHASE3   \n",
       "4   Venetoclax, Decitabine, Cedazuridine, Bone Mar...  ...          PHASE2   \n",
       "5                         Cabozantinib, Pembrolizumab  ...          PHASE2   \n",
       "6                                MAb 216, Vincristine  ...          PHASE1   \n",
       "7                                conventional surgery  ...          PHASE3   \n",
       "8                                            QLF32004  ...          PHASE1   \n",
       "9        Perifosine, Capecitabine, Perifosine Placebo  ...          PHASE2   \n",
       "10                          PRI-724, PRI-724, PRI-724  ...  PHASE1, PHASE2   \n",
       "11                         Tranylcypromine, Tretinoin  ...  PHASE1, PHASE2   \n",
       "12                                           DT388IL3  ...  PHASE1, PHASE2   \n",
       "13  Tislelizumab, Pemetrexed (Nonsquamous NSCLC) o...  ...          PHASE2   \n",
       "14                                         entinostat  ...          PHASE1   \n",
       "15  Sentinel lymph node procedure, Bone marrow asp...  ...  PHASE1, PHASE2   \n",
       "16  Fludarabine, Cyclophosphamide, Mesna, CD19-CD2...  ...          PHASE1   \n",
       "17  Bortezomib, Rituximab, Doxorubicin, Cyclophosp...  ...  PHASE1, PHASE2   \n",
       "18  Paxman Scalp Cooling System, Eribulin, Sacituz...  ...          PHASE2   \n",
       "19  Pembrolizumab, Lenvatinib, Carboplatin, Pemetr...  ...          PHASE2   \n",
       "20                                           Avelumab  ...          PHASE2   \n",
       "21                                        Mitomycin c  ...          PHASE4   \n",
       "22  Cobimetinib, Ponatinib, Brigatinib, Colchicine...  ...          PHASE2   \n",
       "23                        autologous gp96 vaccination  ...  PHASE1, PHASE2   \n",
       "24  cisplatin, paclitaxel, brachytherapy, radiatio...  ...  PHASE1, PHASE2   \n",
       "25               Sacituzumab Govitecan, Pembrolizumab  ...          PHASE2   \n",
       "26                                 Erlotinib, Placebo  ...          PHASE3   \n",
       "27                                       TFX06 tablet  ...  PHASE1, PHASE2   \n",
       "28                            Er:YAG AFL-PDT, MAL-PDT  ...          PHASE1   \n",
       "29                 304 injection, rituximab injection  ...          PHASE1   \n",
       "30                                         Sintilimab  ...          PHASE2   \n",
       "31  Elotuzumab, Pomalidomide, Dexamethasone, Nivol...  ...          PHASE2   \n",
       "32                                             CT-322  ...          PHASE1   \n",
       "33                                       UCAR-T Cells  ...  PHASE1, PHASE2   \n",
       "34  Velcade, Melphalan, Prednisone, Daratumumab IV...  ...          PHASE3   \n",
       "35    Fludarabine, Busulfan, Rabbit ATG, Methotrexate  ...          PHASE1   \n",
       "36                                  SHR-1501+SHR-2005  ...  PHASE1, PHASE2   \n",
       "37                               FT-1101, Azacitidine  ...          PHASE1   \n",
       "38                                Bevacizumab, TH-302  ...          PHASE2   \n",
       "39  carboplatin, cisplatin, gemcitabine hydrochloride  ...          PHASE2   \n",
       "40                 Gemcitabine, Carboplatin, LY900003  ...          PHASE2   \n",
       "41                      Pegzilarginase, Pembrolizumab  ...  PHASE1, PHASE2   \n",
       "42  Physician Intervention, Physician and Patient ...  ...  PHASE2, PHASE3   \n",
       "43                               Durvalumab, Olaparib  ...          PHASE2   \n",
       "44                            Osimertinib Oral Tablet  ...          PHASE2   \n",
       "45                                     Ropidoxuridine  ...          PHASE2   \n",
       "46                                   GAd-PEV, MVA-PEV  ...          PHASE1   \n",
       "47  Bortezomib, Melphalan, Prednisone, Thalidomide...  ...          PHASE3   \n",
       "48                             Sintilimab, Decitabine  ...          PHASE2   \n",
       "49                                        C11-Choline  ...          PHASE1   \n",
       "\n",
       "   primary_completion_date                                   primary_outcomes  \\\n",
       "0               2023-10-17  Safety as Measured by Number of Participants W...   \n",
       "1               2021-09-22  Safety - Adverse reactions are classified acco...   \n",
       "2               2026-12-15  Progression-free survival (PFS) assessed by BI...   \n",
       "3               2022-05-20                        Overall Response Rate (ORR)   \n",
       "4               2028-03-15  Composite complete response (CR) rate (CR/comp...   \n",
       "5               2023-11-25  Percentage of Participants with Progression-fr...   \n",
       "6               2009-02-15  In this phase I study the endpoint is the dete...   \n",
       "7                      NaT                                                NaN   \n",
       "8               2024-12-30  Dose-Limiting Toxicity (DLT); Maximum Tolerate...   \n",
       "9               2010-12-15       Effects of perifosine on time to progression   \n",
       "10              2016-12-30                       DLT (Dose Limiting Toxicity)   \n",
       "11              2017-09-15  Analysis of the cumulative response rate (CR,C...   \n",
       "12              2017-07-27  Overall Response Rate (CR+PR+SD): Percentage o...   \n",
       "13              2024-02-29                                 Resectability rate   \n",
       "14              2008-04-15  Dose-limiting toxicities and maximum tolerated...   \n",
       "15              2009-01-15  To assess the extent of upstaging due to the S...   \n",
       "16              2030-01-15  Recommended phase 2 dose (RP2D) of CD19-CD22-C...   \n",
       "17              2015-11-15  Maximal Tolerated Doses of Bortezomib and Vinc...   \n",
       "18              2026-06-01                                     Hair Loss Rate   \n",
       "19              2023-10-31  Objective Response Rate (ORR) as Assessed by B...   \n",
       "20              2021-07-26                        Overall response rate (ORR)   \n",
       "21              2029-02-01                  Two-year Recurrence Free Survival   \n",
       "22              2028-02-17                      Objective response rate (ORR)   \n",
       "23              2016-11-15  blood count; blood count; blood count; blood c...   \n",
       "24              2007-01-15                                                NaN   \n",
       "25              2026-12-31  Incidence of Adverse Events, Graded According ...   \n",
       "26              2018-06-04  Oral Cancer-free Survival in Participants Rece...   \n",
       "27              2024-12-30  Recommended phase 2 Dose (RP2D); Disease Contr...   \n",
       "28              2013-02-15  Difference the efficacy between Er:YAG AFL-PDT...   \n",
       "29              2019-06-30                         AUC [0-t]; AUC [0-∞]; Cmax   \n",
       "30              2023-12-15                 Pathologic Complete Response (pCR)   \n",
       "31              2019-07-29  Progression Free Survival (PFS); Objective Res...   \n",
       "32              2008-11-15                  Safety and tolerability of CT-322   \n",
       "33              2024-12-31  Dose-limiting toxicity (DLT); Incidence of Tre...   \n",
       "34              2017-11-21                    Progression Free Survival (PFS)   \n",
       "35              2019-06-07  Number of patients who are surviving at 100-Da...   \n",
       "36              2027-10-01  Phase I : Incidence of dose limiting toxicitie...   \n",
       "37              2019-03-15  Maximum Tolerated Dose (MTD); Dose Limiting To...   \n",
       "38              2019-01-04             Number of Patients With Adverse Events   \n",
       "39              2008-09-29  Objective response measured by RECIST criteria...   \n",
       "40                     NaT                                                NaN   \n",
       "41              2021-01-01  1. Phase 1: Incidence of treatment-related adv...   \n",
       "42              2013-07-15  Colorectal Cancer (CRC) Screening Completion; ...   \n",
       "43              2026-09-15                    Progression-free survival (PFS)   \n",
       "44              2024-07-31                          Progression free survival   \n",
       "45              2026-08-15  Number of patients treated with oral ropidoxur...   \n",
       "46              2024-10-31  Safety and tolerability: incidence of treatmen...   \n",
       "47              2014-07-15  Determine whether the V-MPT combination improv...   \n",
       "48              2022-12-31                             complete response rate   \n",
       "49              2013-08-15  To evaluate our ability to obtain reliable and...   \n",
       "\n",
       "                                   secondary_outcomes     sex start_date  \\\n",
       "0   Major Pathologic Response Rate; Progression Fr...     ALL 2019-07-08   \n",
       "1              Efficacy - local immunological changes     ALL 2021-02-26   \n",
       "2   overall survival (OS); Progression Free Surviv...     ALL 2024-11-29   \n",
       "3                                                 NaN     ALL 2019-07-25   \n",
       "4   Rate of partial response (PR) following treatm...     ALL 2024-01-29   \n",
       "5   Percentage of Grade 3-5 Adverse Events; Overal...     ALL 2020-02-04   \n",
       "6   A decrease in leukemic blasts. The study will ...     ALL 2006-05-15   \n",
       "7                                                 NaN  FEMALE 1999-01-15   \n",
       "8   Treatment-Emergent Adverse Event (TEAE); Maxim...     ALL 2021-11-09   \n",
       "9   Toxicity; Comparison of time to progression to...     ALL 2005-08-15   \n",
       "10                     Preliminary Efficacy Endpoints     ALL 2012-07-15   \n",
       "11  number of participants with adverse events as ...     ALL 2014-09-15   \n",
       "12                                                NaN     ALL 2013-05-15   \n",
       "13  Major pathological response rate (MPR); Pathol...     ALL 2023-03-12   \n",
       "14  Acetylation of histones in peripheral blood; T...     ALL 2001-03-15   \n",
       "15  To evaluate the accuracy of the SLN procedure ...     ALL 2000-05-15   \n",
       "16                                                NaN     ALL 2025-05-15   \n",
       "17  An Estimate of the Overall Response Rate (ORR)...     ALL 2008-02-15   \n",
       "18  Change in Patient Reported Quality of Life; Ch...     ALL 2021-10-07   \n",
       "19  Objective Response Rate (ORR) as Assessed by i...     ALL 2022-07-01   \n",
       "20  Disease control rate (DCR); Duration of respon...     ALL 2017-11-15   \n",
       "21  Five-year RFS; Number of patients in need of a...     ALL 2025-02-24   \n",
       "22  Disease control rate (DCR); Duration of respon...     ALL 2025-02-17   \n",
       "23  Disease-free survival; overall survive; change...     ALL 2012-03-15   \n",
       "24                                                NaN  FEMALE 1999-11-15   \n",
       "25                                                NaN     ALL 2023-05-23   \n",
       "26                                                NaN     ALL 2006-11-03   \n",
       "27  Incidence of Treatment-Emergent Adverse Events...  FEMALE 2023-04-17   \n",
       "28  Difference of the cosmetic outcomes between Er...     ALL 2011-03-15   \n",
       "29      tmax; t1/2; MRT; Vz; CLz; ADA; Adverse events     ALL 2018-12-18   \n",
       "30                                                NaN  FEMALE 2021-03-15   \n",
       "31  Objective Response Rate (ORR); Progression Fre...     ALL 2016-02-09   \n",
       "32  To evaluate the pharmacokinetics of CT-322 in ...     ALL 2006-08-15   \n",
       "33  Persistence of CAR-T cells; Objective response...     ALL 2022-12-05   \n",
       "34  Overall Response Rate (ORR); Percentage of Par...     ALL 2014-12-09   \n",
       "35  Time to marrow engraftment; Assessing all subj...     ALL 2016-09-06   \n",
       "36  Phase I : CR rate at 3 months; Phase II : Inci...     ALL 2024-10-01   \n",
       "37  Area under the plasma concentration versus tim...     ALL 2015-09-15   \n",
       "38                          Progression Free Survival     ALL 2015-05-15   \n",
       "39  Toxicity assessed by NCI CTC v2.0; Overall sur...     ALL 2003-10-27   \n",
       "40                                                NaN     ALL 2002-06-15   \n",
       "41  Objective Response Rate; Clinical Benefit Rate...     ALL 2017-12-21   \n",
       "42           Provider Recommendation of CRC Screening     ALL 2010-04-15   \n",
       "43  Incidence, severity and grading of adverse eve...     ALL 2024-10-09   \n",
       "44  Objective Response Rate (ORR); Overall Surviva...     ALL 2021-07-01   \n",
       "45  Overall survival at 12 months; Radiographic Re...     ALL 2024-09-02   \n",
       "46  RP2D confirmation 2. Clinical efficacy:; Clini...     ALL 2021-06-11   \n",
       "47  Determine whether the VMPT combination improve...     ALL 2006-05-15   \n",
       "48  overall response rate; 1-year progression free...     ALL 2020-04-01   \n",
       "49  Perform semi-quantitative analysis of tracer u...     ALL 2010-03-15   \n",
       "\n",
       "                       stdage study_first_post_date study_first_submit_date  \\\n",
       "0          ADULT, OLDER_ADULT            2019-03-18              2019-03-15   \n",
       "1          ADULT, OLDER_ADULT            2020-10-19              2020-09-07   \n",
       "2          ADULT, OLDER_ADULT            2024-11-04              2024-11-01   \n",
       "3          ADULT, OLDER_ADULT            2020-04-24              2020-04-22   \n",
       "4          ADULT, OLDER_ADULT            2023-04-05              2023-03-22   \n",
       "5          ADULT, OLDER_ADULT            2019-11-15              2019-11-13   \n",
       "6          ADULT, OLDER_ADULT            2006-04-11              2006-04-07   \n",
       "7   CHILD, ADULT, OLDER_ADULT            2003-01-27              2000-04-06   \n",
       "8          ADULT, OLDER_ADULT            2021-11-05              2021-10-22   \n",
       "9          ADULT, OLDER_ADULT            2006-11-14              2006-11-06   \n",
       "10         ADULT, OLDER_ADULT            2012-05-25              2012-05-16   \n",
       "11         ADULT, OLDER_ADULT            2014-10-10              2014-09-23   \n",
       "12         ADULT, OLDER_ADULT            2006-11-09              2006-11-08   \n",
       "13         ADULT, OLDER_ADULT            2022-11-10              2022-11-04   \n",
       "14         ADULT, OLDER_ADULT            2003-01-27              2001-07-11   \n",
       "15  CHILD, ADULT, OLDER_ADULT            2009-01-22              2009-01-13   \n",
       "16               CHILD, ADULT            2025-01-16              2025-01-10   \n",
       "17         ADULT, OLDER_ADULT            2008-03-12              2008-02-11   \n",
       "18         ADULT, OLDER_ADULT            2021-08-03              2021-07-20   \n",
       "19         ADULT, OLDER_ADULT            2022-02-28              2022-02-17   \n",
       "20         ADULT, OLDER_ADULT            2017-09-11              2017-08-23   \n",
       "21         ADULT, OLDER_ADULT            2025-01-17              2025-01-14   \n",
       "22         ADULT, OLDER_ADULT            2025-02-06              2025-02-03   \n",
       "23         ADULT, OLDER_ADULT            2014-05-07              2014-05-03   \n",
       "24         ADULT, OLDER_ADULT            2003-01-27              1999-11-01   \n",
       "25         ADULT, OLDER_ADULT            2023-01-09              2022-12-22   \n",
       "26         ADULT, OLDER_ADULT            2006-11-22              2006-11-20   \n",
       "27         ADULT, OLDER_ADULT            2023-07-03              2023-06-03   \n",
       "28         ADULT, OLDER_ADULT            2013-12-23              2013-11-29   \n",
       "29         ADULT, OLDER_ADULT            2019-06-10              2019-06-06   \n",
       "30                      ADULT            2021-03-22              2021-03-19   \n",
       "31         ADULT, OLDER_ADULT            2015-11-24              2015-11-20   \n",
       "32         ADULT, OLDER_ADULT            2006-09-11              2006-09-08   \n",
       "33  CHILD, ADULT, OLDER_ADULT            2022-12-06              2022-11-25   \n",
       "34         ADULT, OLDER_ADULT            2014-07-21              2014-07-18   \n",
       "35         ADULT, OLDER_ADULT            2016-09-28              2016-08-15   \n",
       "36         ADULT, OLDER_ADULT            2024-09-19              2024-09-05   \n",
       "37         ADULT, OLDER_ADULT            2015-09-07              2015-09-01   \n",
       "38         ADULT, OLDER_ADULT            2015-01-19              2015-01-14   \n",
       "39         ADULT, OLDER_ADULT            2004-03-09              2004-03-08   \n",
       "40         ADULT, OLDER_ADULT            2002-08-06              2002-08-02   \n",
       "41         ADULT, OLDER_ADULT            2017-12-13              2017-11-20   \n",
       "42         ADULT, OLDER_ADULT            2010-04-14              2010-04-12   \n",
       "43         ADULT, OLDER_ADULT            2024-05-17              2024-05-03   \n",
       "44         ADULT, OLDER_ADULT            2021-07-23              2021-07-16   \n",
       "45         ADULT, OLDER_ADULT            2024-04-11              2024-03-24   \n",
       "46         ADULT, OLDER_ADULT            2021-08-04              2021-07-15   \n",
       "47                OLDER_ADULT            2010-02-05              2010-02-04   \n",
       "48         ADULT, OLDER_ADULT            2020-02-21              2020-02-19   \n",
       "49         ADULT, OLDER_ADULT            2010-01-18              2010-01-15   \n",
       "\n",
       "        study_type  \n",
       "0   INTERVENTIONAL  \n",
       "1   INTERVENTIONAL  \n",
       "2   INTERVENTIONAL  \n",
       "3   INTERVENTIONAL  \n",
       "4   INTERVENTIONAL  \n",
       "5   INTERVENTIONAL  \n",
       "6   INTERVENTIONAL  \n",
       "7   INTERVENTIONAL  \n",
       "8   INTERVENTIONAL  \n",
       "9   INTERVENTIONAL  \n",
       "10  INTERVENTIONAL  \n",
       "11  INTERVENTIONAL  \n",
       "12  INTERVENTIONAL  \n",
       "13  INTERVENTIONAL  \n",
       "14  INTERVENTIONAL  \n",
       "15  INTERVENTIONAL  \n",
       "16  INTERVENTIONAL  \n",
       "17  INTERVENTIONAL  \n",
       "18  INTERVENTIONAL  \n",
       "19  INTERVENTIONAL  \n",
       "20  INTERVENTIONAL  \n",
       "21  INTERVENTIONAL  \n",
       "22  INTERVENTIONAL  \n",
       "23  INTERVENTIONAL  \n",
       "24  INTERVENTIONAL  \n",
       "25  INTERVENTIONAL  \n",
       "26  INTERVENTIONAL  \n",
       "27  INTERVENTIONAL  \n",
       "28  INTERVENTIONAL  \n",
       "29  INTERVENTIONAL  \n",
       "30  INTERVENTIONAL  \n",
       "31  INTERVENTIONAL  \n",
       "32  INTERVENTIONAL  \n",
       "33  INTERVENTIONAL  \n",
       "34  INTERVENTIONAL  \n",
       "35  INTERVENTIONAL  \n",
       "36  INTERVENTIONAL  \n",
       "37  INTERVENTIONAL  \n",
       "38  INTERVENTIONAL  \n",
       "39  INTERVENTIONAL  \n",
       "40  INTERVENTIONAL  \n",
       "41  INTERVENTIONAL  \n",
       "42  INTERVENTIONAL  \n",
       "43  INTERVENTIONAL  \n",
       "44  INTERVENTIONAL  \n",
       "45  INTERVENTIONAL  \n",
       "46  INTERVENTIONAL  \n",
       "47  INTERVENTIONAL  \n",
       "48  INTERVENTIONAL  \n",
       "49  INTERVENTIONAL  \n",
       "\n",
       "[50 rows x 35 columns]"
      ]
     },
     "execution_count": 29,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.head(50)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "1016c95e",
   "metadata": {},
   "source": [
    "Remove all the rows that have Nan values in their date columns "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "id": "7f976375",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(55590, 35)"
      ]
     },
     "execution_count": 30,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Replace '?' with NaN in a temporary view of the date columns\n",
    "df_temp = df[date_cols].replace('?', pd.NA)\n",
    "\n",
    "# Identify rows that have NaN or '?'\n",
    "rows_with_nan_or_question = df_temp.isna().any(axis=1)\n",
    "\n",
    "# Remove those rows from the original dataframe\n",
    "df = df[~rows_with_nan_or_question].reset_index(drop=True)\n",
    "df.shape\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "id": "19aee9b2",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['brief_summary', 'completion_date', 'conditions', 'country',\n",
       "       'design_primary_purpose', 'detailed_description',\n",
       "       'eligibility_criteria', 'enrollment', 'interventions_description',\n",
       "       'interventions_name', 'is_same', 'keywords', 'last_update_post_date',\n",
       "       'lead_sponsor', 'location_city', 'location_country',\n",
       "       'location_facility', 'location_state', 'maximum_age', 'minimum_age',\n",
       "       'organization_fullname', 'overall_officials_affiliation',\n",
       "       'overall_officials_name', 'overall_status', 'oversight_has_dmc',\n",
       "       'phase', 'primary_completion_date', 'primary_outcomes',\n",
       "       'secondary_outcomes', 'sex', 'start_date', 'stdage',\n",
       "       'study_first_post_date', 'study_first_submit_date', 'study_type'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 31,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "id": "615da2d3",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "keywords                         20465\n",
       "detailed_description             17688\n",
       "overall_officials_affiliation     9647\n",
       "overall_officials_name            9577\n",
       "secondary_outcomes                8314\n",
       "interventions_description         5318\n",
       "location_city                     2833\n",
       "location_state                    2833\n",
       "location_facility                 2833\n",
       "location_country                  2833\n",
       "is_same                           2833\n",
       "country                           2833\n",
       "primary_outcomes                   995\n",
       "conditions                           1\n",
       "brief_summary                        0\n",
       "completion_date                      0\n",
       "enrollment                           0\n",
       "design_primary_purpose               0\n",
       "eligibility_criteria                 0\n",
       "maximum_age                          0\n",
       "lead_sponsor                         0\n",
       "last_update_post_date                0\n",
       "interventions_name                   0\n",
       "overall_status                       0\n",
       "oversight_has_dmc                    0\n",
       "organization_fullname                0\n",
       "minimum_age                          0\n",
       "primary_completion_date              0\n",
       "phase                                0\n",
       "sex                                  0\n",
       "start_date                           0\n",
       "stdage                               0\n",
       "study_first_post_date                0\n",
       "study_first_submit_date              0\n",
       "study_type                           0\n",
       "dtype: int64"
      ]
     },
     "execution_count": 32,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.isnull().sum().sort_values(ascending=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "id": "9435ec7a",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>brief_summary</th>\n",
       "      <th>completion_date</th>\n",
       "      <th>conditions</th>\n",
       "      <th>country</th>\n",
       "      <th>design_primary_purpose</th>\n",
       "      <th>detailed_description</th>\n",
       "      <th>eligibility_criteria</th>\n",
       "      <th>enrollment</th>\n",
       "      <th>interventions_description</th>\n",
       "      <th>interventions_name</th>\n",
       "      <th>...</th>\n",
       "      <th>phase</th>\n",
       "      <th>primary_completion_date</th>\n",
       "      <th>primary_outcomes</th>\n",
       "      <th>secondary_outcomes</th>\n",
       "      <th>sex</th>\n",
       "      <th>start_date</th>\n",
       "      <th>stdage</th>\n",
       "      <th>study_first_post_date</th>\n",
       "      <th>study_first_submit_date</th>\n",
       "      <th>study_type</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>The investigartors will conduct a randomized, ...</td>\n",
       "      <td>2032-02-01</td>\n",
       "      <td>Non-Muscle Invasive Bladder Cancer</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Tumour recurrence aft...</td>\n",
       "      <td>272</td>\n",
       "      <td>Chemoablation</td>\n",
       "      <td>Mitomycin c</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE4</td>\n",
       "      <td>2029-02-01</td>\n",
       "      <td>Two-year Recurrence Free Survival</td>\n",
       "      <td>Five-year RFS; Number of patients in need of a...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2025-02-24</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2025-01-17</td>\n",
       "      <td>2025-01-14</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>86</th>\n",
       "      <td>This is an open-label, single arm, phase 2 stu...</td>\n",
       "      <td>2022-12-31</td>\n",
       "      <td>Acute Myeloid Leukemia</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>In this single-center, open-label, nonrandomiz...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Age: 60-75\\n* Relapse...</td>\n",
       "      <td>29</td>\n",
       "      <td>A humanized monoclonal immunoglobulin; A DNA m...</td>\n",
       "      <td>Camrelizumab(SHR-1210), Decitabine</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2020-12-31</td>\n",
       "      <td>Overall response rate; Complete remission (CR)...</td>\n",
       "      <td>Progress-free survival (PFS); Overall survival...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2020-04-25</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2020-04-20</td>\n",
       "      <td>2020-04-14</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>120</th>\n",
       "      <td>Time to progression (physical examination and ...</td>\n",
       "      <td>2008-06-15</td>\n",
       "      <td>Ovarian Cancer</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* patients with primary...</td>\n",
       "      <td>105</td>\n",
       "      <td>4 cycles of Carboplatin AUC 5 every 3 weeks. 1...</td>\n",
       "      <td>Paclitaxel</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2008-04-15</td>\n",
       "      <td>Progression-free Survival. Progression is Defi...</td>\n",
       "      <td>Toxicity</td>\n",
       "      <td>FEMALE</td>\n",
       "      <td>2003-07-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2005-09-12</td>\n",
       "      <td>2005-09-09</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>148</th>\n",
       "      <td>Our study aims at assessment of response, surv...</td>\n",
       "      <td>2022-09-01</td>\n",
       "      <td>Advanced Ovarian Cancer</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Ovarian cancer is the most lethal gynecologic ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Female patients diagn...</td>\n",
       "      <td>40</td>\n",
       "      <td>The chemotherapy regimen will be Paclitaxel (1...</td>\n",
       "      <td>Bevacizumab</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2022-08-31</td>\n",
       "      <td>progression free survival</td>\n",
       "      <td>NaN</td>\n",
       "      <td>FEMALE</td>\n",
       "      <td>2018-09-01</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2018-08-02</td>\n",
       "      <td>2018-07-17</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>163</th>\n",
       "      <td>Endometrial cancer (EC) is the 8th most common...</td>\n",
       "      <td>2014-04-15</td>\n",
       "      <td>Recurrent Endometrial Cancer</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Patients receive weekly Ixabepilone 32 mg/m2 (...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Histologically confi...</td>\n",
       "      <td>24</td>\n",
       "      <td>Ixabepilone 40 mg/m2 Lapatinib 250 mg</td>\n",
       "      <td>Lapatinib and ixempra</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2013-04-15</td>\n",
       "      <td>Determine the Maximum Tolerated Dosage (MTD) o...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>FEMALE</td>\n",
       "      <td>2011-03-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2011-10-19</td>\n",
       "      <td>2011-09-28</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>55435</th>\n",
       "      <td>The investigators plan to to study an extended...</td>\n",
       "      <td>2013-01-15</td>\n",
       "      <td>Bipolar Disorder, Mania</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Clonidine has been reported to be effective in...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* meet SCID criteria fo...</td>\n",
       "      <td>5</td>\n",
       "      <td>Subjects will received 0.2 mg extended-release...</td>\n",
       "      <td>extended-release clonidine</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE4</td>\n",
       "      <td>2013-01-15</td>\n",
       "      <td>Score on a Mania Rating Scale</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2012-01-15</td>\n",
       "      <td>ADULT</td>\n",
       "      <td>2017-02-28</td>\n",
       "      <td>2012-11-06</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>55457</th>\n",
       "      <td>The purpose of this study is to assess the eff...</td>\n",
       "      <td>2011-09-15</td>\n",
       "      <td>Allergic Rhinitis Due to Dust Mite</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>After the screening period, the patients will ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Male or female outpat...</td>\n",
       "      <td>471</td>\n",
       "      <td>300 IR, once a day, for one year.; once a day,...</td>\n",
       "      <td>Dpte and Dfar Allergen Extracts, placebo</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>2011-01-15</td>\n",
       "      <td>Efficacy Assessment</td>\n",
       "      <td>Efficacy Assessment at the end of the treatmen...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2009-10-15</td>\n",
       "      <td>CHILD</td>\n",
       "      <td>2010-09-10</td>\n",
       "      <td>2010-09-09</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>55479</th>\n",
       "      <td>The purpose of this study is to provide an inv...</td>\n",
       "      <td>2005-05-15</td>\n",
       "      <td>Hypercholesterolemia, Familial, Lipid Metaboli...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Homozygous familial h...</td>\n",
       "      <td>49</td>\n",
       "      <td>Ezetimibe (MK0653) 10 mg once daily for 3 years.</td>\n",
       "      <td>Comparator: ezetimibe</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>2005-05-15</td>\n",
       "      <td>Incidence of clinical and laboratory adverse e...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2002-07-15</td>\n",
       "      <td>CHILD, ADULT, OLDER_ADULT</td>\n",
       "      <td>2004-09-28</td>\n",
       "      <td>2004-09-23</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>55550</th>\n",
       "      <td>This study will assess the efficacy of a singl...</td>\n",
       "      <td>2011-08-15</td>\n",
       "      <td>Staphylococcus Aureus, Bacteremia, Mediastinitis</td>\n",
       "      <td>NaN</td>\n",
       "      <td>PREVENTION</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Participant is schedu...</td>\n",
       "      <td>8031</td>\n",
       "      <td>0.5-mL single injection of V710 (60 µg); 0.5-m...</td>\n",
       "      <td>V710, Placebo</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2, PHASE3</td>\n",
       "      <td>2011-08-15</td>\n",
       "      <td>Number of Participants With Staphylococcus Aur...</td>\n",
       "      <td>Number of Participants With Invasive Staphyloc...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2007-12-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2007-08-21</td>\n",
       "      <td>2007-08-17</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>55570</th>\n",
       "      <td>In this study, we propose to employ a randomiz...</td>\n",
       "      <td>2016-09-11</td>\n",
       "      <td>Post-traumatic Stress Disorder</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Men and women between...</td>\n",
       "      <td>10</td>\n",
       "      <td>Pomaglumetad Methionil 160mg, one dose, one ti...</td>\n",
       "      <td>Pomaglumetad Methionil 160mg, Pomaglumetad Met...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2016-02-11</td>\n",
       "      <td>To Evaluate the Effect of 160mg and 40mg of Po...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2014-09-15</td>\n",
       "      <td>ADULT</td>\n",
       "      <td>2014-09-09</td>\n",
       "      <td>2014-09-03</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2833 rows × 35 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                           brief_summary completion_date  \\\n",
       "20     The investigartors will conduct a randomized, ...      2032-02-01   \n",
       "86     This is an open-label, single arm, phase 2 stu...      2022-12-31   \n",
       "120    Time to progression (physical examination and ...      2008-06-15   \n",
       "148    Our study aims at assessment of response, surv...      2022-09-01   \n",
       "163    Endometrial cancer (EC) is the 8th most common...      2014-04-15   \n",
       "...                                                  ...             ...   \n",
       "55435  The investigators plan to to study an extended...      2013-01-15   \n",
       "55457  The purpose of this study is to assess the eff...      2011-09-15   \n",
       "55479  The purpose of this study is to provide an inv...      2005-05-15   \n",
       "55550  This study will assess the efficacy of a singl...      2011-08-15   \n",
       "55570  In this study, we propose to employ a randomiz...      2016-09-11   \n",
       "\n",
       "                                              conditions country  \\\n",
       "20                    Non-Muscle Invasive Bladder Cancer     NaN   \n",
       "86                                Acute Myeloid Leukemia     NaN   \n",
       "120                                       Ovarian Cancer     NaN   \n",
       "148                              Advanced Ovarian Cancer     NaN   \n",
       "163                         Recurrent Endometrial Cancer     NaN   \n",
       "...                                                  ...     ...   \n",
       "55435                            Bipolar Disorder, Mania     NaN   \n",
       "55457                 Allergic Rhinitis Due to Dust Mite     NaN   \n",
       "55479  Hypercholesterolemia, Familial, Lipid Metaboli...     NaN   \n",
       "55550   Staphylococcus Aureus, Bacteremia, Mediastinitis     NaN   \n",
       "55570                     Post-traumatic Stress Disorder     NaN   \n",
       "\n",
       "      design_primary_purpose  \\\n",
       "20                 TREATMENT   \n",
       "86                 TREATMENT   \n",
       "120                TREATMENT   \n",
       "148                TREATMENT   \n",
       "163                TREATMENT   \n",
       "...                      ...   \n",
       "55435              TREATMENT   \n",
       "55457              TREATMENT   \n",
       "55479              TREATMENT   \n",
       "55550             PREVENTION   \n",
       "55570              TREATMENT   \n",
       "\n",
       "                                    detailed_description  \\\n",
       "20                                                   NaN   \n",
       "86     In this single-center, open-label, nonrandomiz...   \n",
       "120                                                  NaN   \n",
       "148    Ovarian cancer is the most lethal gynecologic ...   \n",
       "163    Patients receive weekly Ixabepilone 32 mg/m2 (...   \n",
       "...                                                  ...   \n",
       "55435  Clonidine has been reported to be effective in...   \n",
       "55457  After the screening period, the patients will ...   \n",
       "55479                                                NaN   \n",
       "55550                                                NaN   \n",
       "55570                                                NaN   \n",
       "\n",
       "                                    eligibility_criteria enrollment  \\\n",
       "20     Inclusion Criteria:\\n\\n* Tumour recurrence aft...        272   \n",
       "86     Inclusion Criteria:\\n\\n* Age: 60-75\\n* Relapse...         29   \n",
       "120    Inclusion Criteria:\\n\\n* patients with primary...        105   \n",
       "148    Inclusion Criteria:\\n\\n* Female patients diagn...         40   \n",
       "163    Inclusion Criteria:\\n\\n1. Histologically confi...         24   \n",
       "...                                                  ...        ...   \n",
       "55435  Inclusion Criteria:\\n\\n* meet SCID criteria fo...          5   \n",
       "55457  Inclusion Criteria:\\n\\n* Male or female outpat...        471   \n",
       "55479  Inclusion Criteria:\\n\\n* Homozygous familial h...         49   \n",
       "55550  Inclusion Criteria:\\n\\n* Participant is schedu...       8031   \n",
       "55570  Inclusion Criteria:\\n\\n* Men and women between...         10   \n",
       "\n",
       "                               interventions_description  \\\n",
       "20                                         Chemoablation   \n",
       "86     A humanized monoclonal immunoglobulin; A DNA m...   \n",
       "120    4 cycles of Carboplatin AUC 5 every 3 weeks. 1...   \n",
       "148    The chemotherapy regimen will be Paclitaxel (1...   \n",
       "163                Ixabepilone 40 mg/m2 Lapatinib 250 mg   \n",
       "...                                                  ...   \n",
       "55435  Subjects will received 0.2 mg extended-release...   \n",
       "55457  300 IR, once a day, for one year.; once a day,...   \n",
       "55479   Ezetimibe (MK0653) 10 mg once daily for 3 years.   \n",
       "55550  0.5-mL single injection of V710 (60 µg); 0.5-m...   \n",
       "55570  Pomaglumetad Methionil 160mg, one dose, one ti...   \n",
       "\n",
       "                                      interventions_name  ...           phase  \\\n",
       "20                                           Mitomycin c  ...          PHASE4   \n",
       "86                    Camrelizumab(SHR-1210), Decitabine  ...          PHASE2   \n",
       "120                                           Paclitaxel  ...          PHASE2   \n",
       "148                                          Bevacizumab  ...          PHASE2   \n",
       "163                                Lapatinib and ixempra  ...          PHASE1   \n",
       "...                                                  ...  ...             ...   \n",
       "55435                         extended-release clonidine  ...          PHASE4   \n",
       "55457           Dpte and Dfar Allergen Extracts, placebo  ...          PHASE3   \n",
       "55479                              Comparator: ezetimibe  ...          PHASE3   \n",
       "55550                                      V710, Placebo  ...  PHASE2, PHASE3   \n",
       "55570  Pomaglumetad Methionil 160mg, Pomaglumetad Met...  ...          PHASE1   \n",
       "\n",
       "      primary_completion_date  \\\n",
       "20                 2029-02-01   \n",
       "86                 2020-12-31   \n",
       "120                2008-04-15   \n",
       "148                2022-08-31   \n",
       "163                2013-04-15   \n",
       "...                       ...   \n",
       "55435              2013-01-15   \n",
       "55457              2011-01-15   \n",
       "55479              2005-05-15   \n",
       "55550              2011-08-15   \n",
       "55570              2016-02-11   \n",
       "\n",
       "                                        primary_outcomes  \\\n",
       "20                     Two-year Recurrence Free Survival   \n",
       "86     Overall response rate; Complete remission (CR)...   \n",
       "120    Progression-free Survival. Progression is Defi...   \n",
       "148                            progression free survival   \n",
       "163    Determine the Maximum Tolerated Dosage (MTD) o...   \n",
       "...                                                  ...   \n",
       "55435                      Score on a Mania Rating Scale   \n",
       "55457                                Efficacy Assessment   \n",
       "55479  Incidence of clinical and laboratory adverse e...   \n",
       "55550  Number of Participants With Staphylococcus Aur...   \n",
       "55570  To Evaluate the Effect of 160mg and 40mg of Po...   \n",
       "\n",
       "                                      secondary_outcomes     sex start_date  \\\n",
       "20     Five-year RFS; Number of patients in need of a...     ALL 2025-02-24   \n",
       "86     Progress-free survival (PFS); Overall survival...     ALL 2020-04-25   \n",
       "120                                             Toxicity  FEMALE 2003-07-15   \n",
       "148                                                  NaN  FEMALE 2018-09-01   \n",
       "163                                                  NaN  FEMALE 2011-03-15   \n",
       "...                                                  ...     ...        ...   \n",
       "55435                                                NaN     ALL 2012-01-15   \n",
       "55457  Efficacy Assessment at the end of the treatmen...     ALL 2009-10-15   \n",
       "55479                                                NaN     ALL 2002-07-15   \n",
       "55550  Number of Participants With Invasive Staphyloc...     ALL 2007-12-15   \n",
       "55570                                                NaN     ALL 2014-09-15   \n",
       "\n",
       "                          stdage study_first_post_date  \\\n",
       "20            ADULT, OLDER_ADULT            2025-01-17   \n",
       "86            ADULT, OLDER_ADULT            2020-04-20   \n",
       "120           ADULT, OLDER_ADULT            2005-09-12   \n",
       "148           ADULT, OLDER_ADULT            2018-08-02   \n",
       "163           ADULT, OLDER_ADULT            2011-10-19   \n",
       "...                          ...                   ...   \n",
       "55435                      ADULT            2017-02-28   \n",
       "55457                      CHILD            2010-09-10   \n",
       "55479  CHILD, ADULT, OLDER_ADULT            2004-09-28   \n",
       "55550         ADULT, OLDER_ADULT            2007-08-21   \n",
       "55570                      ADULT            2014-09-09   \n",
       "\n",
       "      study_first_submit_date      study_type  \n",
       "20                 2025-01-14  INTERVENTIONAL  \n",
       "86                 2020-04-14  INTERVENTIONAL  \n",
       "120                2005-09-09  INTERVENTIONAL  \n",
       "148                2018-07-17  INTERVENTIONAL  \n",
       "163                2011-09-28  INTERVENTIONAL  \n",
       "...                       ...             ...  \n",
       "55435              2012-11-06  INTERVENTIONAL  \n",
       "55457              2010-09-09  INTERVENTIONAL  \n",
       "55479              2004-09-23  INTERVENTIONAL  \n",
       "55550              2007-08-17  INTERVENTIONAL  \n",
       "55570              2014-09-03  INTERVENTIONAL  \n",
       "\n",
       "[2833 rows x 35 columns]"
      ]
     },
     "execution_count": 33,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[df['is_same'].isna()]"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "6858cda0",
   "metadata": {},
   "source": [
    "Dropping data for which primary outcomes are null"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "id": "b99bb206",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0        Safety as Measured by Number of Participants W...\n",
       "1        Safety - Adverse reactions are classified acco...\n",
       "2        Progression-free survival (PFS) assessed by BI...\n",
       "3                              Overall Response Rate (ORR)\n",
       "4        Composite complete response (CR) rate (CR/comp...\n",
       "                               ...                        \n",
       "55585    Number of Participants With Treatment Emergent...\n",
       "55586    Best Objective Response Rate (ORR) Within 6 Mo...\n",
       "55587    Frequency of dose-limiting toxicities (DLT's) ...\n",
       "55588    Remission of the metabolic syndrome following ...\n",
       "55589    Percentage of Participants Who Achieved Comple...\n",
       "Name: primary_outcomes, Length: 55590, dtype: object"
      ]
     },
     "execution_count": 34,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['primary_outcomes']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "id": "8d818180",
   "metadata": {},
   "outputs": [],
   "source": [
    "df = df[~(df['primary_outcomes'].isna() | (df['primary_outcomes'].str.strip() == ''))]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "id": "cf8d7403",
   "metadata": {},
   "outputs": [],
   "source": [
    "df = df[~(df['conditions'].isna())]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "id": "1b8a09d2",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "keywords                         20392\n",
       "detailed_description             17572\n",
       "overall_officials_affiliation     9553\n",
       "overall_officials_name            9484\n",
       "secondary_outcomes                7321\n",
       "interventions_description         4405\n",
       "location_city                     2775\n",
       "location_state                    2775\n",
       "location_facility                 2775\n",
       "location_country                  2775\n",
       "is_same                           2775\n",
       "country                           2775\n",
       "conditions                           0\n",
       "brief_summary                        0\n",
       "completion_date                      0\n",
       "interventions_name                   0\n",
       "enrollment                           0\n",
       "design_primary_purpose               0\n",
       "eligibility_criteria                 0\n",
       "maximum_age                          0\n",
       "lead_sponsor                         0\n",
       "last_update_post_date                0\n",
       "organization_fullname                0\n",
       "overall_status                       0\n",
       "oversight_has_dmc                    0\n",
       "phase                                0\n",
       "minimum_age                          0\n",
       "primary_completion_date              0\n",
       "primary_outcomes                     0\n",
       "sex                                  0\n",
       "start_date                           0\n",
       "stdage                               0\n",
       "study_first_post_date                0\n",
       "study_first_submit_date              0\n",
       "study_type                           0\n",
       "dtype: int64"
      ]
     },
     "execution_count": 37,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.isnull().sum().sort_values(ascending=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "id": "ec08e85a",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(54594, 35)"
      ]
     },
     "execution_count": 38,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "id": "05481d11",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0                                 Johns Hopkins University\n",
       "1                              Zealand University Hospital\n",
       "2                                                      NaN\n",
       "3                           SINOPHARM, Zhejiang University\n",
       "4               Vanderbilt University/Ingram Cancer Center\n",
       "                               ...                        \n",
       "55585                                               AbbVie\n",
       "55586                          M.D. Anderson Cancer Center\n",
       "55587    Emory University Hospital/Winship Cancer Insti...\n",
       "55588    Hospital Universitari San Joan de Reus (Tarrag...\n",
       "55589                                                  NaN\n",
       "Name: overall_officials_affiliation, Length: 54594, dtype: object"
      ]
     },
     "execution_count": 39,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['overall_officials_affiliation']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "id": "0354b4d2",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "keywords                         20392\n",
       "detailed_description             17572\n",
       "overall_officials_affiliation     9553\n",
       "overall_officials_name            9484\n",
       "secondary_outcomes                7321\n",
       "interventions_description         4405\n",
       "location_city                     2775\n",
       "location_state                    2775\n",
       "location_facility                 2775\n",
       "location_country                  2775\n",
       "is_same                           2775\n",
       "country                           2775\n",
       "conditions                           0\n",
       "brief_summary                        0\n",
       "completion_date                      0\n",
       "interventions_name                   0\n",
       "enrollment                           0\n",
       "design_primary_purpose               0\n",
       "eligibility_criteria                 0\n",
       "maximum_age                          0\n",
       "lead_sponsor                         0\n",
       "last_update_post_date                0\n",
       "organization_fullname                0\n",
       "overall_status                       0\n",
       "oversight_has_dmc                    0\n",
       "phase                                0\n",
       "minimum_age                          0\n",
       "primary_completion_date              0\n",
       "primary_outcomes                     0\n",
       "sex                                  0\n",
       "start_date                           0\n",
       "stdage                               0\n",
       "study_first_post_date                0\n",
       "study_first_submit_date              0\n",
       "study_type                           0\n",
       "dtype: int64"
      ]
     },
     "execution_count": 40,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.isnull().sum().sort_values(ascending=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "id": "cab79b6c",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(54594, 35)"
      ]
     },
     "execution_count": 41,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "id": "cbd8cd7a",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "np.int64(0)"
      ]
     },
     "execution_count": 42,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.duplicated().sum()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "id": "f8c94fce",
   "metadata": {},
   "outputs": [],
   "source": [
    "df['is_same'] = df['is_same'].astype(bool)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "id": "6d37e175",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "✅ For is_same == True:\n",
      "overall_status\n",
      "COMPLETED     32.098149\n",
      "TERMINATED    25.468912\n",
      "Name: proportion, dtype: float64\n",
      "\n",
      "❌ For is_same == False:\n",
      "overall_status\n",
      "COMPLETED     35.909522\n",
      "TERMINATED    33.889816\n",
      "Name: proportion, dtype: float64\n"
     ]
    }
   ],
   "source": [
    "# Filter True and False separately\n",
    "true_group = df[df['is_same'] == True]['overall_status'].value_counts(normalize=True) * 100\n",
    "false_group = df[df['is_same'] == False]['overall_status'].value_counts(normalize=True) * 100\n",
    "\n",
    "# Display counts with percentages\n",
    "print(\"✅ For is_same == True:\")\n",
    "print(true_group[['COMPLETED', 'TERMINATED']])\n",
    "\n",
    "print(\"\\n❌ For is_same == False:\")\n",
    "print(false_group[['COMPLETED', 'TERMINATED']])\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "id": "51692465",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Counts:\n",
      "is_same\n",
      "False    30549\n",
      "True     24045\n",
      "Name: count, dtype: int64\n"
     ]
    }
   ],
   "source": [
    "counts = df['is_same'].astype(bool).value_counts()\n",
    "print(\"Counts:\")\n",
    "print(counts)\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "beffaec2",
   "metadata": {},
   "source": [
    "Dropping rows that have empty location_facility"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "id": "302d0353",
   "metadata": {},
   "outputs": [],
   "source": [
    "df = df.dropna(subset=['location_facility'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "id": "50d49749",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(51819, 35)"
      ]
     },
     "execution_count": 47,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "id": "fca1e46e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['brief_summary', 'completion_date', 'conditions', 'country',\n",
       "       'design_primary_purpose', 'detailed_description',\n",
       "       'eligibility_criteria', 'enrollment', 'interventions_description',\n",
       "       'interventions_name', 'is_same', 'keywords', 'last_update_post_date',\n",
       "       'lead_sponsor', 'location_city', 'location_country',\n",
       "       'location_facility', 'location_state', 'maximum_age', 'minimum_age',\n",
       "       'organization_fullname', 'overall_officials_affiliation',\n",
       "       'overall_officials_name', 'overall_status', 'oversight_has_dmc',\n",
       "       'phase', 'primary_completion_date', 'primary_outcomes',\n",
       "       'secondary_outcomes', 'sex', 'start_date', 'stdage',\n",
       "       'study_first_post_date', 'study_first_submit_date', 'study_type'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 48,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "id": "f680c8a9",
   "metadata": {},
   "outputs": [],
   "source": [
    "df.drop(['keywords','detailed_description'], axis=1, inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "id": "01c61533",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "overall_officials_affiliation    8461\n",
       "overall_officials_name           8395\n",
       "secondary_outcomes               6886\n",
       "interventions_description        4117\n",
       "brief_summary                       0\n",
       "design_primary_purpose              0\n",
       "completion_date                     0\n",
       "country                             0\n",
       "conditions                          0\n",
       "is_same                             0\n",
       "last_update_post_date               0\n",
       "lead_sponsor                        0\n",
       "location_city                       0\n",
       "location_country                    0\n",
       "eligibility_criteria                0\n",
       "enrollment                          0\n",
       "interventions_name                  0\n",
       "maximum_age                         0\n",
       "location_state                      0\n",
       "location_facility                   0\n",
       "organization_fullname               0\n",
       "overall_status                      0\n",
       "oversight_has_dmc                   0\n",
       "phase                               0\n",
       "minimum_age                         0\n",
       "primary_completion_date             0\n",
       "primary_outcomes                    0\n",
       "sex                                 0\n",
       "start_date                          0\n",
       "stdage                              0\n",
       "study_first_post_date               0\n",
       "study_first_submit_date             0\n",
       "study_type                          0\n",
       "dtype: int64"
      ]
     },
     "execution_count": 50,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.isnull().sum().sort_values(ascending=False)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "42441328",
   "metadata": {},
   "source": [
    "Checking that if officials are from the same university, then what is the ratio of it beign completed/terminated "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "id": "0e75c7f7",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>overall_officials_affiliation</th>\n",
       "      <th>overall_officials_name</th>\n",
       "      <th>organization_fullname</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Johns Hopkins University</td>\n",
       "      <td>Tanguy Lim-Seiwert, MD</td>\n",
       "      <td>Sidney Kimmel Comprehensive Cancer Center at J...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Zealand University Hospital</td>\n",
       "      <td>Ismail Gögenur, Professor</td>\n",
       "      <td>Zealand University Hospital</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Suzhou Suncadia Biopharmaceuticals Co., Ltd.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>SINOPHARM, Zhejiang University</td>\n",
       "      <td>Shanghai Institute Of Biological Products Co.,...</td>\n",
       "      <td>Shanghai Institute Of Biological Products</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Vanderbilt University/Ingram Cancer Center</td>\n",
       "      <td>Sanjay Mohan, MD</td>\n",
       "      <td>Vanderbilt-Ingram Cancer Center</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Chao Family Comprehensive Cancer Center</td>\n",
       "      <td>Farshid Dayyani, MD, PhD</td>\n",
       "      <td>Chao Family Comprehensive Cancer Center, Unive...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Stanford University</td>\n",
       "      <td>Nelson N Teng</td>\n",
       "      <td>Stanford University School of Medicine</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Qilu Pharmaceutical Co., Ltd.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Online Collaborative Oncology Group</td>\n",
       "      <td>Craig Henderson, MD</td>\n",
       "      <td>AEterna Zentaris</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>M.D. Anderson Cancer Center</td>\n",
       "      <td>Jorge Cortes, MD</td>\n",
       "      <td>Prism Pharma Co., Ltd.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>Martin-Luther-Universität Halle-Wittenberg</td>\n",
       "      <td>Carsten Mueller-Tidow, Prof.</td>\n",
       "      <td>Martin-Luther-Universität Halle-Wittenberg</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>UT Southwestern Medical Center</td>\n",
       "      <td>Arthur E. Frankel, MD</td>\n",
       "      <td>University of Texas Southwestern Medical Center</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>Beijing Tsinghua Chang Gung Hospital</td>\n",
       "      <td>Donghong Chen, Dr.</td>\n",
       "      <td>Beijing Tsinghua Chang Gung Hospital</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>NCI - Medical Oncology Branch</td>\n",
       "      <td>Shivaani Kummar, MD</td>\n",
       "      <td>National Institutes of Health Clinical Center ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>aktuell: Spitalzentrum Biel-Bienne, Kantonsspi...</td>\n",
       "      <td>Carsten T. Viehl, MD, Markus Zuber, MD</td>\n",
       "      <td>University Hospital, Basel, Switzerland</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>St. Jude Children's Research Hospital</td>\n",
       "      <td>Rebecca Epperly, MD</td>\n",
       "      <td>St. Jude Children's Research Hospital</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>Emory University</td>\n",
       "      <td>Christopher Flowers, MD</td>\n",
       "      <td>Emory University Winship Cancer Institute</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>Dana-Farber Cancer Institute</td>\n",
       "      <td>Elahe Salehi, DNP, ANP-BC</td>\n",
       "      <td>Dana-Farber Cancer Institute</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>Department of Respiratory Medicine, Juntendo U...</td>\n",
       "      <td>Ryo Ko, MD, PhD</td>\n",
       "      <td>Juntendo Urayasu Hospital, St. Marianna Univer...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>Sunnybrook Health Sciences Centre</td>\n",
       "      <td>Simron Singh</td>\n",
       "      <td>Sunnybrook Health Sciences Centre</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>Princess Margaret Cancer Centre</td>\n",
       "      <td>Robert C. Grant, MD</td>\n",
       "      <td>University Health Network, Toronto</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>Cancer Insititute and Hospital,Chinese Academy...</td>\n",
       "      <td>Jianqiang Cai, meidical, Lei Yu, medical</td>\n",
       "      <td>Cure&amp;Sure Biotech Co., LTD</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>M.D. Anderson Cancer Center</td>\n",
       "      <td>Clinton Yam, MD</td>\n",
       "      <td>M.D. Anderson Cancer Center</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>M.D. Anderson Cancer Center</td>\n",
       "      <td>Vassiliki Papadimitrakopoulou, M.D.</td>\n",
       "      <td>Emory University Winship Cancer Institute, The...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>Fudan University Affiliated Cancer Hospital</td>\n",
       "      <td>Jian Zhang</td>\n",
       "      <td>Shenzhen Yangli Pharmaceutical Technology Co.,...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>Dong-A University</td>\n",
       "      <td>Ki-Hoon Song, M.D., Ph.D.</td>\n",
       "      <td>Dong-A University</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Sunshine Guojian Pharmaceutical (Shanghai) Co....</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>The First Affiliated Hospital of Sun Yat-sen U...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>Bristol-Myers Squibb</td>\n",
       "      <td>Bristol Myers Squibb</td>\n",
       "      <td>Bristol-Myers Squibb</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Adnexus, A Bristol-Myers Squibb R&amp;D Company</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>920th Hospital of Joint Logistics Support Forc...</td>\n",
       "      <td>Wang Sanbin, Doctor</td>\n",
       "      <td>920th Hospital of Joint Logistics Support Forc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>Janssen Research &amp; Development, LLC</td>\n",
       "      <td>Janssen Research &amp; Development, LLC Clinical T...</td>\n",
       "      <td>Janssen Research &amp; Development, LLC</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>Dartmouth-Hitchcock Medical Center</td>\n",
       "      <td>Kenneth Meehan, MD</td>\n",
       "      <td>Dartmouth-Hitchcock Medical Center</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>Fudan University</td>\n",
       "      <td>Dingwei Ye, MD</td>\n",
       "      <td>Fudan University Shanghai Cancer Center</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>Forma Therapeutics, Inc.</td>\n",
       "      <td>Patrick Kelly, MD</td>\n",
       "      <td>Novo Nordisk A/S</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>University of Texas Health Science Center San ...</td>\n",
       "      <td>Andrew Brenner, MD</td>\n",
       "      <td>Dana-Farber Cancer Institute, University of Te...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>Princess Margaret Hospital, Canada</td>\n",
       "      <td>Lillian L. Siu, MD, FRCPC</td>\n",
       "      <td>Canadian Cancer Trials Group</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>Aeglea Biotherapeutics, Inc.</td>\n",
       "      <td>Josie Gayton</td>\n",
       "      <td>Aeglea Biotherapeutics</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>Northwestern University</td>\n",
       "      <td>Kenzie A Cameron, PhD</td>\n",
       "      <td>Northwestern University</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>University Hospital Cologne</td>\n",
       "      <td>Jürgen Wolf, MD</td>\n",
       "      <td>University Hospital Cologne</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Qingdao Central Hospital, Qingdao Cancer Hospital</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>42</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Shuttle Pharmaceuticals, Inc.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>43</th>\n",
       "      <td>Nouscom SRL</td>\n",
       "      <td>Sven Gogov, MD</td>\n",
       "      <td>Nouscom SRL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>44</th>\n",
       "      <td>Divisione di Ematologia dell'Università di Tor...</td>\n",
       "      <td>Mario Boccadoro, MD</td>\n",
       "      <td>Fondazione EMN Italy Onlus</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>45</th>\n",
       "      <td>Beijing Tongren Hospital</td>\n",
       "      <td>Jing-wen Wang, M.D.</td>\n",
       "      <td>Beijing Tongren Hospital</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>46</th>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Wake Forest University Health Sciences</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>47</th>\n",
       "      <td>University of Kentucky</td>\n",
       "      <td>Zhonglin Hao, MD</td>\n",
       "      <td>University of Kentucky</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>48</th>\n",
       "      <td>Princess Margaret Cancer Centre</td>\n",
       "      <td>Srikala Sridhar, M.D.</td>\n",
       "      <td>University Health Network, Toronto</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>49</th>\n",
       "      <td>Oncotartis, Inc.</td>\n",
       "      <td>Eric Rowinsky, MD</td>\n",
       "      <td>Oncotartis, Inc.</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>50</th>\n",
       "      <td>University of British Columbia</td>\n",
       "      <td>Kristin L Campbell, PhD</td>\n",
       "      <td>University of British Columbia Breast Cancer R...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                        overall_officials_affiliation  \\\n",
       "0                            Johns Hopkins University   \n",
       "1                         Zealand University Hospital   \n",
       "2                                                 NaN   \n",
       "3                      SINOPHARM, Zhejiang University   \n",
       "4          Vanderbilt University/Ingram Cancer Center   \n",
       "5             Chao Family Comprehensive Cancer Center   \n",
       "6                                 Stanford University   \n",
       "7                                                 NaN   \n",
       "8                 Online Collaborative Oncology Group   \n",
       "9                         M.D. Anderson Cancer Center   \n",
       "10         Martin-Luther-Universität Halle-Wittenberg   \n",
       "11                     UT Southwestern Medical Center   \n",
       "12               Beijing Tsinghua Chang Gung Hospital   \n",
       "13                      NCI - Medical Oncology Branch   \n",
       "14  aktuell: Spitalzentrum Biel-Bienne, Kantonsspi...   \n",
       "15              St. Jude Children's Research Hospital   \n",
       "16                                   Emory University   \n",
       "17                       Dana-Farber Cancer Institute   \n",
       "18  Department of Respiratory Medicine, Juntendo U...   \n",
       "19                  Sunnybrook Health Sciences Centre   \n",
       "21                    Princess Margaret Cancer Centre   \n",
       "22  Cancer Insititute and Hospital,Chinese Academy...   \n",
       "23                        M.D. Anderson Cancer Center   \n",
       "24                        M.D. Anderson Cancer Center   \n",
       "25        Fudan University Affiliated Cancer Hospital   \n",
       "26                                  Dong-A University   \n",
       "27                                                NaN   \n",
       "28                                                NaN   \n",
       "29                               Bristol-Myers Squibb   \n",
       "30                                                NaN   \n",
       "31  920th Hospital of Joint Logistics Support Forc...   \n",
       "32                Janssen Research & Development, LLC   \n",
       "33                 Dartmouth-Hitchcock Medical Center   \n",
       "34                                   Fudan University   \n",
       "35                           Forma Therapeutics, Inc.   \n",
       "36  University of Texas Health Science Center San ...   \n",
       "37                 Princess Margaret Hospital, Canada   \n",
       "38                       Aeglea Biotherapeutics, Inc.   \n",
       "39                            Northwestern University   \n",
       "40                        University Hospital Cologne   \n",
       "41                                                NaN   \n",
       "42                                                NaN   \n",
       "43                                        Nouscom SRL   \n",
       "44  Divisione di Ematologia dell'Università di Tor...   \n",
       "45                           Beijing Tongren Hospital   \n",
       "46                                                NaN   \n",
       "47                             University of Kentucky   \n",
       "48                    Princess Margaret Cancer Centre   \n",
       "49                                   Oncotartis, Inc.   \n",
       "50                     University of British Columbia   \n",
       "\n",
       "                               overall_officials_name  \\\n",
       "0                              Tanguy Lim-Seiwert, MD   \n",
       "1                           Ismail Gögenur, Professor   \n",
       "2                                                 NaN   \n",
       "3   Shanghai Institute Of Biological Products Co.,...   \n",
       "4                                    Sanjay Mohan, MD   \n",
       "5                            Farshid Dayyani, MD, PhD   \n",
       "6                                       Nelson N Teng   \n",
       "7                                                 NaN   \n",
       "8                                 Craig Henderson, MD   \n",
       "9                                    Jorge Cortes, MD   \n",
       "10                       Carsten Mueller-Tidow, Prof.   \n",
       "11                              Arthur E. Frankel, MD   \n",
       "12                                 Donghong Chen, Dr.   \n",
       "13                                Shivaani Kummar, MD   \n",
       "14             Carsten T. Viehl, MD, Markus Zuber, MD   \n",
       "15                                Rebecca Epperly, MD   \n",
       "16                            Christopher Flowers, MD   \n",
       "17                          Elahe Salehi, DNP, ANP-BC   \n",
       "18                                    Ryo Ko, MD, PhD   \n",
       "19                                       Simron Singh   \n",
       "21                                Robert C. Grant, MD   \n",
       "22           Jianqiang Cai, meidical, Lei Yu, medical   \n",
       "23                                    Clinton Yam, MD   \n",
       "24                Vassiliki Papadimitrakopoulou, M.D.   \n",
       "25                                         Jian Zhang   \n",
       "26                          Ki-Hoon Song, M.D., Ph.D.   \n",
       "27                                                NaN   \n",
       "28                                                NaN   \n",
       "29                               Bristol Myers Squibb   \n",
       "30                                                NaN   \n",
       "31                                Wang Sanbin, Doctor   \n",
       "32  Janssen Research & Development, LLC Clinical T...   \n",
       "33                                 Kenneth Meehan, MD   \n",
       "34                                     Dingwei Ye, MD   \n",
       "35                                  Patrick Kelly, MD   \n",
       "36                                 Andrew Brenner, MD   \n",
       "37                          Lillian L. Siu, MD, FRCPC   \n",
       "38                                       Josie Gayton   \n",
       "39                              Kenzie A Cameron, PhD   \n",
       "40                                    Jürgen Wolf, MD   \n",
       "41                                                NaN   \n",
       "42                                                NaN   \n",
       "43                                     Sven Gogov, MD   \n",
       "44                                Mario Boccadoro, MD   \n",
       "45                                Jing-wen Wang, M.D.   \n",
       "46                                                NaN   \n",
       "47                                   Zhonglin Hao, MD   \n",
       "48                              Srikala Sridhar, M.D.   \n",
       "49                                  Eric Rowinsky, MD   \n",
       "50                            Kristin L Campbell, PhD   \n",
       "\n",
       "                                organization_fullname  \n",
       "0   Sidney Kimmel Comprehensive Cancer Center at J...  \n",
       "1                         Zealand University Hospital  \n",
       "2        Suzhou Suncadia Biopharmaceuticals Co., Ltd.  \n",
       "3           Shanghai Institute Of Biological Products  \n",
       "4                     Vanderbilt-Ingram Cancer Center  \n",
       "5   Chao Family Comprehensive Cancer Center, Unive...  \n",
       "6              Stanford University School of Medicine  \n",
       "7                       Qilu Pharmaceutical Co., Ltd.  \n",
       "8                                    AEterna Zentaris  \n",
       "9                              Prism Pharma Co., Ltd.  \n",
       "10         Martin-Luther-Universität Halle-Wittenberg  \n",
       "11    University of Texas Southwestern Medical Center  \n",
       "12               Beijing Tsinghua Chang Gung Hospital  \n",
       "13  National Institutes of Health Clinical Center ...  \n",
       "14            University Hospital, Basel, Switzerland  \n",
       "15              St. Jude Children's Research Hospital  \n",
       "16          Emory University Winship Cancer Institute  \n",
       "17                       Dana-Farber Cancer Institute  \n",
       "18  Juntendo Urayasu Hospital, St. Marianna Univer...  \n",
       "19                  Sunnybrook Health Sciences Centre  \n",
       "21                 University Health Network, Toronto  \n",
       "22                         Cure&Sure Biotech Co., LTD  \n",
       "23                        M.D. Anderson Cancer Center  \n",
       "24  Emory University Winship Cancer Institute, The...  \n",
       "25  Shenzhen Yangli Pharmaceutical Technology Co.,...  \n",
       "26                                  Dong-A University  \n",
       "27  Sunshine Guojian Pharmaceutical (Shanghai) Co....  \n",
       "28  The First Affiliated Hospital of Sun Yat-sen U...  \n",
       "29                               Bristol-Myers Squibb  \n",
       "30        Adnexus, A Bristol-Myers Squibb R&D Company  \n",
       "31  920th Hospital of Joint Logistics Support Forc...  \n",
       "32                Janssen Research & Development, LLC  \n",
       "33                 Dartmouth-Hitchcock Medical Center  \n",
       "34            Fudan University Shanghai Cancer Center  \n",
       "35                                   Novo Nordisk A/S  \n",
       "36  Dana-Farber Cancer Institute, University of Te...  \n",
       "37                       Canadian Cancer Trials Group  \n",
       "38                             Aeglea Biotherapeutics  \n",
       "39                            Northwestern University  \n",
       "40                        University Hospital Cologne  \n",
       "41  Qingdao Central Hospital, Qingdao Cancer Hospital  \n",
       "42                      Shuttle Pharmaceuticals, Inc.  \n",
       "43                                        Nouscom SRL  \n",
       "44                         Fondazione EMN Italy Onlus  \n",
       "45                           Beijing Tongren Hospital  \n",
       "46             Wake Forest University Health Sciences  \n",
       "47                             University of Kentucky  \n",
       "48                 University Health Network, Toronto  \n",
       "49                                   Oncotartis, Inc.  \n",
       "50  University of British Columbia Breast Cancer R...  "
      ]
     },
     "execution_count": 51,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[['overall_officials_affiliation', 'overall_officials_name','organization_fullname']].head(50)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "id": "b1a266e9",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "overall_officials_name\n",
       "Clinical Trials              722\n",
       "Pfizer CT.gov Call Center    627\n",
       "Novartis Pharmaceuticals     609\n",
       "Bristol-Myers Squibb         470\n",
       "Medical Director             436\n",
       "                            ... \n",
       "Jeremy S Connors, MD           1\n",
       "James K Mangan, MD, PhD        1\n",
       "Sarah Taylor, MD               1\n",
       "Yanhua Ding                    1\n",
       "Afshin Dowlati                 1\n",
       "Name: count, Length: 27974, dtype: int64"
      ]
     },
     "execution_count": 52,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['overall_officials_name'].value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "id": "2b359701",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Matching rows (fuzzy): 28325 out of 51819 (54.66%)\n"
     ]
    }
   ],
   "source": [
    "\n",
    "def is_similar(a, b, threshold=85):\n",
    "    a_clean = clean_text(a)\n",
    "    b_clean = clean_text(b)\n",
    "    return fuzz.token_set_ratio(a_clean, b_clean) >= threshold\n",
    "\n",
    "# Apply the fuzzy match row-wise\n",
    "df['affiliation_matches_org'] = df.apply(\n",
    "    lambda row: is_similar(row['overall_officials_affiliation'], row['organization_fullname']), axis=1\n",
    ")\n",
    "\n",
    "# Get percentage\n",
    "total = df.shape[0]\n",
    "matches = df['affiliation_matches_org'].sum()\n",
    "percentage = (matches / total) * 100\n",
    "\n",
    "print(f\"Matching rows (fuzzy): {matches} out of {total} ({percentage:.2f}%)\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "id": "30b83574",
   "metadata": {},
   "outputs": [],
   "source": [
    "df = df[df['overall_status'].isin(['COMPLETED', 'TERMINATED', 'RECRUITING'])]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "a74edf72",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Status distribution for MATCHED rows:\n",
      "overall_status\n",
      "COMPLETED     43.91\n",
      "TERMINATED    39.05\n",
      "Name: proportion, dtype: float64\n",
      "\n",
      "Status distribution for UNMATCHED rows:\n",
      "overall_status\n",
      "COMPLETED     41.91\n",
      "TERMINATED    36.84\n",
      "Name: proportion, dtype: float64\n"
     ]
    }
   ],
   "source": [
    "# Filter matched and unmatched rows\n",
    "matched = df[df['affiliation_matches_org'] == True]\n",
    "unmatched = df[df['affiliation_matches_org'] == False]\n",
    "\n",
    "# Get counts for COMPLETED and TERMINATED in matched\n",
    "matched_status_counts = matched['overall_status'].value_counts(normalize=True) * 100\n",
    "\n",
    "# Get counts for COMPLETED and TERMINATED in unmatched\n",
    "unmatched_status_counts = unmatched['overall_status'].value_counts(normalize=True) * 100\n",
    "\n",
    "print(\"Status distribution for MATCHED rows:\")\n",
    "print(matched_status_counts[['COMPLETED', 'TERMINATED']].fillna(0).round(2))\n",
    "\n",
    "print(\"\\nStatus distribution for UNMATCHED rows:\")\n",
    "print(unmatched_status_counts[['COMPLETED', 'TERMINATED']].fillna(0).round(2))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "id": "38400b59",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['brief_summary', 'completion_date', 'conditions', 'country',\n",
       "       'design_primary_purpose', 'eligibility_criteria', 'enrollment',\n",
       "       'interventions_description', 'interventions_name', 'is_same',\n",
       "       'last_update_post_date', 'lead_sponsor', 'location_city',\n",
       "       'location_country', 'location_facility', 'location_state',\n",
       "       'maximum_age', 'minimum_age', 'organization_fullname',\n",
       "       'overall_officials_affiliation', 'overall_officials_name',\n",
       "       'overall_status', 'oversight_has_dmc', 'phase',\n",
       "       'primary_completion_date', 'primary_outcomes', 'secondary_outcomes',\n",
       "       'sex', 'start_date', 'stdage', 'study_first_post_date',\n",
       "       'study_first_submit_date', 'study_type', 'affiliation_matches_org'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 57,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "id": "1004c190",
   "metadata": {},
   "outputs": [],
   "source": [
    "df.rename(columns={'is_same':'organization_match'}, inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "d9b69e10",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0        Head and Neck Squamous Cell Carcinoma, Head an...\n",
       "1                                        Colorectal Cancer\n",
       "2                               Non-small Cell Lung Cancer\n",
       "3                            Diffuse Large B-Cell Lymphoma\n",
       "4                         Recurrent Acute Myeloid Leukemia\n",
       "                               ...                        \n",
       "55585                                  Alzheimer's Disease\n",
       "55586    Locally Advanced Lung Non-Squamous Non-Small C...\n",
       "55587    Mycosis Fungoides, Primary Cutaneous T-Cell No...\n",
       "55588                                   Metabolic Syndrome\n",
       "55589                             Hemophilia A, Congenital\n",
       "Name: conditions, Length: 41761, dtype: object"
      ]
     },
     "execution_count": 61,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 67,
   "id": "89aeb3f7",
   "metadata": {},
   "outputs": [],
   "source": [
    "df['eligibility_criteria'] = df['eligibility_criteria'].str.replace(r'^.*?\\n\\n', '', regex=True)\n",
    "df['eligibility_criteria'] = df['eligibility_criteria'].str.replace('/', '')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 72,
   "id": "be68e6f0",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0     Cohort 2: Subjects must have histologically co...\n",
       "1     * Patients must be mentally capable of underst...\n",
       "2     1. Age 18 to 75 years old (inclusive), Female ...\n",
       "3     * 18-75 years old, male or female;\\n* Patients...\n",
       "4     * Age \\>= 18 years at the time of signing the ...\n",
       "6     3.1.2 Diagnosis\\n\\n3.1.2.1 Histologic Verifica...\n",
       "8        - Capecitabine 825 mgm2 BID days 1 - 14 q 3...\n",
       "9     1. Patients 18 years or older\\n2. Part I: Pati...\n",
       "11      * Histologically or morphologically confirme...\n",
       "12    * Written informed consent provided.\\n* Unrese...\n",
       "13    * Histologically confirmed malignancy that is ...\n",
       "14    * Colon cancer at any stage diagnosed histolog...\n",
       "16      * For the Phase 1 trial: patients with any o...\n",
       "17    * Men and women with a diagnosis of metastatic...\n",
       "19    * Adults (males or females), aged 18 years or ...\n",
       "23    1. Female or male patients 18 years of age or ...\n",
       "24    1. Male or female patients with one of the fol...\n",
       "25    1. voluntary participation in clinical trials ...\n",
       "26    * patient's request for alternative treatment ...\n",
       "29    1. All subjects must have documented disease p...\n",
       "30    * Histologically proven advanced solid maligna...\n",
       "31    1. Male or female, aged 2-75 years;\\n2. A defi...\n",
       "32    * Participant must have documented multiple my...\n",
       "33    1. Age less than or equal to 75 years\\n2. The ...\n",
       "35    * Single agent (SA) Dose Escalation: Histologi...\n",
       "36    * At least 18 years of age\\n* Ability to under...\n",
       "37      * All histological subtypes eligible\\n  * Lo...\n",
       "38    1. Patient is able and willing to provide writ...\n",
       "39    * Patients aged 50-75 years of age (in month 1...\n",
       "41    Participant must have Eastern Cooperative Onco...\n",
       "42    * Written informed consent form signed and dat...\n",
       "44    * Age \\> 65 year old and not a candidate for s...\n",
       "46    * Newly diagnosed or recurrent patients with l...\n",
       "48    * Histologically confirmed squamous cell carci...\n",
       "50    * newly diagnosed with stage I-IIIA breast can...\n",
       "51    * This trial will include subjects with stage ...\n",
       "52      * AML arising after an antecedent hematologi...\n",
       "53    1. Histologically or cytologically confirmed a...\n",
       "54    * Age ≥ 18 years\\n* Subjects eligible for SCT\\...\n",
       "55    * Histologically confirmed metastatic ER+ ando...\n",
       "57    1. Histologically confirmed unresectable stage...\n",
       "58    Exclusion Criteria:\\n\\n1) Patients may not hav...\n",
       "59    * Age 18 years or older\\n* HIV-1 infection\\n* ...\n",
       "60    Patients must meet the following criteria for ...\n",
       "61    * Signs of a bleeding in the stomach\\n* One en...\n",
       "62    * Histologically confirmed CD30+ classical Hod...\n",
       "65    1. A healthy adult whose age is over 19 years ...\n",
       "67    * Hodgkin Lymphoma, intermediate or advanced s...\n",
       "69    1. Histologically confirmed Primary Central Ne...\n",
       "70      * Recurrent or persistent disease\\n\\n    * H...\n",
       "Name: eligibility_criteria, dtype: object"
      ]
     },
     "execution_count": 72,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['eligibility_criteria'].head(50)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "4feb08ee",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "count     41761.000000\n",
       "mean        143.857163\n",
       "std        1137.824399\n",
       "min           0.000000\n",
       "25%          16.000000\n",
       "50%          40.000000\n",
       "75%         100.000000\n",
       "max      150000.000000\n",
       "Name: enrollment, dtype: float64"
      ]
     },
     "execution_count": 84,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['enrollment'] = df['enrollment'].astype(str).str.replace('?', '0').astype(int)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "abeb4988",
   "metadata": {},
   "source": [
    "Checking for correlation between people enrolled and the status of the trial"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "4768dbb7",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/tmp/ipykernel_7816/2966261209.py:8: FutureWarning: A value is trying to be set on a copy of a DataFrame or Series through chained assignment using an inplace method.\n",
      "The behavior will change in pandas 3.0. This inplace method will never work because the intermediate object on which we are setting values always behaves as a copy.\n",
      "\n",
      "For example, when doing 'df[col].method(value, inplace=True)', try using 'df.method({col: value}, inplace=True)' or df[col] = df[col].method(value) instead, to perform the operation inplace on the original object.\n",
      "\n",
      "\n",
      "  df['enrollment'].fillna(0, inplace=True)\n",
      "/tmp/ipykernel_7816/2966261209.py:23: FutureWarning: DataFrameGroupBy.apply operated on the grouping columns. This behavior is deprecated, and in a future version of pandas the grouping columns will be excluded from the operation. Either pass `include_groups=False` to exclude the groupings or explicitly select the grouping columns after groupby to silence this warning.\n",
      "  filtered_df = filtered_df.groupby('overall_status', group_keys=False).apply(remove_outliers_iqr)\n",
      "/tmp/ipykernel_7816/2966261209.py:27: FutureWarning: \n",
      "\n",
      "Passing `palette` without assigning `hue` is deprecated and will be removed in v0.14.0. Assign the `x` variable to `hue` and set `legend=False` for the same effect.\n",
      "\n",
      "  sns.boxplot(data=filtered_df, x='overall_status', y='enrollment', palette='Set2')\n"
     ]
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 800x500 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Summary statistics:\n",
      "                  count       mean        std  min   25%   50%   75%    max\n",
      "overall_status                                                             \n",
      "COMPLETED       16104.0  59.787941  54.843728  0.0  22.0  41.0  78.0  270.0\n",
      "TERMINATED      14090.0  28.152023  32.574724  0.0   6.0  15.0  38.0  157.0\n",
      "\n",
      "T-test Results: t-statistic = 61.796, p-value = 0.00000\n",
      "\n",
      "✅ There is a **statistically significant** difference in enrollment between COMPLETED and TERMINATED trials.\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import seaborn as sns\n",
    "import matplotlib.pyplot as plt\n",
    "from scipy.stats import ttest_ind\n",
    "\n",
    "# Convert to numeric and handle missing\n",
    "df['enrollment'] = pd.to_numeric(df['enrollment'], errors='coerce')\n",
    "df['enrollment'].fillna(0, inplace=True)\n",
    "\n",
    "# Filter for only relevant statuses\n",
    "filtered_df = df[df['overall_status'].isin(['COMPLETED', 'TERMINATED'])]\n",
    "\n",
    "# Remove outliers using IQR method for each group\n",
    "def remove_outliers_iqr(group):\n",
    "    Q1 = group['enrollment'].quantile(0.25)\n",
    "    Q3 = group['enrollment'].quantile(0.75)\n",
    "    IQR = Q3 - Q1\n",
    "    lower_bound = Q1 - 1.5 * IQR\n",
    "    upper_bound = Q3 + 1.5 * IQR\n",
    "    return group[(group['enrollment'] >= lower_bound) & (group['enrollment'] <= upper_bound)]\n",
    "\n",
    "# Apply outlier removal\n",
    "filtered_df = filtered_df.groupby('overall_status', group_keys=False).apply(remove_outliers_iqr)\n",
    "\n",
    "# Boxplot after removing outliers\n",
    "plt.figure(figsize=(8, 5))\n",
    "sns.boxplot(data=filtered_df, x='overall_status', y='enrollment', palette='Set2')\n",
    "plt.title('Enrollment Distribution by Trial Status (Outliers Removed)')\n",
    "plt.ylabel('Number of People Enrolled')\n",
    "plt.xlabel('Trial Status')\n",
    "plt.tight_layout()\n",
    "plt.show()\n",
    "\n",
    "# Summary statistics\n",
    "summary = filtered_df.groupby('overall_status')['enrollment'].describe()\n",
    "print(\"\\nSummary statistics:\")\n",
    "print(summary)\n",
    "\n",
    "# T-test: Compare mean enrollments\n",
    "completed = filtered_df[filtered_df['overall_status'] == 'COMPLETED']['enrollment']\n",
    "terminated = filtered_df[filtered_df['overall_status'] == 'TERMINATED']['enrollment']\n",
    "\n",
    "t_stat, p_value = ttest_ind(completed, terminated, equal_var=False)\n",
    "print(f\"\\nT-test Results: t-statistic = {t_stat:.3f}, p-value = {p_value:.5f}\")\n",
    "\n",
    "# Verdict\n",
    "if p_value < 0.05:\n",
    "    print(\"\\n✅ There is a **statistically significant** difference in enrollment between COMPLETED and TERMINATED trials.\")\n",
    "else:\n",
    "    print(\"\\n❌ There is **no statistically significant** difference in enrollment between COMPLETED and TERMINATED trials.\")\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "f53ad4b1",
   "metadata": {},
   "source": [
    "Quite a positive relation between the number of people enrolled for the trial and its overall status"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 89,
   "id": "9e7298ec",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['brief_summary', 'completion_date', 'conditions', 'country',\n",
       "       'design_primary_purpose', 'eligibility_criteria', 'enrollment',\n",
       "       'interventions_description', 'interventions_name', 'organization_match',\n",
       "       'last_update_post_date', 'lead_sponsor', 'location_city',\n",
       "       'location_country', 'location_facility', 'location_state',\n",
       "       'maximum_age', 'minimum_age', 'organization_fullname',\n",
       "       'overall_officials_affiliation', 'overall_officials_name',\n",
       "       'overall_status', 'oversight_has_dmc', 'phase',\n",
       "       'primary_completion_date', 'primary_outcomes', 'secondary_outcomes',\n",
       "       'sex', 'start_date', 'stdage', 'study_first_post_date',\n",
       "       'study_first_submit_date', 'study_type', 'affiliation_matches_org'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 89,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 93,
   "id": "842f5dcd",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "secondary_outcomes           5881\n",
       "interventions_description    3735\n",
       "conditions                      0\n",
       "brief_summary                   0\n",
       "country                         0\n",
       "design_primary_purpose          0\n",
       "eligibility_criteria            0\n",
       "completion_date                 0\n",
       "interventions_name              0\n",
       "organization_match              0\n",
       "last_update_post_date           0\n",
       "lead_sponsor                    0\n",
       "location_city                   0\n",
       "location_country                0\n",
       "location_facility               0\n",
       "enrollment                      0\n",
       "location_state                  0\n",
       "maximum_age                     0\n",
       "organization_fullname           0\n",
       "minimum_age                     0\n",
       "oversight_has_dmc               0\n",
       "phase                           0\n",
       "primary_completion_date         0\n",
       "overall_status                  0\n",
       "primary_outcomes                0\n",
       "sex                             0\n",
       "start_date                      0\n",
       "stdage                          0\n",
       "study_first_post_date           0\n",
       "study_first_submit_date         0\n",
       "study_type                      0\n",
       "affiliation_matches_org         0\n",
       "dtype: int64"
      ]
     },
     "execution_count": 93,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.isnull().sum().sort_values(ascending=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 91,
   "id": "78649d1e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['brief_summary', 'completion_date', 'conditions', 'country',\n",
       "       'design_primary_purpose', 'eligibility_criteria', 'enrollment',\n",
       "       'interventions_description', 'interventions_name', 'organization_match',\n",
       "       'last_update_post_date', 'lead_sponsor', 'location_city',\n",
       "       'location_country', 'location_facility', 'location_state',\n",
       "       'maximum_age', 'minimum_age', 'organization_fullname',\n",
       "       'overall_officials_affiliation', 'overall_officials_name',\n",
       "       'overall_status', 'oversight_has_dmc', 'phase',\n",
       "       'primary_completion_date', 'primary_outcomes', 'secondary_outcomes',\n",
       "       'sex', 'start_date', 'stdage', 'study_first_post_date',\n",
       "       'study_first_submit_date', 'study_type', 'affiliation_matches_org'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 91,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 92,
   "id": "91d2e17f",
   "metadata": {},
   "outputs": [],
   "source": [
    "df.drop(['overall_officials_affiliation', 'overall_officials_name'], axis=1, inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 94,
   "id": "075ad9b6",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0     One dose of Nivolumab 480mg given four weeks p...\n",
       "1     Intratumoral application of an unattenuated in...\n",
       "2     SHR-A2009 monotherapy ，SHR-A2009 will be admin...\n",
       "3            Injection，100mg/10ml; Injection，100mg/10ml\n",
       "4     Given by mouth; Given by mouth; Given by mouth...\n",
       "6     Dosage: 1.25mg/kg intravenous with dose escala...\n",
       "8     Perifosine 50 mg/d qd; Capecitabine 825 mg/m\\^...\n",
       "9     PRI-724; PRI-724 in combination with dasatinib...\n",
       "11    Intravenously via a 3 cc plastic syringe as a ...\n",
       "12    Tislelizumab: 200mg, IV, day 1 of each 21-day ...\n",
       "13                                                  NaN\n",
       "14    After careful mobilization of the affected col...\n",
       "16    Bortezomib 1.6 mg/m² given on days 1 and 8; Ri...\n",
       "17    Cap attached to coolant lines connected to a r...\n",
       "19    Avelumab will be administered intravenously as...\n",
       "23               Given by IV (vein); Given by IV (vein)\n",
       "24         150 mg by mouth daily; Tablet by mouth daily\n",
       "25                            TFX06 tablet taken orally\n",
       "26    AFL was performed using a 2940-nm Er:YAG ablat...\n",
       "29                                                  NaN\n",
       "30                     IV solution, weekly or bi-weekly\n",
       "31    UCAR-T Cellswill be administered by vein. The ...\n",
       "32    Participants will receive velcade 1.3 mg/m\\^2,...\n",
       "33    Fludarabine: 30 mg/m2 daily for 5 days; Busulf...\n",
       "35    FT-1101 will be supplied as 5 mg, 20 mg or 100...\n",
       "36                                    10mg/kg; 670mg/m2\n",
       "37                                                  NaN\n",
       "38                     Administered IV; Administered IV\n",
       "39    Physicians at these clinics will participate i...\n",
       "41    Osimertinib, 80mg, oral daily; bevacizumab (av...\n",
       "42    Ropidoxuridine is administered daily, 5 days a...\n",
       "44    Induction therapy:\\n\\n9 courses with weekly VE...\n",
       "46    15 mCi 11C-choline will be administered intrav...\n",
       "48    Avelumab is a fully human monoclonal antibody ...\n",
       "50    An acute bout of exercise performed 24 hours p...\n",
       "51                        Correlative studies; Given IV\n",
       "52    Venetoclax administered orally once daily on d...\n",
       "53    25 mg/m\\^2 administered by intravenous (IV) ro...\n",
       "54    Azacitidine; Donor lymphocytes in patients wit...\n",
       "55    Palbociclib at a dose of 125 mg should be take...\n",
       "57    Part I Safety Run in:\\n\\nCohort 1.1: RO6874281...\n",
       "58    Arm I-II: Patients receive one of two differen...\n",
       "59    Lopinavir/ritonavir 200/50mg plus Emtricitabin...\n",
       "60    A166 is an Antibody Drug Conjugate (ADC) targe...\n",
       "61                                                  NaN\n",
       "62        25mg/m2; 10mg/m2; 6mg/m2; 375mg/m2; 1.2 mg/kg\n",
       "65    Memantine Tab. 10mg\\* 2T/day, QD, PO; Memantin...\n",
       "67    50mg/m2 day 1 + 15; 375mg/m2 day 1 + 15; day 1...\n",
       "69    375mg/m2 intravenous infusion d1, every 3 week...\n",
       "70                                             Given IV\n",
       "Name: interventions_description, dtype: object"
      ]
     },
     "execution_count": 94,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['interventions_description'].head(50)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 95,
   "id": "3b578f12",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(41761, 32)"
      ]
     },
     "execution_count": 95,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.shape"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "3d6456b7",
   "metadata": {},
   "source": [
    "Adding a new feature of the days in which the trial is completed"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 99,
   "id": "38d977cd",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>completion_date</th>\n",
       "      <th>primary_completion_date</th>\n",
       "      <th>start_date</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>2023-10-17</td>\n",
       "      <td>2023-10-17</td>\n",
       "      <td>2019-07-08</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2021-11-01</td>\n",
       "      <td>2021-09-22</td>\n",
       "      <td>2021-02-26</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2027-06-15</td>\n",
       "      <td>2026-12-15</td>\n",
       "      <td>2024-11-29</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2022-05-20</td>\n",
       "      <td>2022-05-20</td>\n",
       "      <td>2019-07-25</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>2029-03-15</td>\n",
       "      <td>2028-03-15</td>\n",
       "      <td>2024-01-29</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>2009-07-15</td>\n",
       "      <td>2009-02-15</td>\n",
       "      <td>2006-05-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>2011-10-15</td>\n",
       "      <td>2010-12-15</td>\n",
       "      <td>2005-08-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>2016-12-30</td>\n",
       "      <td>2016-12-30</td>\n",
       "      <td>2012-07-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>2017-07-27</td>\n",
       "      <td>2017-07-27</td>\n",
       "      <td>2013-05-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>2024-04-30</td>\n",
       "      <td>2024-02-29</td>\n",
       "      <td>2023-03-12</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>2008-10-15</td>\n",
       "      <td>2008-04-15</td>\n",
       "      <td>2001-03-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>2009-01-15</td>\n",
       "      <td>2009-01-15</td>\n",
       "      <td>2000-05-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>2015-11-15</td>\n",
       "      <td>2015-11-15</td>\n",
       "      <td>2008-02-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>2028-06-01</td>\n",
       "      <td>2026-06-01</td>\n",
       "      <td>2021-10-07</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>2023-07-06</td>\n",
       "      <td>2021-07-26</td>\n",
       "      <td>2017-11-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>2026-12-31</td>\n",
       "      <td>2026-12-31</td>\n",
       "      <td>2023-05-23</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>2018-06-04</td>\n",
       "      <td>2018-06-04</td>\n",
       "      <td>2006-11-03</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>2025-04-30</td>\n",
       "      <td>2024-12-30</td>\n",
       "      <td>2023-04-17</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>2013-09-15</td>\n",
       "      <td>2013-02-15</td>\n",
       "      <td>2011-03-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>2020-06-12</td>\n",
       "      <td>2019-07-29</td>\n",
       "      <td>2016-02-09</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>2009-02-15</td>\n",
       "      <td>2008-11-15</td>\n",
       "      <td>2006-08-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>2025-12-31</td>\n",
       "      <td>2024-12-31</td>\n",
       "      <td>2022-12-05</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>2024-08-07</td>\n",
       "      <td>2017-11-21</td>\n",
       "      <td>2014-12-09</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>2022-02-11</td>\n",
       "      <td>2019-06-07</td>\n",
       "      <td>2016-09-06</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>2019-03-15</td>\n",
       "      <td>2019-03-15</td>\n",
       "      <td>2015-09-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>2019-12-04</td>\n",
       "      <td>2019-01-04</td>\n",
       "      <td>2015-05-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>2009-02-10</td>\n",
       "      <td>2008-09-29</td>\n",
       "      <td>2003-10-27</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>2021-01-01</td>\n",
       "      <td>2021-01-01</td>\n",
       "      <td>2017-12-21</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>2013-09-15</td>\n",
       "      <td>2013-07-15</td>\n",
       "      <td>2010-04-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41</th>\n",
       "      <td>2024-12-31</td>\n",
       "      <td>2024-07-31</td>\n",
       "      <td>2021-07-01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>42</th>\n",
       "      <td>2027-02-15</td>\n",
       "      <td>2026-08-15</td>\n",
       "      <td>2024-09-02</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>44</th>\n",
       "      <td>2014-07-15</td>\n",
       "      <td>2014-07-15</td>\n",
       "      <td>2006-05-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>46</th>\n",
       "      <td>2013-08-15</td>\n",
       "      <td>2013-08-15</td>\n",
       "      <td>2010-03-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>48</th>\n",
       "      <td>2024-12-31</td>\n",
       "      <td>2024-12-31</td>\n",
       "      <td>2018-08-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>50</th>\n",
       "      <td>2016-05-25</td>\n",
       "      <td>2016-05-25</td>\n",
       "      <td>2016-01-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>51</th>\n",
       "      <td>2019-04-01</td>\n",
       "      <td>2018-01-04</td>\n",
       "      <td>2014-10-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>52</th>\n",
       "      <td>2026-07-15</td>\n",
       "      <td>2026-07-15</td>\n",
       "      <td>2024-06-03</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>53</th>\n",
       "      <td>2009-09-15</td>\n",
       "      <td>2009-09-15</td>\n",
       "      <td>2007-01-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>54</th>\n",
       "      <td>2026-12-15</td>\n",
       "      <td>2026-12-15</td>\n",
       "      <td>2022-11-22</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>55</th>\n",
       "      <td>2023-03-31</td>\n",
       "      <td>2020-03-13</td>\n",
       "      <td>2017-06-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>57</th>\n",
       "      <td>2022-07-14</td>\n",
       "      <td>2022-07-14</td>\n",
       "      <td>2019-06-24</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>58</th>\n",
       "      <td>2004-04-27</td>\n",
       "      <td>2004-04-27</td>\n",
       "      <td>1998-06-19</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>59</th>\n",
       "      <td>2012-07-15</td>\n",
       "      <td>2012-02-15</td>\n",
       "      <td>2007-04-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>60</th>\n",
       "      <td>2022-01-12</td>\n",
       "      <td>2022-01-12</td>\n",
       "      <td>2018-07-16</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>61</th>\n",
       "      <td>2007-12-15</td>\n",
       "      <td>2007-12-15</td>\n",
       "      <td>2005-10-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>62</th>\n",
       "      <td>2022-06-02</td>\n",
       "      <td>2016-12-15</td>\n",
       "      <td>2015-03-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>65</th>\n",
       "      <td>2018-06-04</td>\n",
       "      <td>2018-05-21</td>\n",
       "      <td>2018-04-16</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>67</th>\n",
       "      <td>2016-02-15</td>\n",
       "      <td>2014-04-15</td>\n",
       "      <td>2010-04-15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>69</th>\n",
       "      <td>2022-11-15</td>\n",
       "      <td>2022-10-15</td>\n",
       "      <td>2020-01-01</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>70</th>\n",
       "      <td>2009-07-15</td>\n",
       "      <td>2009-07-15</td>\n",
       "      <td>2005-05-15</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   completion_date primary_completion_date start_date\n",
       "0       2023-10-17              2023-10-17 2019-07-08\n",
       "1       2021-11-01              2021-09-22 2021-02-26\n",
       "2       2027-06-15              2026-12-15 2024-11-29\n",
       "3       2022-05-20              2022-05-20 2019-07-25\n",
       "4       2029-03-15              2028-03-15 2024-01-29\n",
       "6       2009-07-15              2009-02-15 2006-05-15\n",
       "8       2011-10-15              2010-12-15 2005-08-15\n",
       "9       2016-12-30              2016-12-30 2012-07-15\n",
       "11      2017-07-27              2017-07-27 2013-05-15\n",
       "12      2024-04-30              2024-02-29 2023-03-12\n",
       "13      2008-10-15              2008-04-15 2001-03-15\n",
       "14      2009-01-15              2009-01-15 2000-05-15\n",
       "16      2015-11-15              2015-11-15 2008-02-15\n",
       "17      2028-06-01              2026-06-01 2021-10-07\n",
       "19      2023-07-06              2021-07-26 2017-11-15\n",
       "23      2026-12-31              2026-12-31 2023-05-23\n",
       "24      2018-06-04              2018-06-04 2006-11-03\n",
       "25      2025-04-30              2024-12-30 2023-04-17\n",
       "26      2013-09-15              2013-02-15 2011-03-15\n",
       "29      2020-06-12              2019-07-29 2016-02-09\n",
       "30      2009-02-15              2008-11-15 2006-08-15\n",
       "31      2025-12-31              2024-12-31 2022-12-05\n",
       "32      2024-08-07              2017-11-21 2014-12-09\n",
       "33      2022-02-11              2019-06-07 2016-09-06\n",
       "35      2019-03-15              2019-03-15 2015-09-15\n",
       "36      2019-12-04              2019-01-04 2015-05-15\n",
       "37      2009-02-10              2008-09-29 2003-10-27\n",
       "38      2021-01-01              2021-01-01 2017-12-21\n",
       "39      2013-09-15              2013-07-15 2010-04-15\n",
       "41      2024-12-31              2024-07-31 2021-07-01\n",
       "42      2027-02-15              2026-08-15 2024-09-02\n",
       "44      2014-07-15              2014-07-15 2006-05-15\n",
       "46      2013-08-15              2013-08-15 2010-03-15\n",
       "48      2024-12-31              2024-12-31 2018-08-15\n",
       "50      2016-05-25              2016-05-25 2016-01-15\n",
       "51      2019-04-01              2018-01-04 2014-10-15\n",
       "52      2026-07-15              2026-07-15 2024-06-03\n",
       "53      2009-09-15              2009-09-15 2007-01-15\n",
       "54      2026-12-15              2026-12-15 2022-11-22\n",
       "55      2023-03-31              2020-03-13 2017-06-15\n",
       "57      2022-07-14              2022-07-14 2019-06-24\n",
       "58      2004-04-27              2004-04-27 1998-06-19\n",
       "59      2012-07-15              2012-02-15 2007-04-15\n",
       "60      2022-01-12              2022-01-12 2018-07-16\n",
       "61      2007-12-15              2007-12-15 2005-10-15\n",
       "62      2022-06-02              2016-12-15 2015-03-15\n",
       "65      2018-06-04              2018-05-21 2018-04-16\n",
       "67      2016-02-15              2014-04-15 2010-04-15\n",
       "69      2022-11-15              2022-10-15 2020-01-01\n",
       "70      2009-07-15              2009-07-15 2005-05-15"
      ]
     },
     "execution_count": 99,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "date_cols = [\n",
    "    'completion_date',\n",
    "    'primary_completion_date',\n",
    "    'start_date',\n",
    "]\n",
    "\n",
    "df[date_cols].head(50)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 97,
   "id": "a5530c1c",
   "metadata": {},
   "outputs": [],
   "source": [
    "df.drop(['study_first_submit_date', 'study_first_post_date','last_update_post_date'], axis=1, inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 100,
   "id": "01912ba1",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Ensure the date columns are in datetime format\n",
    "df['start_date'] = pd.to_datetime(df['start_date'], errors='coerce')\n",
    "df['completion_date'] = pd.to_datetime(df['completion_date'], errors='coerce')\n",
    "df['primary_completion_date'] = pd.to_datetime(df['primary_completion_date'], errors='coerce')\n",
    "\n",
    "# Create new columns with duration in days\n",
    "df['total_study_duration_days'] = (df['completion_date'] - df['start_date']).dt.days\n",
    "df['primary_outcome_duration_days'] = (df['primary_completion_date'] - df['start_date']).dt.days\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 102,
   "id": "d365d1e5",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "start_date                       datetime64[ns]\n",
       "completion_date                  datetime64[ns]\n",
       "primary_completion_date          datetime64[ns]\n",
       "total_study_duration_days                 int64\n",
       "primary_outcome_duration_days             int64\n",
       "dtype: object"
      ]
     },
     "execution_count": 102,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[['start_date', 'completion_date', 'primary_completion_date',\n",
    "    'total_study_duration_days', 'primary_outcome_duration_days']].dtypes\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 103,
   "id": "b09428db",
   "metadata": {},
   "outputs": [],
   "source": [
    "df.drop(['start_date', 'completion_date','primary_completion_date'], axis=1, inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 104,
   "id": "b7aa9cf6",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['brief_summary', 'conditions', 'country', 'design_primary_purpose',\n",
       "       'eligibility_criteria', 'enrollment', 'interventions_description',\n",
       "       'interventions_name', 'organization_match', 'lead_sponsor',\n",
       "       'location_city', 'location_country', 'location_facility',\n",
       "       'location_state', 'maximum_age', 'minimum_age', 'organization_fullname',\n",
       "       'overall_status', 'oversight_has_dmc', 'phase', 'primary_outcomes',\n",
       "       'secondary_outcomes', 'sex', 'stdage', 'study_type',\n",
       "       'affiliation_matches_org', 'total_study_duration_days',\n",
       "       'primary_outcome_duration_days'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 104,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.columns"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "42a56e87",
   "metadata": {},
   "source": [
    "Checking for trend in lead sponsors and its relation with 'COMPLETED'/'TERMINATED'/'RECRUITING'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 113,
   "id": "7fa457ef",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "overall_status                                      COMPLETED_%  TERMINATED_%\n",
      "lead_sponsor                                                                 \n",
      "Radiation Therapy Oncology Group                      94.444444      5.555556\n",
      "NCIC Clinical Trials Group                            92.753623      7.246377\n",
      "Children's Oncology Group                             87.341772      0.632911\n",
      "SCRI Development Innovations, LLC                     86.065574     12.295082\n",
      "Alliance for Clinical Trials in Oncology              85.148515      8.910891\n",
      "...                                                         ...           ...\n",
      "Regeneron Pharmaceuticals                             11.538462     43.589744\n",
      "Cancer Institute and Hospital, Chinese Academy ...     7.272727      0.000000\n",
      "Second Affiliated Hospital, School of Medicine,...     3.703704      3.703704\n",
      "National Institute of Allergy and Infectious Di...     3.092784     95.876289\n",
      "Sichuan Baili Pharmaceutical Co., Ltd.                 0.000000      1.694915\n",
      "\n",
      "[122 rows x 2 columns]\n"
     ]
    }
   ],
   "source": [
    "# Count number of trials per sponsor\n",
    "sponsor_counts = df['lead_sponsor'].value_counts()\n",
    "\n",
    "# Keep sponsors with more than 100 trials\n",
    "top_sponsors = sponsor_counts[sponsor_counts > 50].index\n",
    "\n",
    "# Filter DataFrame for top sponsors only\n",
    "top_df = df[df['lead_sponsor'].isin(top_sponsors)]\n",
    "\n",
    "# Group by sponsor and trial status\n",
    "status_counts = top_df.groupby(['lead_sponsor', 'overall_status']).size().unstack(fill_value=0)\n",
    "\n",
    "# Compute total trials\n",
    "total_trials = status_counts.sum(axis=1)\n",
    "\n",
    "# Compute percentage for COMPLETED and TERMINATED only\n",
    "percent_df = status_counts[['COMPLETED', 'TERMINATED']].div(total_trials, axis=0) * 100\n",
    "\n",
    "# Rename columns for clarity\n",
    "percent_df = percent_df.rename(columns={\n",
    "    'COMPLETED': 'COMPLETED_%',\n",
    "    'TERMINATED': 'TERMINATED_%'\n",
    "})\n",
    "\n",
    "# Sort by total number of trials (optional)\n",
    "percent_df = percent_df.loc[percent_df.index, ['COMPLETED_%', 'TERMINATED_%']]\n",
    "\n",
    "# Sort by COMPLETED_% in descending order\n",
    "percent_df_sorted = percent_df.sort_values(by='COMPLETED_%', ascending=False)\n",
    "\n",
    "print(percent_df_sorted)\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 116,
   "id": "99d40691",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "(7896, 28)\n"
     ]
    }
   ],
   "source": [
    "recruiting_count = df[df['overall_status'] == 'RECRUITING'].shape\n",
    "print(recruiting_count)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "7221de60",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
